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Abstract 
How do we assess the impact of Health Technology Assessment (HTA)?  Whilst 
high-income countries (HIC) may have led the way, lower-income countries are 
increasingly beginning to develop HTA processes to assist in their healthcare 
decision-making.  Understanding how we might quantify the costs and benefits 
of investing in HTA is important to policy makers and donors.  Very few studies 
have, however, estimated the benefits of the process of HTA in terms of its 
value to the health system.  The global expansion of HTA, its variable 
implementation, the lack of quantified evidence on health outcomes, along with 
an increasing investment in these processes at the systems level in low- and 
middle-income countries (LMIC) has generated greater interest from policy 
makers about the value and return on investment (ROI) of HTA.  A lack of longer-
term impact assessment (IA) may undermine its importance and value.   
To fill this research gap, we have developed a methodological framework to 
estimate the ROI in HTA using net health benefits (NHB) as our measure of value. 
This is the difference between QALYs gained by an intervention and QALYs that 
could have been gained if the money required to deliver it had been spent on 
other interventions.  We use a mixed-methods approach to quantify the value of 
HTA and to produce explanatory programme theory on the mechanisms by which 
HTA impact can be optimised.  It is also important to consider opportunity costs 
when establishing HTA processes but which are often overlooked.  The aim is to 
convey the concepts of potential and realised population NHB, and what we can 
attribute to the HTA process.  Central to understanding this is the ‘value of 
implementation’ (VOImp).  Theory-driven approaches will be used to generate 
and test contextual explanations for gaps between expected and actual gains in 
population health.   
We envisage the use of this research will encourage accountability of spending 
decisions and help to optimise the impact of HTA in an era of investment and 
expansion, in particular, for LMICs, through better understanding of HTA’s role 
in delivering health outcomes and value for money at the system level.  This 
research will offer a forward-looking model that LMICs can point to as a 
reference for their own implementation.  
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Part 1: Background and introduction  
Part 1 sets out the background to this research and introduces its aims, 
objectives and thesis structure.  The objective of this first part of the thesis is to 
explain how and why our HTA impact framework was developed and to put it in 
the context of the existing literature.  It comprises chapters 1 – 3 as described 
below. 
Chapter 1 introduces the rationale for, and background to, this research.  It also 
outlines the thesis chapters which are structured in 4 Parts. 
Chapter 2 is a review of the literature on evaluating the impact of HTA.  We are 
specifically interested in the impact HTA has on net health benefits (NHB) and 
its value to the health system. 
Chapter 3 discusses philosophical and methodological issues regarding causality, 
the different ways of thinking about this, the nature of its measurement and the 
challenge it presents in the design of impact evaluations, especially of complex 
interventions such as HTA.  A comparison group (a counterfactual) enables us to 
estimate changes in outcome that can we can attribute to an intervention, here 
the HTA process.  A comparator is crucial to impact evaluations as without this, 
it can lead to erroneous measures and conclusions of impact with attribution 
which could be wrongly assigned or interpreted.  This chapter provides a 
discussion of, on the one hand, the counterfactual approach to cause and effect 
and different means by which we might measure and apply this to HTA; and, on 
the other, theory driven approaches to understand what underpins outcomes 
leading to impact.  
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1 Introduction  
1.1 Background 
Health care resources are finite in every setting and, irrespective of the 
financing and organisation of a country’s healthcare system, decisions on what 
interventions to cover, and under what circumstances, have to be made in an 
evidence-based and fair way(1).  Health technology assessment (HTA) is one of 
the tools for priority setting.  The World Health Organisation (WHO) defines HTA 
as: ‘the systematic evaluation of properties, effects, and/or impacts of health 
technology. It is a multidisciplinary process to evaluate the social, economic, 
organisational and ethical issues of a health intervention or health technology. 
The main purpose of conducting an assessment is to inform a policy decision 
making’(2).  This is just one of several definitions of HTA in current usage.  We 
expand on its definition and terminology later in this chapter and make a 
distinction between HTA at the systems level, and its discrete application to one 
or several health technologies.  In essence, HTA helps decision-makers to 
understand the consequences of one (or several) alternative course of actions 
and to select the options that produce the best outcomes at the lowest cost. 
Globally, a growing commitment to universal health coverage (UHC) is promoting 
the role and institutionalisation of HTA (3-6) including in low- and middle-income 
countries (LMIC).  Institutionalisation of HTA is seen as pivotal to supporting UHC 
as a means of supporting better allocation of finite resources, cost containment 
and the maximisation of health.  All countries face complex financing challenges 
on the journey to sustainable development.  As countries’ Gross Domestic 
Product (GDP) per capita increases, they are expected to transition from aid and 
to take responsibility for strategic planning of their investments to progress 
towards UHC.  For those countries transitioning from donor support to a greater 
reliance on domestic resources and consequently, with an increased risk of 
financing gaps in the social sector in particular(7), priority setting in health is a 
necessary response to inform decision-makers on which interventions are best 
able to achieve UHC goals in a budget constrained environment(8). 
Thus, whilst high-income countries (HIC) may have led the way, LMIC are 
increasingly beginning to develop HTA processes to assist in their healthcare 
17 
 
decision-making.  For example, in India, HTA has been used to inform national 
clinical guidelines and quality standards to improve the quality-of-care delivery; 
and in Sub-Saharan Africa, countries such as Ghana, Tanzania and Zambia are 
seeking to use HTA for their health benefit package design and other purchasing 
decisions(9-11).  In Thailand, a country at the forefront of UHC, HTA has been 
used to inform decision-making for over a decade, notably to define the benefits 
package and the National List of Essential Medicines (NLEM)(12).  
The benefits concerning the link between HTA at the systems level and 
outcomes in terms of health improvements have, however, rarely been 
quantified.  A lack of longer-term impact assessment (IA) may undermine its 
importance and value.  Furthermore, it is evident that significant amounts of 
scarce resources are invested in HTA.  It has been estimated that the National 
Institute for Health and Care Excellence (NICE) for England and Wales depends 
on about 2,000 external experts and spends on average £150,000 for conducting 
an hta on each new drug, as based on an invitation to tender issued by the 
Department of Health in 2009(13).  Although countries where HTA has been 
institutionalised spend relatively little as a percentage of total health spending 
(estimates range from 0.01–1 percent of total public spending) on these 
processes(14, 15), HTA competes with other health priorities in the context of 
scarce resources.  Budget constraints and a lack of funding was identified as a 
key reason by 77 countries out of 111 country respondents for not investing in 
HTA according to a survey undertaken by the WHO in 2015(16).   
The global expansion of HTA, the lack of quantified evidence on health 
outcomes, its variable implementation resulting in sub-optimal impact, along 
with an increasing investment in these processes at the systems level, has 
generated greater interest from policy makers and donors about the value and 
return on investment (ROI) in HTA.  Indeed, this research was initiated by the 
international Decision Support Initiative (iDSI), a partnership-based initiative 
working towards achieving UHC and which is funded by the Bill and Melinda 
Gates Foundation (BMGF), the Rockefeller Foundation and the UK Department 
for International Development (DFID).   The next two sub-sections describe the 
work of iDSI in relation to this research. 
18 
 
1.1.1 The international Decision Support Initiative 
Established in November 2013, iDSI is a global network of health, policy and 
economic expertise, working to increase the value and impact of health 
spending(11). The initiative was launched by the Global Health and Development 
Group at Imperial College London, the Health Intervention and Technology 
Assessment Program, Thailand (HITAP), the Center for Global Development, 
Priority Cost Effective Lessons for Systems Strengthening South Africa (PRICELESS 
SA), and the China National Development and Research Center (CHNDRC).  iDSI 
supports countries to make better decisions about how much public money to 
spend on healthcare and how to make that money go further.  Their strategy is 
‘to work with LMIC governments and global development funders to create 
lasting, country-owned institutional capacity for evidence-informed priority 
setting – leading to more cost-effective, equitable and sustainable resource 
allocation which will translate into higher quality healthcare coverage, reduced 
financial impoverishment for households, and ultimately better health and more 
lives saved’(11).  iDSI offers skills and expertise on priority setting in health, 
ranging from the production of research and cost-effectiveness tools to policy 
support and technical assistance.  It relies on national institutions and invests in 
building local capacity to conduct priority setting exercises.  To this end, iDSI 
supports countries to build a sustainable and locally relevant HTA mechanism for 
priority setting to support progress towards UHC(17). 
1.1.2 Measuring the impact of ‘Better Decisions’ 
Integral to their work is iDSI’s commitment to measuring the impact of ‘better 
decisions’ to share learning with partners around the world.  In order to do this, 
a specialist monitoring and evaluation (M&E) agency, itad1, partnered with iDSI 
to develop a monitoring, evaluation and learning (MEL) framework based on a 
Theory of Change (ToC).  This ToC [Figure 1.1] states that combining demand-
driven support and policy-informed knowledge products with institutional and 
procedural support would encourage better decisions about the use of resources 
for health(18).  It encompasses the three main components of ‘effective 
partnerships’, ‘stronger institutions’ and ‘better decisions’ to help elevate the 
 
1 Note: itad is not an abbreviation 
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value of priority-setting.  As resources are used more consistently to prevent, 
detect and treat the major burdens of disease across societies, the theory 
stipulates that population health improves.   
  
 
 
Figure 1-1  itad/iDSI Theory of Change 
 
Source: Reproduced from itad Theory of Change Review Report with permission from Itad Ltd(18) 
 
 
The ToC recognises that there is a complex translation process between better 
decisions and better health dependent on many assumptions about local factors 
and systems, including linkage between decisions and budgets, delivery, 
implementation and data accuracy.  The key assumptions in this ToC are: 
decisions are implemented, health practitioner behaviour follows evidence and 
policy, beneficiaries choose to access healthcare when it is available and, lack 
of healthcare, or poor quality of healthcare, is a key driver for poor health 
outcomes(18).  Only when those decisions result in implementation and practice 
change, can better health be achieved.  Yet, we know that implementation of 
HTA recommendations and decisions are variable(19-23).  The data for studies of 
the implementation of reimbursement decisions are scarce but available 
evidence indicates that there is a gap between decisions and implementation, 
resulting in an inefficient use of new drugs and a consequent loss of value(24).   
Figure 1.2 shows the ToC being applied in practice by iDSI in introducing HTA to 
Ghana.  This reflects the positioning of HTA in Ghana but stops at better 
decisions(9).  It is this last part of the ToC regarding implementation of those 
decisions and their translation into health outcomes which is currently under-
evaluated and under-theorised so that everything we are focusing on here is a 
step on from HTA dissemination.  Thus, it is on this final part of the ToC that our 
research concentrates, to both quantify impact as well as theorise the 
mechanisms by which the impact of HTA can be optimised.   
 
 
Figure 1-2  Example of ToC in practice 
 
Source: Hollingworth et al. Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus 
on people, policy, and process. International Journal of Technology Assessment in Health Care. 2020;36(1):8-11(9). Reproduced with permission from 
Cambridge University Press and Copyright Clearance Center.   
 
 
 
Finally, this linear schematic [Figure 1.3] potentially masks a lot of the 
complexity of getting evidence into practice (in a UK context) with HTA placed 
about half way down the chain between research at one end and healthcare 
delivery at the other(25).  We can, though, usefully draw on this to develop a 
realist lens [see Chapter 3] by which to highlight the complexity in the 
implementation of HTA findings and to address the interplay between 
complexity-informed policy making - without any expectation that variance is 
taken out of decision-making practices by HTA.  We use a realist approach to 
embrace the established understanding that health outcomes are complex, 
context-bound and produced by systems, not by singular interventions.   
Figure 1-3  From HTA to health care delivery 
 
Source: Cooksey D, 2006(26) cited in Braithwaite et al, When complexity science meets 
implementation science: a theoretical and empirical analysis of systems change. BMC 
Medicine. 2018;16(1):63(25).  Use of this image is supported by the Creative Commons CC 
BYhttps://creativecommons.org/licenses/. 
 
1.2 Terminology 
1.2.1 Health Technology Assessment 
We consider here some definitions and terminology surrounding HTA, and 
introduce how we are defining HTA in this thesis.  We presented the WHO 
definition of HTA above.  Until very recently, the Professional Society for Health 
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Economics and Outcomes Research (ISPOR) defined HTA as ‘an evidence-based, 
multidisciplinary process intended to support healthcare decision making by 
assessing properties and effects of one or more new or existing health 
technologies in comparison with a current standard. Aiming at determining 
added value, HTA uses explicit analytical frameworks based on research and the 
scientific method in a systematic, transparent, unbiased way’(27).  Typically, 
HTA refers to individual studies on a specific technology, and both WHO and 
ISPOR’s original definitions reflected this by referring solely to the systematic 
evaluation of a health technology (or technologies).  A health technology can 
include evidence-based interventions, practices or policies.   
More recently, an international joint task group co-led and convened by the 
International Network of Agencies for Health Technology Assessment (INAHTA) 
and Health Technology Assessment international (HTAi), have proposed an 
updated definition of HTA which has replaced other’s definitions.  The new 
definition is as follows: ‘A multidisciplinary process that uses explicit methods to 
determine the value of a health technology at different points in its lifecycle. 
The purpose is to inform decision-making in order to promote an equitable, 
efficient and high-quality health system’(28).  Whilst this definition, similarly, 
refers to the evaluation of a health technology, it also brings in the value to the 
health system as a whole – with perhaps more potential for traction at the policy 
level.  Indeed, increasingly HTA is used to refer to a more systematic ‘process at 
the systems levels to inform priority setting and decision making ie as a tool for 
priority setting with its explicit consideration of costs and benefits’(17, 29).   
This is a key distinction we make throughout this thesis.  We are concerned with 
HTA’s value to the health system, with our focus being the evaluation of HTA at 
the systems (ie a country or jurisdiction) level.  We thus distinguish between 
‘HTA’ (in capitals) at the systems level as a tool or process for priority setting, 
and ‘hta’ (in small letters) as an assessment and/or appraisal of an individual 
technology (or technologies).   However, in order to get to the value of investing 
in HTA at the systems levels (hereafter, referred to as HTA), we need to look at 
what the process is delivering.  In other words, we need to quantify and 
aggregate the value of individual htas.  Additionally, whilst we recognise HTA 
may include several activities, for example, horizon scanning, assessment and 
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appraisal, pricing, we consider its overall purpose is to inform decision-
making(28).  We also apply the definition of HTA as ‘locally relevant, fair and 
evidence-informed processes’(30) used to inform health benefit plans or 
essential medicines lists recognising that existing priority setting mechanisms, in 
LMICs in particular, are not always (or, at all) referred to as HTA but to which 
this framework, we believe, can still usefully apply.   
Where we refer to the implementation of hta recommendations, we mean this to 
be about enacting upon those decisions (rather than the undertaking of hta as a 
process of itself).   We may use the terms recommendations, findings and 
decisions interchangeably acknowledging that these are all the outcomes of an 
hta, be it the scientific evidence from an assessment or the actual evidence-
informed decision following its appraisal.  Either way, we are focusing on the 
step beyond decision-making and dissemination to the implementation and 
realisation of those decisions.  We also use ‘implementation’ and ‘uptake’ 
interchangeably as used in the implementation science literature when referring 
to the adoption of evidence-based interventions(31). 
Finally, others refer to HTA at different levels by categorising it into 3 types(32): 
• Micro: appraisal of individual technologies (or related groups thereof)  
• Meso: clinical practice guidelines to manage patient care pathways within 
a healthcare system 
• Macro: efficiency, organisation and strengthening of the healthcare 
system  
We see this distinction relating to the type of health technology being assessed.  
This terminology would, therefore, come under our usage of the term hta as a 
discrete application of assessment and/or appraisal of one (or several) micro, 
meso or macro level interventions. 
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1.2.2 Value 
The concept of value can take many different forms - normative and subjective, 
and indeed, in health economics, has many different usages.  It can refer to a 
utility theory of value representing individual preferences, value for money in 
terms of cost-effectiveness, the valuation of health states and outcomes, and 
value frameworks incorporating many different elements of value.  In this thesis, 
we refer to value (whether it be that of a technology or hta/HTA) in terms of 
net health benefits (NHB) [see Chapter 4], reflecting that a health economist’s 
concern with value will always mean looking for improvement in final (health) 
outcomes(33).  We define the value of HTA to be achieved through increasing 
the uptake of net beneficial technologies and decreasing the uptake of non-net 
beneficial technologies.  We refer to the value of an hta in terms of how its 
attributable NHB compared with the cost of undertaking the hta process.  We 
also refer to the value of HTA at a systems level as an aggregate of the value of 
all individual htas. 
1.2.3 Outcomes and impact 
Realist inquiry talks about ‘outcomes’ whereas the objective of this research is 
to measure ‘impact’.  The former usually refers to the goal of an intervention 
(for example, we refer to the uptake of a technology following an hta as our 
outcome of interest), the latter to longer term consequences (for example, on 
health).  It is helpful to use this conceptualisation which comes from classic logic 
models (and which are influential in public health) and is useful even within the 
realist school(34).  However, the terms are often used in diametrically opposed 
ways in different sectors.  For example, in health evaluation, 'impact' is short 
term and 'outcome' is long term.  In international development, 'outcome' is 
short term and usually specific to participants in the program, and impact is 
both long term and (often) population wide.  In realist evaluation, the term 
outcome is used to include all kinds of outcomes and impacts, depending on 
things like the scale and time period of the evaluation. (35) 
In this thesis, we refer to an impact framework - the term ‘impact’ fitting the 
current rhetoric of research bodies better which are concerned with the changes 
and benefits attributable to research(36).  We keep the usage of outcomes in 
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the realist synthesis though we do make a distinction between intermediate 
outcomes and final impact [Chapter 6, Table 6.2].   
1.3 The aims and objectives of this research 
1.3.1 Aim 
This research aims to conceptualise, value and measure the impact of HTA at a 
systems level. 
1.3.2 Objectives 
• To develop a conceptual and methodological framework to quantify the 
impact of HTA.  
• To explore the use of mixed methods in order to produce data-driven 
theory that considers individual, interpersonal, institutional and systems-
level components and their interactions on the mechanisms by which HTA 
impact can be optimised. 
1.4 Ethics 
As all data are secondary, no ethics permission was required.  Indeed, our 
framework aims to utilise routine administrative data and HTA outputs which are 
available in the public domain. 
1.5 Thesis structure and chapter outline 
The thesis is structured into 4 parts and contains 10 chapters.   Each of the 4 
parts is summarised below along with chapter outlines. 
1.5.1 Part 1: Background and introduction 
Part 1 sets out the background to this research and introduces its aims, 
objectives and thesis structure.  The objective of this first part of the thesis is to 
explain how and why our HTA impact framework was developed and to put it in 
the context of the existing literature.  It comprises chapters 1 – 3 as described 
below. 
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Chapter 1: Introduction 
Chapter 1 introduces the rationale for, and background to, this research.  It also 
outlines the thesis chapters which are structured in 4 Parts. 
Chapter 2: Literature Review 
Chapter 2 is a review of the literature on evaluating the impact of HTA.  We are 
specifically interested in the impact HTA has on net health gains and its value to 
the health system. 
Chapter 3: Philosophical and methodological issues regarding causation 
Chapter 3 discusses philosophical and methodological issues regarding causality, 
the different ways of thinking about this, the nature of its measurement and the 
challenge it presents in the design of impact evaluations, especially of complex 
interventions such as HTA.  A comparison group (a counterfactual) enables us to 
estimate changes in outcome that can we can attribute to an intervention, here 
the HTA process.  A comparator is crucial to impact evaluations as without this, 
it can lead to erroneous measures and conclusions of impact with attribution 
which could be wrongly assigned or interpreted.  This chapter provides a 
discussion of, on the one hand, the counterfactual approach to cause and effect 
and different means by which we might measure and apply this to HTA; and, on 
the other, theory driven approaches to understand what underpins outcomes 
leading to impact. 
1.5.2 Part 2: A framework for conceptualising, measuring and 
valuing the impact of HTA 
Part 2 presents our methodological framework for measuring the impact of HTA.  
This is a key output of this research.  It describes both the quantitative 
framework and the realist theory driven evaluation.  It comprises of chapters 4 -
6 as described below.  
Chapter 4:  NHB-ROI Framework 
Chapter 4 presents our Net-Health Benefit Return on Investment (NHB-ROI) 
Framework for quantifying the impact HTA and how it addresses limitations 
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identified in Chapters 2 and 3.  We believe this is important as a lack of longer-
term impact assessment may undermine the importance and value of HTA. We 
describe our mixed methods approach to quantify the value of investing in HTA 
as well as to explain how outcomes and impact are achieved.  This framework 
addresses one of the most overlooked yet, one of the most critical aspects of 
evaluation, namely the opportunity costs associated with the capital investment 
and ongoing running costs required to sustain an HTA infrastructure at the 
systems level(37).  If we think priority setting should be better informed by 
evidence, and use tools such as HTA, this necessarily implies institutional change 
to establish a sustainable system.  Consequently, we have to consider the 
opportunity costs associated with its establishment and ongoing running(38).    
Chapter 5: Realist protocol 
Chapter 5 outlines our plans for how we will review and analyse the literature as 
a realist synthesis to develop theory as to what underpins HTA outcomes.  By 
outcomes, we refer here to the uptake or implementation of hta decisions. 
Whilst impact on NHB is our final outcome of interest, this is usually only 
observable over a much longer timeframe than research follow-up allows and 
thus, we use modelled health outcomes.  We theorise contextual factors and 
mechanisms to provide greater insight into how ‘better decisions’ translate into 
‘health impact’ through the uptake of hta findings. 
Chapter 6: Realist synthesis 
Chapter 6 presents the realist synthesis and its results.  We draw on formal 
theories in the literature to help diagnosis of the implementing context and to 
understand readiness to implement or enact upon those decisions following an 
hta.  We extract context-mechanism-outcomes (CMO) from the literature 
retrieved from our original literature search (see Chapter 2) as well as additional 
articles reviewed as part of the realist synthesis.  We then draw lines between 
these CMO and our programme theory to demonstrate the links and hypotheses 
on capability and willingness to implement.   
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1.5.3 Part 3: Case studies 
Part 3 presents two case studies as illustrative examples of how the framework 
can be put into practice.  We use case study design to illustrate the value of 
introducing a single hta.  We draw on routine administrative data and hta 
reports to populate our impact framework from which we estimate the NHB-ROI 
of these processes.  It comprises of Chapters 7 – 9 as described below. 
Chapter 7:  China National Health Development Research Center case study 
Chapter 7 draws on an existing evaluation of stroke clinical pathways (CP) as 
undertaken by the China National Health Development Research Center 
(CNHDRC) to populate our NHB-ROI framework.  Uptake of the CP was based on 
an evaluation using routinely collected longitudinal data and their longer-term 
impact was modelled as part of the hta.  We draw on these results to estimate 
realised population NHB and what we can attribute to the hta process.  We 
offset this against the estimated costs of investing in HTA.  By offsetting the 
attributable benefits against the costs associated with the process, we show high 
returns from simply introducing a single hta.  
Chapter 8:  Scottish Health Technologies Group case study 
Chapter 8 uses the economic outputs of an existing HTA Evidence Note produced 
by the Scottish Health Technologies Group (SHTG) on a glucose monitoring 
sensor for diabetics to populate our framework.  We analyse routine 
administrative data on its prescribing using quasi-experimental methods to 
establish a counterfactual and a credible measure of uptake of the technology, 
and what can be attributed to the hta.  Again, by offsetting the attributable 
benefits against the costs associated with the process, we show high returns 
from simply introducing a single hta. 
Chapter 9 
Chapter 9 brings together the programme theory with the two case studies.  This 
shows how the ROI-NHB and realist framework looks when brought together. 
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1.5.4 Part 4: Synthesis  
Part 4 synthesises the research, discusses implications and makes 
recommendations.  It comprises Chapter 10 as described below. 
Chapter 10: Recommendations and Further Research 
Chapter 10 provides a synthesis of the research to make practical 
recommendations for decision-makers and researchers.  We outline what our 
framework adds to the existing body of work on HTA impact and, suggest 
potential next steps for future research. 
1.6 Description of my role and contribution of others 
As stated in my Declaration, I have opted to write throughout the thesis in the 
plural ‘we’ to recognise the contribution of others who I have formally thanked 
in my Acknowledgements.  Here, I explicitly describe my role and the invaluable 
support I received from my supervisors and other colleagues as part of an 
iterative process, enabling me to develop the research into a coherent body of 
work.  
UoG was sub-contracted by the CHE, University of York and as part of iDSI, 
during 2014-16 to develop a conceptual framework to measure the impact of 
HTA.  Based on this work, a larger grant to further develop this research was 
awarded directly to HEHTA, UoG from 2016 -18.  This grant supported my time 
to undertake this research and forming part of my PhD (enrolled 2016 – 2020).  
I independently undertook the background literature review (Chapter 2) and 
continued to update this throughout the duration of the research.  I am very 
grateful for the guidance and input from UoG MVLS librarian, Paul Cannon, on 
search terms and strategy.   
Initial work was co-developed by CHE, York and HEHTA, UoG.  Conveying the 
concepts of potential and realised population NHB, dependent upon the extent 
to which clinical practice is changed ie the VOImp, was the starting point to this 
work.  At HTAsiaLink conference 2015, CHE/HEHTA jointly presented on this 
work, albeit at an early stage of the framework.  There, I used a case study from 
32 
 
HITAP to illustrate these concepts empirically, expressing impact in terms of full 
and current implementation and equating this to potential and realised 
population NHB. I am indebted to Profs Mark Sculpher and Paul Revill, CHE for 
their invaluable contribution of coming up with these initial concepts which have 
underpinned the research from the outset, in particular, Chapter 4.  
Explaining the gap between expected and actual gain in health was the next 
step.  As iDSI had developed a theory-based approach to their monitoring and 
evaluation, it seemed appropriate to be able to tie into this work by theorising 
the mechanisms by which impact could be optimised (as well as quantifying 
impact).  Having independently reviewed theory-based approaches to 
evaluation, I opted to draw upon realist inquiry to highlight the complexity in 
the implementation of HTA findings.  Prof Hannah Hesselgreaves, who 
subsequently joined HEHTA, had expertise in applying this approach in 
evaluations.  I developed the protocol and carried out the realist synthesis 
(Chapters 5 and 6) under the supervision of Hannah, drawing on her extensive 
expertise in this area.  Again, I acknowledge Paul Cannon’s help in developing 
search terms.   
The VOImp was further developed at a later stage with the support of my main 
supervisor, Prof Andy Briggs, with the addition of drawing in a counterfactual to 
obtain a measure of attributable NHBs (Figures 4-2 and 4-3).  I independently 
explored methods by how we might practically undertake such an analysis, 
drawing on the most appropriate quasi-experimental methods given what routine 
health data may be available.  I acknowledge my colleague, Janet Bouttell, for 
helpfully and kindly allowing me to adapt her summary review of methods in this 
field (Table 3-5).  Given the different paradigms to causality which I had drawn 
upon to develop the framework (counterfactual and theory-based), I brought 
these together in Chapter 3 to illustrate the challenge of the counterfactual in 
the design of impact evaluations of complex interventions.   
In terms of aggregating from an individual hta to impact at the systems level in 
order to quantify a NHB-ROI (Equation 4-5 and Figure 4-4), I am indebted to Prof 
Briggs for drawing this out.  I independently undertook Chapters 7 and 8 in 
applying the quantitative framework to two case studies as illustrative of the 
proof-of-method.  I am immensely grateful to CNHDRC and SHTG for their 
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generosity in allowing me to use their technology assessments.  This also 
enabled me to test the theory in Chapter 9 and to integrate the mixed methods.  
In Chapter 10, I synthesised the research to make practical recommendations for 
decision-makers and researchers.  This last chapter makes reference to a book 
chapter co-authored by myself and colleagues in HEHTA, Janet Bouttell and Prof 
Neil Hawkins. 
Finally, I am indebted to all those who have provided constructive feedback on 
drafts throughout, including my supervisors, Olivia Wu, Hannah Hesselgreaves 
and Andy Briggs and many iDSI colleagues.  Below is a summary of these 
contributions by chapter.  
Chapter 1  
Chapter 2 – with acknowledgements to Paul Cannon 
Chapter 3 – with acknowledgements to Janet Bouttell 
Chapter 4 – informed by early work with York and co-developed with Andy Briggs 
Chapter 5 – under supervision of Hannah Hesselgreaves/ librarian input 
Chapter 6 – under supervision of Hannah Hesselgreaves 
Chapter 7 – with thanks to CNHDRC 
Chapter 8 – with thanks to SHTG 
Chapter 9  
Chapter 10 – reference to Bouttell, Grieve, Hawkins book chapter 
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2 Impact of HTA: a literature review 
2.1 Introduction 
The benefits concerning the link between HTA and impact in terms of net health 
improvements have rarely been quantified; ‘the literature on assessment of HTA 
influence is still quite limited and there is little on longer term effects on 
clinical practice and health outcomes’(39).  By net health improvements, we 
mean the difference between health gained by an intervention and health that 
could have been gained if the money required to deliver it had been spent on 
other interventions.  Capturing the impact of HTA on clinical practice and health 
is difficult given the potential requirements in terms of data.  Even in countries 
where HTA is well established, evidence which identifies such impact in terms of 
net health gains is limited.  It is especially challenging in LMIC where routine 
administrative monitoring and evaluation data are often lacking, leading to poor 
data capture and reporting.  This has led some to claim that ‘there is currently 
insufficient evidence that the use of priority setting tools improves health 
outcomes and reverses existing inequities...we have ample evidence that the 
lack of a rational and transparent process generates inequity and stagnation in 
mortality levels’(40). 
Whilst much research has been undertaken on establishing what factors 
influence improved decision-making(41-44), how those influences on decision-
making interact with local context and health systems, leading to impact on 
clinical practice and health, is less understood.  For countries with greater 
capacity constraints, how decision-making interacts with ‘context’ leading to 
impact on health is even less explored and arguably, of critical importance(45). 
Straus et al(46), as cited in(47), state ‘a review of the existing literature on HTA 
reveals a startling lack of depth, particularly on the impact HTA has had on 
health-care budgets, efficiency and on societal health outcomes….whereas the 
previous 10 years have been well-spent on building the HTA/evidence-based 
medicine infrastructure and evidence base, the next 10 should focus on the 
outcomes’. 
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2.2 Search terms and strategy  
A literature review on the evaluation of HTA was undertaken, focusing on impact 
in terms of health gains, and the methods and frameworks used.  The search 
terms [Table 2.1] were run on Ovid MEDLINE(R) without Revisions 1996 to May 
Week 4 2020, and Embase 1996 to 2020 Week 22, last updated 1 June 2020. 
Table 2-1  Search terms 
1 exp Technology Assessment, Biomedical/ 
2 ((health technolog$ adj3 assessment$) or HTA).mp. 
3 1 or 2  
4 (("evaluat$" or "method$" or "framework$" or "model$" or "concept$" 
or "empirical research" or "theor$" or "cost benefit analys$") adj5 
(health technolog$ or HTA)).tw.  
 
5 (("impact$" or "value" or "gain$" or "benefit$" or "influence$" or 
"return$ on investment" or "ROI" or "social adj3 return$" or 
"economic adj3 return$") adj5 (health technolog$ or HTA)).tw. 
6 4 or 5 
7 3 and 6 
 
Inclusion criteria: framework, model or evaluation of HTA; implementation or 
uptake of a technology following an hta. 
Exclusion criteria:  methodology on measuring outcomes and/or value in 
economic evaluations; uptake of a technology without going through an hta; 
foreign language. 
2.3 Results 
2.3.1 Articles retrieved 
The Prisma flow diagram is shown below [Figure 2.1].  Annex A lists the final 
articles included.   
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Figure 2-1  Prisma flow diagram 
 
 
2.3.2 HTA impact frameworks  
Several HTA evaluation frameworks were identified in the literature.  We 
describe those acknowledging the need to capture impact on health in 
chronological order below(19, 48-54). 
Jacob & McGregor framework 
Jacob and McGregor, in one of the earliest HTA impact frameworks(49), define 
the impact of htas so as to ‘influence the diffusion and use of health technology 
in such a way as to increase the efficiency of the health care system (by 
increasing its effectiveness or reducing its costs)’.  Using interviews, 
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questionnaires and data banks, they estimated the impact of 21 hta reports on 
policies, technology diffusion and utilisation.  They found cost-savings into the 
millions (Canadian dollars) through a systematic documentation of its effects.   
Payback framework 
Buxton and Hanney’s Payback Framework(50), previously commissioned to assess 
the UK’s National Institute for Health Research (NIHR) HTA programme’s first ten 
years (1993–2003)(55), is recognised as the most dominant methodological 
framework used to assess the impact of healthcare research(56).  This 
framework categorises benefits of health research ranging from traditional 
knowledge production, and research training and targeting, to impacts on policy, 
product development, health and economic gains [Figure 2.2].  Measurable 
impacts primarily focus on knowledge generation, perceived policy impact and, 
to some extent, on practice – with the conclusion that impact on knowledge 
generation is more easily quantified than that on policy, behaviour or especially, 
health gain.  They note that, in spite of the dedication of HTA agencies to 
evaluation, the impact of their technology assessments on health policy is rarely 
assessed.  
Figure 2-2  Payback model 
 
Source: Reprinted by permission from Springer Nature and Copyright Clearance Center. 
Springer Nature, Health Research Policy and Systems, Proposed methods for reviewing the 
outcomes of health research: the impact of funding by the UK's 'Arthritis Research 
Campaign', Hanney S, SPRINGER NATURE LICENSE, 2004 cited in Oortwijn et al (57). 
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Davies et al 
Davies et al(51) used decision analytic modelling to conduct ex ante assessments 
of the relative value for money of htas in terms of their expected net costs and 
health benefits to society in order to assist in their prioritisation for assessment 
[Figures 2.3 – 2.5].  It is assumed that the principal objective of HTA is to 
provide information and evidence to influence health care practice and improve 
the efficiency of health care provision.  The perspective of the model includes 
consideration of the costs and benefits to the research funding body, the 
providers of health and social care services and, the patients who are likely to 
receive the health care interventions(51).  They acknowledge that priorities 
could be set according to a range of criteria but focus on a quantitative measure 
of ‘value’ or ‘payback’, noting that most previous analyses were ex post 
assessments.  Broader costs and benefits to society (value of knowledge, 
political and administrative benefits, skills etc) were excluded partly because 
they are difficult to assess but also as they would accrue irrespective of the 
technology in question.  Figure 2.3 illustrates the processes through which HTA 
can change the efficiency of health care provision.  Figure 2.4 illustrates the 
range of factors which may modify the impact of HTA on the provision of health 
care.  Figure 2.5 illustrates the conceptual structure of the prioritisation model.  
Utilisation rates were assumed to increase (decrease) with the addition of 
evidence on the effectiveness (ineffectiveness) of a technology from the hta.   
Figure 2-3  Davies et al – Process of HTA impact on health care provision 
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Figure 2-4  Davies et al - Adoption and utilisation of HTA results 
 
 
Figure 2-5  Davies et al - Economic prioritisation model 
 
Source:  Figs 2.3 – 2.5 Reproduced from Davies et al. Prioritizing investments in health 
technology assessment. Can we assess potential value for money? Article in International 
Journal of Technology Assessment in Health Care · February 2000(51) with permission from 
Cambridge University Press and Copyright Clearance Center 
 
Wanke et al 
 
Wanke et al(53) propose a generic evaluation framework for HTA agencies.  They 
conducted a review of agencies to understand what aspects of HTA have been 
evaluated, and how.  They took a logic model approach to their conceptual 
model which was informed by Stufflebeam’s classification of 22 evaluation 
approaches(58), Hailey’s exploration of HTA effectiveness(59), existing 
literature at that time on the impact of HTA(49, 60-63) and a survey to members 
of the International Network of Agencies for Health Technology Assessment 
(INAHTA)(54).  They also identified four older HTA evaluations noting their 
limitations of accounting for attribution and upstream outcomes(49, 64-66). 
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Wanke et al’s framework [Figure 2.6](53) depicts the range of dimensions 
conceived for an evaluation of an HTA agency.  Level 1 depicts the context in 
which HTA agencies operate.  In Level 2, the HTA which operates within the 
Level 1 technology diffusion process, is depicted as a logic model with 
inputs/structures, processes, outputs, outcomes and ultimate impact.  The items 
listed under these headings represent the items upon which an evaluation may 
be focused.  The authors state that only when an HTA agency has matured and is 
stable, should an impact evaluation be undertaken with a view to determining 
the programme’s merit or worth.  Most of the reviews or evaluations included in 
their review (14 out of 16) were identified by a direct request to INAHTA 
members.   
  
 
 
Figure 2-6  Wanke et al framework 
 
Source: [Figure 4 Dimensions evaluated] in Margaret Wanke, Don Juzwishin, Richard Thornley, Liza Chan HTA Initiative #16. An Exploratory Review of 
Evaluations of Health Technology Assessment Agencies. February 2006(53).  Permission sought from the Alberta Heritage Foundation for Medical 
Research (AHFMR) 17 June 2020 by email. 
 
 
 
Lafortune L et al. 
Lafortune et al(52) were concerned with an HTA agency’s performance.  Based 
on Parson’s social action theory(67), Lafortune et al propose a conceptual model 
that includes four functions an organisation needs to balance to perform well:  
goal attainment, production, adaption to environment and, culture and values 
maintenance [Figure 2.7].  They identified specific dimensions under each of 
these functions in relation to performance, and compared this against existing 
evaluations of HTA agencies thus enabling any gaps to be highlighted.  The goal 
attainment function includes the dimension of ‘impact’ on decision-making, 
organisation and service, society, research and efficiency.  Lafortune et al’s 
framework captures health outcomes under ‘societal impact’.   
RAND Europe 
RAND Europe evaluated the impact of UK’s NIHR HTA Programme 2003-2013(68), 
with a separate report assessing the potential economic returns(19).  The NIHR 
HTA Programme funds research about the clinical and cost effectiveness, and 
broader impact of healthcare technologies for those who plan, provide or 
receive care in the UK’s National Health Service (NHS)(69).  The RAND Europe 
evaluation intended to capture the savings to the NHS by estimating the health 
benefits to patients and converting these into monetary terms.  They examined 
the impact of the HTA programme to understand its potential economic 
benefits, taking 10 HTA-funded projects that had shown a new treatment could 
offer benefits if introduced in the NHS, either by saving costs or by improving 
health through better treatment.  They included some additional short 
illustrative case studies providing more context.   
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Figure 2-7  Lafortune et al framework 
 
Source: Reproduced from Lafortune L et al. Assessing the performance of health 
technology assessment organizations: a framework. Int J Technol Assess Health Care. 
2008;24(1):76-86(52) with permission from Cambridge University Press and Copyright 
Clearance Center. 
 
INAHTA impact framework 
INAHTA has developed a framework for reporting information on htas for which 
there are some indication of impact on decisions by government at the regional, 
national or international level. Positive, interim and negative indications of 
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impact are all to be included.  This is a form that is completed by the HTA 
agency requiring boxes to be ticked on an hta’s indications of impact, the 
agency’s and external opinion on the level of impact (from no apparent 
influence to major influence) along with free text to provide further information 
and evidence.  Indications of impact range from the hta being considered by a 
decision maker to linked to clinical practice change or changes in health status.  
The form is available on the INAHTA website(54).  
OECD 
The OECD aimed to capture the impact of HTA at a country or systems level 
[Figure 2.8] by measuring its impact on life expectancy and public spending(48).  
Using a quantitative approach, the OECD investigated how several different 
policies and institutions helped achieve value for money in healthcare.   For 
HTA, a score was computed based on countries’ responses to questions on their 
structure and capacity for HTA, whether cost-effectiveness and affordability 
were taken into account, and how the information was used.  Regression-based 
analysis was used to assess the effects of policies and institutions on health 
spending and life expectancy.  They found that HTA’s use in providing evidence 
related to new technologies was likely to both magnify life expectancy gains but 
also that of spending on health care.  Results for HTA showed a statistically 
significant improvement in health outcomes but also a statistically significant 
increase in public spending.  Given the necessary existence of institutional 
structures and capacity for technology assessment and its purpose in 
encouraging the additional use of effective services, HTA’s scores were 
associated with both higher public expenditures and higher care quality as 
suggested by the positive and significant coefficients(48).  This was contrasted 
with policies which increased life expectancy but also moderated health 
spending, such as those aimed at increasing the scope of goods and services 
covered by primary health care.  The cost drivers of HTA were mainly related to 
‘the additional use of effective services, as well as cost increases related to the 
up-front investment to create, expand and operate health technology 
assessment agencies’(48).  As an example, empirical estimates showed that 
NICE’s recommendations for the adoption of new technologies have cost the NHS 
an additional GBP 1.65 billion per year(70).  
45 
 
Figure 2-8  OECD Effect of policies on life expectancy & public spending 
 
Source: Reproduced from Lorenzoni, L. et al. (2018), “Which policies increase value for 
money in health care?”, OECD Health Working Papers, No. 104, OECD Publishing, Paris. 
http://dx.doi.org/10.1787/a46c5b1f-en OECD Fig 2. (48) with permission from OECD as 
source and copyright owner. 
 
2.3.3 Individual country level HTA impact evaluations 
Articles retrieved on countries which have undertaken an impact evaluation of 
HTA at country level included Austria(71), Catalonia(72), Canada(49), 
Denmark(73), Iran(74), Malaysia(75), Poland(76), Taiwan(77), the 
Netherlands(57), Thailand (abstract only retrieved).  Each country HTA 
evaluation is summarised below [Table 2.2]. 
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Table 2-2  Country level HTA impact evaluations 
Country and 
Years of analysis 
What was evaluated Methods  Limitations 
Austria 
2001 - 2010 
A conceptual model developed for 
assessing the impact of HTA in the 
Austrian healthcare system(71) used 
multidimensional aspects of impact,  
namely, awareness, acceptance, policy 
process, policy decisions, clinical 
practice, outcomes and enlightenment.   
It was based on indicators 
developed by Gerhardus et 
al(78) and Weiss’ theory of 
research utilisation(79). 
This model did not address health 
outcomes due to methodological 
limitations.  The authors make the 
recommendation that further research 
should address the methodology on how 
to improve impact measuring, in 
particular the relationship between 
HTA and the overall improvement of 
health / health care systems.   
Catalonia 
2000 - 2003 
The current and past situation of HTA 
in Catalonia(72, 80). 
An historical review of facts and 
landmarks; semi-structured 
interviews. 
‘We miss the opportunity to measure 
the impact of our recommendations…By 
missing this impact analysis, we all miss 
the opportunity to convince our policy 
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makers of the need for HTA and its 
goodness’. 
Canada 
63 hta’s from 
2001 onwards 
Impact of various CETS reports.  McGill 
Technology Assessment Unit (TAU) – 
local hta – covered 63 assessments.  
 
Case study approach to assess 
the impact on policy.  
Attribution of HTA to costs to 
the healthcare system dealt 
with by sensitivity analysis on 
upper and lower limits. 
Impact was measured by the 
number of recommendations 
accepted and the dollars spent 
on new technologies versus 
those saved through the 
adoption of cost saving 
recommendations.  
Methods dependent on judgement of 
the analyst, policy impact not 
documented, time interval between 
HTA and its effect, the challenge of 
what would have happened without the 
HTA noting that no amount of input 
from key actors can totally remove the 
uncertainty regarding this estimate. 
It is estimated the TAU saved the 
hospital an average of CAD$1.14 million 
annually(81). 
Did not take actual implementation into 
account. 
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Denmark  
Overview from 
1997 
Individual hta’s(73) 
 
Qualitative; individuals’ 
experiences of HTA projects. 
Descriptive 
Experience still too limited to evaluate 
benefits.  ‘Above all, the 
implementation of HTA results will be 
one of the greatest challenges in the 
coming years’. (82). 
Iran 
2007 - 2017 
The impact of 23 individual htas, 
identifying the determinant factors 
leading to the implementation of 
report results(74).   
A case study approach 
employing questionnaires and 
semi-structured interviews with 
stakeholders informed by the 
Payback framework.   
No mention of health outcomes, only 
impact on capacity, decision making 
and knowledge. 
 
The 
Netherlands(57) 
2000 - 2003 
The impact of individual HTA projects 
over 3 years 
Payback framework Deemed too early to determine 
whether the HTA programme led to 
actual changes in healthcare policy and 
practice. 
Malaysia (75) 10 years of HTA IHAHTA framework Level of influence of reports and 
decisions are qualitative only. 
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1997 - 2016 
Poland (76) 
2005 - 2015 
10 years of HTA 
 
Descriptive analysis of the drug 
reimbursement criteria before 
and after HTA. 
Descriptive only. 
Taiwan(77) 
2007 - 2017 
10-year implementation of HTA Descriptive analysis of HTA in 
Taiwan. 
Descriptive only. 
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2.3.4 Facilitators and barriers to the uptake and impact of HTA 
Many articles were found identifying facilitators and barriers2 in implementing 
the findings of an ‘hta’ and how this actually changes practice(83). Drummond 
summarised the main elements to successful implementation to be: ‘a) defining 
a clear policy question; b) defining a clear research question; c) making 
recommendations commensurate with the evidence; d) identifying the 
implementation mechanism; e) paying attention to incentives and disincentives; 
and f) clarifying the roles and responsibilities of the various parties’(84).   
Recommendations have been made as to how these factors can then be used to 
improve impact, notably that key stakeholders (patients, providers and industry) 
are adequately involved; decision-makers give a prior commitment to use 
assessment reports (and assessments meet their needs); the necessary resources 
are available for implementing decisions;  there is transparency in the 
assessment and decision-making processes; and collaboration, knowledge and 
skills are transferred across jurisdictions(42).  Evaluations have been undertaken 
to establish specifically what HTA agencies need to do to have greater impact in 
the future(41).  Findings were similar to the facilitator and barriers identified in 
that there is a need to better integrate local practitioners into the HTA process; 
for greater influence at the policy-making level, assessment and appraisal to be 
incorporated within a common structure to provide necessary incentives for 
policy makers to consider the science; and finally, that the HTA agencies would 
need to be handed greater regulatory powers(85).   
Knowledge translation (KT) has emerged as a paradigm to address closing the 
"know-do" gap [see Figure 1.3].  Facilitators and barriers to knowledge 
translation in the context of hta as cited by Fournier et al(86) include 
‘knowledge management (timeliness and relevance, personal contact between 
researchers and policy makers, inclusion of opinion leaders or knowledge brokers 
in research planning), organisational and structural characteristics (facilities, 
resources, financial incentives), as well as personal and professional 
characteristics (skills, attitudes, experiences, tacit knowledge, clinical 
judgment)’(25, 86, 87).   
 
2 ‘Facilitators and barriers’ came from realist search strategy too – see Annex B 
51 
 
Finally, Straus et al(88) identified over 250 implementation barriers.  At the 
socio-political level, factors relating to the organisation and financing of the 
health system were found to affect the utilisation of HTA recommendations; at 
the healthcare organisation level, existing collaborations between the hospital 
and the HTA agency favoured the integration of recommendations into practice. 
Formalism in the organisation also influenced the utilisation of HTA 
recommendations; at the professional level, the high degree of autonomy of 
specialists, the importance of peers and collegial control, and the definition of 
professional roles and responsibilities influenced physicians' willingness to 
integrate HTA recommendations into their practice(80). Unlike other descriptive 
papers, Cheung et al(89) evaluated the relative importance of each barrier and 
facilitator.  Grouping by themes showed that ‘organisations and resources' and 
'policy characteristics' were the most important, with the recommendation made 
of motivation too to encourage positive attitudes toward its use. The less 
important groups were 'policy-maker characteristics', 'research and researcher 
characteristics' and 'contact and collaboration'.  A summary of some of the more 
frequently cited facilitators and barriers in the literature are listed below [Table 
2.3].      
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Table 2-3  Facilitators and barriers to the implementation of hta findings 
Barriers Facilitators 
Costs of implementation, resourcing and inflexibility of 
budgets and resources (22, 90-93) 
Learning through collaboration and exchange of experience; skills, 
ability (94); formal links between producers and users (42); 
Stakeholders are involved and support decisions (61, 95-98) with 
front line engagement, champions (22, 80, 91) 
Uncertainty, weak governance, political constraints (90), 
leadership (91) 
Timeliness (61, 96, 99, 100) 
Poor quality of communication and dissemination (61, 91); too 
few mechanisms to inform; user’s (mis)understanding(22, 99) 
Accuracy and validity(61, 94, 99); Evidence comes from a trusted 
source(93) 
 Relevance (22, 94-96, 99, 100) 
Other Factors Design of health system (90, 93) and broader organisational context (80, 94, 96, 101), including health information 
systems (102), payment mechanisms (90) and alignment of incentives and support from the top (61, 91) – as well as the interaction at 
the human level. Knowledge translation (96, 102). 
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2.4 Discussion 
There has long been a call for the evaluation of HTA organisations(103) yet, 
relatively little has been published.  As Garrido et al(78) state ‘the ultimate 
value of HTA in a health system depends on its contribution to improved health 
status or increased efficiency rather than to increased knowledge.  In this 
respect, HTA does not differ much from other health technologies and must be 
subject to the same rigorous standards of evaluation’.   Yet, much more was 
found on reviewing methods for measuring the impact of health research(104).  
We discuss the findings from the literature review as presented above in terms 
of HTA impact frameworks, country level evaluations and, facilitators and 
barriers to implementation leading to impact. 
2.4.1 HTA impact frameworks 
Each of the frameworks identified stated that they were developed to improve 
the accountability of public funds and to be able to evaluate the contribution, 
performance or impact of HTA bodies.  Jacob et al state that ‘(H)owever 
excellent an HTA may be, if it fails to influence the working of the health care 
system, it is without impact and must be considered without value (p. 69)’(49).   
On the other hand, Lavis(105) suggests that moving beyond impact on decision-
making to health, economic and social outcomes is best left to a focused 
evaluation of that specific intervention or policy: ‘Moving beyond decision-
making outcomes to health, economic and social outcomes, however, is almost 
certainly asking too much.  Research organisations simply want to know whether 
the research knowledge that they produce is having an impact on decision-
making.  Tracing the complex pathways though which informed decisions 
translate into improved implementation or performance and ultimately into 
better health is best left to stand-alone research initiatives.  The same can be 
said of economic and social outcomes’.   
There were a number of limitations in the frameworks found, reflecting the 
complex nature of the process of HTA as an intervention itself. There was little 
quantitative data and, from the impact evaluation studies retrieved and the 
findings of others, most evaluations to-date have made use of only qualitative 
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methods(71).  Wanke et al found the majority of responses they received from 
INAHTA members were qualitative in nature(53).   
The issues of a counterfactual and attribution were also lacking.  Wanke et al 
stated that attribution to HTA can only be partial regarding the acceptance, 
utilisation and impact of products; and that ‘Because the factors influencing 
population health status and the heath system are numerous, outcomes at these 
levels cannot, as a general rule, be directly attributed to HTA agencies or 
programs’(53).  Similar to our proposed framework [Chapter 4], RAND Europe 
used economic analysis to compare potential benefits with the costs, using 
illustrative case studies. In carrying out their evaluation, RAND Europe were 
required to make some assumptions, in particular, that the findings were fully 
implemented across the NHS and that the impact could be wholly attributed to 
the HTA programme(19).  RAND themselves state that many (mostly 
conservative) assumptions but one big (not conservative) assumption was made 
with limited formative value3.  Nevertheless, this gave a ‘headline’ number in 
terms of ROI. Assuming 100% implementation and full attribution of the 
outcomes to the HTA programme, they concluded that 12% of the calculated 
potential net benefit would cover the total cost of the HTA Programme from 
1993 to 2012.  Linking this from research for NICE to its recommendations, NICE 
have carried out audits of the implementation of its guidance(106) but the use 
of simple before-and-after measures, as applied there and by others too(71), 
does not provide a credible measure of uptake. 
Measuring impact on health outcomes was lacking.  Described as ‘ultimate HTA 
outcomes’ by Wanke et al(53), this looks beyond the impact of individual HTA 
outputs and explores the impact of HTA agencies’ mandate on the health status 
of the population or the health system in general(52).  The recommendations of 
a NIHR systematic review(107) support the continued use of the Payback 
Framework as proposed by Buxton and Hanney to measure the impact of health 
research(50, 55, 108).  The payback approach has been identified too as a key 
framework for measuring HTA impact(71).  The authors of the payback approach 
found that impact on health was the more challenging to quantify.  
Furthermore, no existing evaluations of HTA organisations’ impact on ‘health 
 
3 Presenter S Guthrie, RAND. ISPOR 20th Annual European Congress, Second Plenary Session 
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status’ or ‘health systems’ were found by Lafortune et al(52), and there was a 
dearth of literature retrieved under the category of impact on health status 
found by Wanke et al(53) [Figures 2.6 and 2.7].   
Following on from their impact framework, INAHTA has published a recent report 
(109) on the practices of HTA impact assessment in INAHTA member agencies 
with the aim of identifying strategies by which to support HTA agencies to 
improve their practice.  They define HTA impact assessment to be an evaluation 
of the uptake and the effects of an hta report.  They also distinguish between 
the impact of an HTA report and the impact of the agency.  All agencies were 
invited to participate in semi-structured interviews, with 26 out of 47 taking 
part.  Most reported that they had informal approaches to impact evaluation.  
Indicators of impact identified by participants could be grouped into five 
categories related to the report, the agency, the decision maker/policy, health 
system and outside the health system.  Methods of impact assessment included 
analysis of administrative data, interviews, surveys, audits and documents 
analysis.  It was found that linking impacts that exist ‘downstream’ from the 
HTA, such as change in clinical practice can be challenging.  For this reason, 
most agencies chose to measure impact on factors associated with the report 
and decision-maker – with some stating that their role is not to assess the 
impacts further downstream in the health system but rather to produce high 
quality and useful HTAs.  The second part of the study explored factors that 
inhibit or enable HTA impact activities.  The state that few methods and 
strategies have been developed for assessing HTA impact that could assist HTA 
agencies in understanding and measuring the uptake and influence of their work.  
Challenges in establishing a causal relationship between an hta and its impacts 
was noted, as was a reluctance by healthcare providers to open up about their 
uptake (or not) of the recommendations making data collection difficult.  In this 
same vein, Loblova(110) et al present the intrinsic value of HTA to be its focus 
on evidence and transparency - despite the absence of empirical evidence on its 
effects.  Indeed, others recommend that UHC will only be achieved through a 
transparent and participatory process and that states need to institutionalise 
priority setting with such bodies being accountable to their populations, 
government and the judiciary(111).   
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The OECD state that ‘(A)lthough there is scarce empirical evidence on the 
impact of HTA processes on efficiency and cost-containment in the health sector 
as a whole, HTA may be expected to generate overall efficiency gains primarily 
through its use for an evidence-based definition of the package of interventions 
publicly funded (and their specific reimbursement levels) within the health 
system.  On the other hand, the creation and operation of an HTA body adds 
another layer of administrative costs to the health sector and may increase 
expenditure related to the additional use of effective interventions’(48).  Budget 
constraints and a lack of funding was identified as a key reason for not investing 
in HTA according to a survey undertaken by the WHO in 2015(16).  Loblova et 
al(110) also highlight the upfront costs of establishing HTA systems which will 
potentially discourage LMICs from investing in these processes and agencies.   
In terms of our proposed framework [Chapter 4], Davies’ HTA model(51) most 
closely resembles this in that it similarly defines impact in terms of improved 
efficiency through the increased use of efficient health care interventions and 
decreased use of inefficient healthcare interventions which, in turn, is achieved 
through this facilitating change in practice.  A counterfactual is implicit only.  
Furthermore, Wanke et al(53) speak to our realist inquiry [Chapters 5 and 6] 
when they state that ‘because socio-political factors play such an important role 
with respect to HTA, evaluators of HTA agencies, particularly of impact, will 
need to consider contextual factors influencing the operation and success of the 
HTA agency/program’.   
2.4.2 Individual country level HTA impact evaluations 
The approach used by most countries was predominantly the payback method, 
employing qualitative and descriptive analysis using documents, interviews and 
questionnaires(105).   To-date, most evaluations of HTA have focused on outputs 
(number of HTA reports, for example) with methodological challenges being 
cited by some for not evaluating health outcomes(71).  A conceptual model 
developed for assessing the impact of HTA in the Austrian healthcare system(71) 
used multi-dimensional aspects of impact, namely, awareness, acceptance, 
policy process, policy decisions, clinical practice, outcomes and enlightenment 
based on indicators developed by Gerhardus et al(78) and Weiss’ theory of 
research utilisation(79).  This model did not address health outcomes due to 
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methodological limitations, and the authors make the recommendation that 
further research should address the methodology on how to improve impact 
measuring, in particular, the relationship between HTA and the overall 
improvement of health (care systems). 
Denmark, yet to carry out a full impact evaluation, stated that the 
implementation of HTA results will be one of the greatest challenges of the 
years ahead(73).  When agencies are funded publicly, some evaluation of impact 
is obviously desirable even if, in practice, such evaluations are often extremely 
difficult to carry out.  However, ‘failure to make any attempt to assess the 
impact of HTAs is clearly inconsistent with the concept that decisions should be 
evidence-based’(49).  HTA agencies do recognise the need to think about 
implementation and impact as illustrated by the INAHTA report(109) and, in 
particular, CADTH, Canada in its strategic plan 2018-2021 reported: ‘There is 
significant variability in the uptake of health technology assessment 
recommendations at the policy level compared with clinical practice, and gaps 
in the resources and capacity required to make better use of evidence…we will 
engage in a forensic analysis on why sound evidence is ignored or contradicted 
by policy and in practice’.   Indeed, ‘the limited number of studies following 
change in clinical practice and health outcomes indicates that these areas need 
much more attention in the future.  Quality registers and clinical databases are 
growing rapidly around the world and they could be very useful tools for 
analysing the influence of HTAs’(112). 
2.4.3 Facilitators and barriers to the uptake and impact of HTA 
Only when HTA findings and decisions result in implementation and practice 
change, can better health be achieved.  Yet, we know that implementation of 
HTA findings and decisions are variable(19-23).  We come back to facilitators 
and barriers in the realist synthesis which employs the use of theory to offer 
greater explanatory power with regard to uptake.  The importance of studying 
theories underlying different approaches to implementing guidelines and 
changing practice is highlighted by Grol(113) who groups theories in terms of 
educational, epidemiological, behavioural, social interaction, organisational and 
coercive approaches(113). 
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Supply-side constraints relate to the health system, costs of implementation, 
system interactions, uncertainty, weak governance and politics - as well as 
demand-side responses by patients.  The implementation of recommendations 
depends on the type of technology, how funding is tied, professional 
engagement, quality of HTA reports and dissemination and implementation 
strategies, or lack thereof (41, 42, 84, 90, 114-116).  Facilitating factors to the 
implementation of HTA findings set out by Haan and Rutten(117) cited in(118), 
are divided into regulation by directive and regulation by incentive.  
Government policy, administrative arrangements and organisational structure 
can be described as contributing to the context in which decision-making is 
carried out(39).  For the translation of decisions into action, the decision-maker 
will need to have access to effective policy or administrative instruments, with 
the will and power to use these.  Such supporting structures may include 
provider payment, regulation, education, patient empowerment and effective 
leadership.  This interaction between context and mechanism is explored further 
in our realist synthesis [Chapters 5 and 6]. 
2.5 Conclusion 
This review has established a lack of existing evidence and methodology on how 
best to measure, value and quantify the impact of HTA.  The frameworks 
retrieved illustrate both the dearth of literature on health impact and 
limitations with existing methodology to measure this.  We found some examples 
of evaluations of HTA agencies in a range of countries and, whilst useful and 
encouraging in their own right, are mostly only descriptive in nature.  None 
consider what would have happened anyway ie without the HTA process.  A 
comparison group (a counterfactual) enables us to estimate changes in outcome 
that can we can attribute to an intervention, here the HTA process.  A 
comparator is crucial to impact evaluations as without this, it can lead to 
erroneous measures and conclusions of impact with attribution which could be 
wrongly assigned or interpreted.  Similarly, none consider the opportunity costs 
of investing in HTA or attempt to show whether resources are used efficiently.  
Financial benefit is generally presented as cost savings.  This is a narrow 
interpretation of the role of HTA which aims to ensure an efficient use of 
resources as distinct from being simply a cost-cutting exercise. 
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We found many articles listing facilitators and barriers to the uptake of HTA 
decisions.  Only when HTA decisions or recommendations are implemented, does 
this translate into impact on health.  Rather than duplicate this work, we re-
analyse this literature using a realist perspective to produce greater explanation 
as to how and why hta decisions and recommendations are implemented 
[Chapters 5 and 6]. 
2.6 Next steps 
Given this lack of evidence and methodology in the literature, we have 
developed a mixed-methods framework to quantify the value of HTA and 
consider the opportunity costs of establishing HTA processes but which are often 
overlooked.  The focus of our framework is to go beyond ‘intermediate’ 
outcomes as to how informed decisions translate into improved implementation, 
ultimately leading to impact in terms of health gains.   Our impact framework 
and, how it adds to the literature discussed above, is presented in Part 2. 
First, we discuss the nature of causality.  Impact evaluations address what the 
difference is between what happened with an intervention, and what would 
have happened without it.  The lack of establishing this in evaluating the impact 
of HTA is a methodological challenge that does not yet appear to have been fully 
addressed.  We discuss philosophical and methodological issues regarding 
causality, the different ways of thinking about this, the nature of its 
measurement and the challenge it presents in the design of impact evaluations, 
especially of complex interventions such as HTA.   
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3 Methodological and philosophical issues 
regarding causation  
3.1 Introduction 
‘The narrow goal of evaluative research is to identify the causal impact of an 
intervention on outcomes of interest.  The broader goal is to understand the 
mechanisms underlying this impact’(119).  An impact evaluation provides 
information about the impacts produced by an intervention - positive and 
negative, intended and unintended, direct and indirect.  This means that an 
impact evaluation must establish what has been the cause of observed changes 
referred to as causal attribution.  Without this, evaluations risk making false or 
assumed attributions that may produce incorrect findings(120).  In complex 
interventions and contexts, the attribution challenge can also limit the outcomes 
chosen for evaluation, with the evaluation stopping at knowledge or practice 
outcomes, thus missing opportunities to measure patient or health outcomes – as 
was apparent in the literature review on HTA impact [Chapter 2].  In this 
chapter, we describe how we address the challenge of causality and the 
counterfactual which are fundamental to understanding and measuring impact.   
Drummond et al(121) discuss the conceptual and methodological challenges 
associated with benchmarking HTA and highlight that the key question is 
whether HTA has improved healthcare provision.  However, they recognise that 
assessing the improvement in healthcare provision is challenging because of the 
difficulty in specifying the counterfactual(121).  Whilst one study found HTA to 
be cost effective in terms of controlling a rise in health care spending and 
achieving better health outcomes in life expectancy and mortality in HTA versus 
non-HTA countries, correlation versus causality could only be considered(122).  A 
study on cancer drugs looked at whether the addition of a complementary HTA 
and cost-effectiveness evaluation increases the value realised by the drug in 
practice compared to how it would be used without these assessments(24). This 
is one of the few studies found addressing the counterfactual in HTA.   
We consider first the ontology (nature of reality) and epistemology (nature of 
knowledge) of different paradigms to ‘causation’ and their implications for ‘the 
counterfactual’.   ‘What we consider to be ‘real’, what we can know about it, 
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how we might go about valuing it, and how we think programmes or policies 
cause change – are fundamental questions for evaluators.’ (123) Different 
philosophies make different assumptions about how things are caused.  Gates 
and Dyson(124) state that evaluators ought to consider the relevance of 
different ways of addressing causality and lay out five ways of thinking about it: 
‘1) a successionist framework that underlies regularity and counterfactual logics; 
2) narrative stakeholder accounts; 3) generative accounts of processes and 
mechanisms; 4) causal packages and contributory accounts; and 5) nonlinear, 
multidirectional and dynamical accounts of relations as found in complex 
systems’.   We will look at these in more detail, in particular, successionist and 
generative causation. 
Secondly, given we cannot assign ‘treatment’ – in this case, HTA (or, indeed, an 
hta) - randomly and compare with ‘no treatment/no HTA’ in order to provide 
internally valid estimates of effectiveness, a counterfactual needs to be 
created.  We discuss potential ways to construct a counterfactual drawing on 
quasi-experimental methods. 
Finally, we discuss the use of theory driven evaluation to understand the 
mechanisms underlying or driving this impact.  We commit to the idea that the 
reality of health systems is complex (different perspectives exist in systems, 
outcomes are produced by many factors interacting together in an ever-changing 
way, and the systems themselves are outside the control of any one actor in it). 
This is our underpinning for a theory-driven approach, and it this translational 
gap between impact and what happens in practice that has led to calls for the 
greater use of explicit theory in research.  Here, we employ realist inquiry - a 
complementary approach to the iDSI Theory of Change [see Chapter 1] - to build 
theory in order to better understand what it is about context that promotes or 
inhibits uptake and adherence to HTA decisions (as it is only when those 
decisions are implemented, do we have any impact on health outcomes).  In so 
doing, we aim to offer a generalisable framework that could be applied across 
different settings.    
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3.2 Ontology and epistemology 
Ontology deals with the nature of reality and is associated with the key question 
of whether social entities should be perceived as objective or subjective.  
Accordingly, objectivism (or positivism) and subjectivism can be specified as two 
important aspects of ontology.  Epistemology is the theory and logical analysis of 
knowledge.  Table 3.1 lists perspectives on knowledge which reflect different 
views of reality(125).   
Table 3-1  Perspectives on knowledge  
Wholly objective, established by deduction Rationalism 
External to individual, objective and independent of 
social actors. It is discovered or verified by empirical 
means or through experience. 
Empiricism/ 
positivism 
Objective, exists independently of human thoughts and 
beliefs or knowledge or their existence (realist) but is 
interpreted through social conditioning (critical realist). 
Realism 
Subjective, reflecting personal experiences and values. Interpretivism 
Constructed and reconstructed by the individual Constructivism 
Adapted from ‘Access learning in health profession MED5392’ (Week 1), Univ. of Glasgow. 
The above table implies five schools of thought regarding causation.  This 
includes the positivist tradition which rejects unobservables; Popper’s 
Falsification where theories have falsifiability or refutability if there is the 
inherent possibility that they can be proven false; reductionists who view 
multiple causes at different levels down to the micro mediation level; and 
critical realists (CRs) who assume that causal relationships exist outside of the 
human mind and that these valid causal relationships cannot be perceived with 
total accuracy by our imperfect sensory and intellective capacities.  CRs also 
assume causes that we can do something about are the most useful even when 
the ultimate micro level is not known.   
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Similarly, as stated above, Gates and Dyson lay out ways of thinking about 
causality(124) —successionist, narrative, generative, causal package, and 
complex system.  Whilst Table 3-2 presents these as distinct approaches, the 
authors note elements and assumptions of each are often mixed in 
methodological approaches.   
Table 3-2  Ways of Thinking about Causality 
 
Source: Reproduced from Gates E, Dyson L. Implications of the Changing Conversation 
About Causality for Evaluators. American Journal of Evaluation. 2016;38(1):29-46(124) with 
permission from SAGE Publications. 
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We discuss here empiricism and realism as two of these different paradigms we 
adopt in our impact framework. 
Empiricists are aligned to the natural sciences and are generally positivists who 
believe knowledge is external to the individual and can only be discovered by, 
and verified by, empirical means.  The premise of ‘causation via succession’ is 
held which is based on the assumption that causation can be determined from 
high volume correlation of observables(126).  Successionist causation is about 
the description of outcome patterns ie whether something has an effect, not 
why(127).  Successionist causation is about variables and their association; it is 
variables that do the explanatory work. 
Realists also believe in the existence of an independent, external world but 
acknowledge that it may not be possible to verify every aspect of that world 
(125).  Their critique of positivism is that this cannot portray the mechanisms 
and contexts that generate social behaviour.  The explanatory analytical process 
in realist evaluation is based on generative causation which is the assumption 
that underpinning hidden (in the sense of being below the threshold of 
observability and empirical measurement) mechanisms are responsible for the 
manifestation of observable outcomes.  Realists see the quest to achieve control 
in randomised trials is ‘to squeeze out of the picture precisely those mechanism 
and contexts that are required in understanding whether a programme 
works’(128).  As generativism is ‘designed to utilise mechanisms and contexts to 
explain outcome patterns, it provides the most complete approach to causal 
explanation. Because explanation trades in peoples’ choices and societal 
constraint, it calls on the full repertoire of social research to provide supportive 
empirical data’(128). 
Mahoney et al(129) summarise key aspects of ‘causation’ for these two 
paradigms, identifying three fundamental differences that are related to 
paradigmatic differences in the treatment of causation between post-positivist 
and realist logic: (1) the construct of mechanism, (2) the relation between 
mediators and moderators on one hand and, mechanisms and contexts on the 
other hand, and (3) the variable-oriented approach to analysis of causation 
versus the configurational approach.  Table 3-3 outlines the distinction made 
between correlation analysis and causal analysis.  While the former ‘involves 
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identifying antecedents regularly conjoined with outcomes, causal analysis 
consists of identifying the mechanism that underlies and generates empirical 
regularities and outcomes’(130).  Indeed, generative analysis aims to explain 
why correlations exist. 
The ‘issue of causality in evaluation is complicated by the lack of agreement in 
philosophy of science about the nature of causality and broader disagreements in 
the social sciences about how causal claims ought to be warranted’(124).  It is 
recommended that evaluators be ‘literate in multiple ways of thinking about 
causality, be familiar with a range of causal designs and methods [Table 3-4] 
and, layer theories to explain causality at multiple levels’(124).  We look at 
firstly, quasi-experimental methods and secondly, theory-based approaches in 
more detail as used in our impact framework. 
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Table 3-3  Successionist and generative definitions of mechanisms 
 
Source: Adapted from Mahoney J. Beyond Correlational Analysis: Recent Innovations in Theory and Method. Sociological Forum. 2001;16(3):575-93(130) 
cited in Van Belle S, Wong G, Westhorp G, Pearson M, Emmel N, Manzano A, et al. Can "realist" randomised controlled trials be genuinely realist? Trials. 
2016;17(1):313(129). Use of this image is supported by the Creative Commons CC BY https://creativecommons.org/licenses/. 
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Table 3-4  Range of Causal Designs and Methodologies 
 
Source: Reproduced from Gates E, Dyson L. Implications of the Changing Conversation 
About Causality for Evaluators. American Journal of Evaluation. 2016;38(1):29-46(124) with 
permission from SAGE Publications. 
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3.3 Positivism  
Successionist or ‘positivism’ has been the dominant framework for thinking 
about causality and is underpinned by the logics of regularity and the 
counterfactual(124).  We describe positivism in relation to the ‘counterfactual’ 
and the use of quasi-experimental methods to construct this.  
3.3.1 Causation by counterfactual 
The core principle of experimental/quasi-experimental methods is that there is 
a ‘counterfactual’ ie observed outcomes from a ‘control’ group that did not 
receive the intervention which can be compared to outcomes from the 
intervention group.(131)  Regularity purports there is a statistical and temporal 
relationship between X and Y; and the counterfactual requires making a 
comparison between two highly similar situations to estimate what would have 
happened in the absence of the intervention.   
However, a research design such as a randomised controlled trial (RCT) is not 
suited to the evaluation of many complex or policy interventions, including HTA, 
as the assignment of individuals to ‘HTA’ or ‘no HTA’ is beyond our control, and 
it is consequently, a non-randomised evaluation.  Alternatively, ‘the simplest 
approach is to choose a control area similar to the area where the intervention 
is being introduced, and compare outcomes in the two areas. The key difficulty 
is finding a control area sufficiently similar to allow outcome differences to be 
attributed to the intervention. Statistical methods of adjustment for differences 
between the areas are limited by the availability of data, and often cannot fully 
account for all the relevant differences’(132).  
3.3.2 Quasi-experimental methods 
Quasi-experimental methods are used in such scenarios above to mimic this 
counterfactual.  There are different approaches as to how to do this dependent 
upon the data available.  Individual level data allow for methods such as 
Regression Discontinuity Design (RDD) to be used where the intervention is 
allocated on a cut-off point in a continuous variable; or the use of Instrumental 
Variables (IV) where a variable is found which predicts treatment allocation but 
is not correlated with outcomes.  Similarly, matching treatment and controls on 
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selected individual characteristics or scoring them on a combination of variables 
using propensity scores is applicable here.   A simple before-and-after 
comparison is one of the weakest forms of design in terms of providing a 
credible measure of effect.   Interrupted time series (ITS) which applies 
regression methods to capture time trends, provides a more credible measure.   
The most basic ITS design requires one experimental group and multiple 
observations before- and after a treatment.  The outcome before the 
intervention is used as a ‘counterfactual’ ie there is an assumption that without 
the intervention the outcome would have remained the same or followed a 
consistent trend(133, 134).  
To overcome lower internal validity associated with such quasi-experimental 
methods, the use of multiple designs are usually recommended to strengthen the 
credibility of results(134).   As ITS makes it difficult to account for observed and 
unobserved confounding factors, it is common to add time series data from a 
non-equivalent comparison group over the same period thus creating a 
comparative ITS (CITS) design(134).  The simplest CITS analysis entails a 
difference-in-difference estimate where the difference between the pre- and 
post-intervention means in the comparison group is used as the counterfactual 
against which the mean difference in the treatment group is evaluated.  As such, 
difference-in-difference additionally brings in an untreated control group and 
compares the temporal changes in the treated group in the intervention area to 
those of the control/untreated group over the same period in the control area. 
This method cannot, however, take account of area-specific trends, ie changes 
other than those attributable to the intervention that occur in one or other of 
the areas(132).  The key assumption for a difference-in-difference design is that 
outcomes in both groups would follow parallel trajectories over time in the 
absence of an intervention.  
Where this assumption does not hold, a synthetic controls approach can instead 
be used.  The synthetic control method attempts to overcome this problem by 
comparing the trend in the outcome of interest in the intervention area with the 
trend in a synthetic composite area.  This uses information on pre-intervention 
levels on the outcomes of interest and predictors of those levels in other 
‘unaffected’ areas, for example, other states or districts where the intervention 
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is not being implemented (which form the ‘donor pool’) and which are then used 
to derive the synthetic control(132).  The control is the weighted average of all 
the areas in the ‘donor pool’ that best mimics the pre-intervention trend in the 
intervention area. The effect of the intervention is then estimated as the 
difference between the post-intervention trends in the intervention area and the 
synthetic control area(132).  Thus, in more complex CITS analyses, the means 
and slopes of the pre-treatment values are used to assess not only changes in 
mean levels but also changes in trend, in the variation around these trends or in 
the pattern of temporal variability(134).  History can also be examined and the 
construct validity of the effect enhanced by collecting time series data for some 
dependent variables that should be affected by a treatment and for others that 
should not(133).  
These quasi-experimental methods are summarised in Table 3-5 along with 
examples of their use in evaluations in healthcare.  We draw on ITS to provide a 
more credible measure of uptake of a technology following an hta [Chapter 4].  
Alternatively, we could simply model scenarios, along with a distribution, to 
represent a counterfactual level of uptake.   
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Table 3-5  Quasi-experimental approaches to dealing with the counterfactual 
Approach Method of dealing with 
confounding 
Limitations Example of use of quasi-exp. 
method in health 
Interrupted time series 
Uncontrolled pre- and post-
approach – the outcome before the 
intervention is used as a 
‘counterfactual’ ie there is an 
assumption that without the 
intervention the outcome would 
have remained the same or 
followed a consistent trend.  
Controlled pre- and post-approach 
– the evaluation includes looking at 
the before and after intervention 
outcomes for another area (the 
‘control area’) where the 
intervention did not take place. 
Both measured and 
unmeasured confounding are 
addressed providing the main 
characteristics of the group 
studied remain broadly stable.   
The similarity in 
characteristics between the 
control area and the 
intervention area should 
minimise bias. 
The changes before and 
after the implementation 
of an intervention may be 
due to the underlying 
trend rather than the 
effect of the 
implementation.  Over the 
medium and long term, 
the characteristics of the 
study group may change. 
It is often difficult to 
identify a unit that is 
sufficiently similar to the 
treated unit.  
Sheldon Trevor A, Cullum Nicky, 
Dawson Diane, Lankshear Annette, 
Lowson Karin, Watt Ian et al. 
What's the evidence that NICE 
guidance has been implemented? 
Results from a national evaluation 
using time series analysis, audit of 
patients' notes, and interviews BMJ 
2004; 329 :999 (135). 
NICE use ITS in one of its ERNIE 
Database reports #40 [see Annex C] 
72 
 
Difference in difference (DiD) 
approach – this method is a version 
of the before and after approach 
with comparator where control 
group is included in the statistical 
analysis. 
Synthetic controls methodology – a 
counterfactual is synthesised using 
a formal statistical approach from a 
pool of potential controls using 
characteristics thought to be 
associated with the outcome.    
Provided that the outcome 
trends are parallel in the pre-
intervention period in the 
intervention and control 
groups, the analysis will 
eliminate unmeasured 
confounding that does not 
vary over time.  The weighting 
of controls in the synthesised 
control is determined by a 
requirement to closely match 
the pre-treatment outcomes 
in the intervention area.  This 
weighting is applied to 
outcome data over time.  
Unmeasured confounding can 
be minimised even if it varies 
over time.  
The approach suffers from 
the same limitations 
identified above with 
regard to similarity of 
characteristics.  The 
parallel trends assumption 
is often not met. 
It is important that the 
characteristics of the units 
selected as potential 
controls should be similar 
to the treated unit. 
Consider constructing synthetic 
controls especially in countries 
where HTA recommendations are 
at a sub national / state level, for 
example, China. 
Lepine A et al. Free primary care in 
Zambia: an impact evaluation using 
a pooled synthetic control method. 
2014.   Abadie, A et al. Synthetic 
Control Methods for Comparative 
Case Studies: Estimating the Effect 
of California's Tobacco Control 
Program. 2010 (136, 137). 
Source: Adapted from Bouttell J, Craig P. University of Glasgow(132, 138).
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3.4 Theory-based evaluation 
Theory-based impact evaluations draw conclusions about an intervention’s 
impact through rigorous testing of whether the causal chains thought to bring 
about change are supported by sufficiently strong evidence and that alternative 
explanations can be ruled out(131)  Theory-based evaluation is explicitly 
concerned with both the extent of the change and why change occurs; ‘it tries 
to get inside the black-box of what happens between inputs and outcomes (and 
outcomes and impacts) and how that is affected by wider contexts’(131).  The 
theory here can be thought of as ‘a set of assumptions about how an 
intervention achieves its goals and under what conditions’(124).  It can derive 
from ‘formal, research-based theory or an unstated, tacit understanding about 
how things work’(139).  Theory-based evaluation makes causal claims by 
considering ‘causal mechanisms’ and the contextual circumstances in which 
these mechanisms operate(124).  As macro-social structures or systems are not 
amenable to being examined by experimental methods, researchers have 
adapted a ‘theory of change’ perspective developed by the Aspen Institute in 
the USA(140) and Pawson and Tilley’s ideas of ‘realistic evaluation’(141).  This 
new conceptualisation of programme theory introduced by Pawson and 
Tilley(139) has become increasingly used in the evaluation of complex 
interventions in health.  These are described below as two examples of theory-
based approaches, and upon which our impact framework draws. 
3.4.1 Theory of Change 
Theories of change (ToC) is about the identification and confirmation of causal 
processes – an explanatory pathway of change(139).  Developed by the Aspen 
Institute(140), it is process orientated as it follows the pathway of a programme 
from its initiation through causal implementation links (to explain how and why 
the desired change is expected to come about) until intended outcomes are 
reached.  The ToC is developed through collaborative stakeholder engagement.  
It requires measurement along the pathway of all that must be achieved before 
the long-term outcome. 
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3.4.2 Realism 
Realism makes a particular set of assumptions about programmes and the nature 
of reality, causality and evidence.  Firstly, realists hold that interventions are 
‘theories in action’ and work through introducing new ideas or resources into 
existing social systems – and in so doing, change the conditions that shape 
decision making and behaviour.  Secondly, regarding causality, outcomes are 
caused by mechanisms – they are the choices, actions, reasoning that people 
make as a result of the resources a programme provides (for example, 
expertise/information).  Mechanisms are triggered when programme resources 
interact with context (institutional, organisation, individual).  Thirdly, realism is 
methodologically pluralist, and any relevant evidence can used to test 
theories(128). 
Influential thinkers and critical realists who have influenced the realist approach 
include R. Bhaskar (1975, 1978), M. Archer (1995) and A. Sayer (1984, 
1992)(133). Proponents of critical realist evaluation have argued that the central 
question is not so much whether certain interventions work in a generalisable 
way but what will work with these stakeholders/actors in this setting at this 
time.  This shifts the focus of evaluation of interventions from a programme-
based view of what works to causal pathways(142)…and to recommendations and 
policy-making that is founded in locality and practice supporting the argument 
that policy-making should be devolved from national governments so it is 
informed by practice locally.  Critical realism makes a distinction between the 
real (underlying nature and causal powers of objects/agents), the actual (what 
happens if/when those powers are activated), and the empirical (what is 
experienced/observed). This distinction is central to an ontological conviction 
that there exists a reality distinct from, and greater than, the empirical and that 
this reality is comprised of structures and mechanisms independent of our 
perceptions.  Mechanisms can coincide under real world conditions to produce 
emergent properties in time and space.  This notion of contingency contrasts 
with positivist notions of universal logical necessity by highlighting that 
propositions may hold true only under certain circumstances(142).  Context is 
key.  Whilst empiricism/positivist approaches purport that we should just stick 
to the observable reality, the critical realist approach is that we have to accept 
we are limited in our perceptive faculties; that there is more to the story, and 
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our perceptions are always limited.  Influenced by critical realists, Pawson(128) 
compares causation in different groupings as follows.  
Successionists – identify causal agents as variables and seek to observe 
associations between variables by means of experimental / non experimental 
data.  Explanation or causation is about distinguishing between associations that 
are real as opposed to spurious.  As discussed above, this relates to employing 
experimental (or quasi-experimental methods in the absence of randomisation) 
in order to obtain a credible empirical measure of effect. 
Configurationists – similar to above but using non experimental methods, it 
promotes approaches that use a variety of microdata sources, statistical 
methods and behavioural models to compare the outcomes of participants in 
social programs with those of non participants(127).  Possibly relates to 
econometric methods. 
Generativists – similarly, they look for measurable patterns and uniformities but 
it is assumed these are brought about by the action of underlying mechanisms 
which are not variables or attributes, and thus not always directly measurable.  
Rather, they are processes describing human actions.  Emergence of social 
uniformities is highly conditional and causal explanation is about producing 
theories of the mechanisms that explain both the presence and absence of the 
uniformity.  The key explanatory tool is the generative mechanism which is able 
to elucidate some of the reasoning and resources and restraints that lead to 
action.  We discuss this in more detail below. 
3.4.3 Generative Causation 
What distinguishes realism is its particular understanding of how causation works 
(143). Realism relies on generative causation, a theory-based explanation of how 
causal processes happen.  Generative explanation is pursued by creating and 
testing theories(128).  It assumes multiple possible causal pathways linking an 
intervention to any outcome which will hold for certain people in certain 
conditions(124).  The addition of a realist theory informed approach is that it 
seeks to explain why interventions work rather than simply to establish 
attribution(144).  Causal powers are ‘understood as potentials or processes 
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inherent in the system studied and processes of reasoning’(128).  We assume 
that there is something about A (inherent powers, mechanisms) that is the 
actual causal force, and that those inherent powers or mechanisms of A were 
activated in conducive contexts.  Realism sits somewhere between positivism 
and constructivism, ‘closer to post-positivism in ontology; closer to some forms 
of constructivism in epistemology.’ (143)  
Thus, realism proposes alternatives to ‘causation via counterfactual’.  Whilst the 
concept of temporal precedence is associated with successionist causation and 
explanation is seen to be located in the variables and ‘attributes’(145) in 
realism, causality concerns not a direct relationship between two observable and 
discrete events but a relationship between ‘the causal powers or liabilities of 
objects or relations, or more generally, their ways-of-acting or mechanisms and 
the outcomes of those mechanisms’(146).  Furthermore, typically in empirical 
research, variables are aspects of reality that are abstracted quantitatively to fit 
into numerical analysis.  Realist inquiry using generative causation is different as 
this narrowly defined quantified data may not have enough explanatory power to 
provide insight into the causal powers of an intervention.(145)   
3.5 Discussion 
Our proposed impact framework employs both empiricism and realism to address 
both complexity, and the measurement and attribution of impact.  It could be 
argued that the aim of theory driven approaches is not to provide definitive 
evidence that the entirety of any measured change can be attributed to an 
intervention(131, 144).  Causal inference is, however, also an important part of 
theory-driven evaluation in order to be able to draw conclusions(147).  Paying 
attention to congruency, counterfactual comparisons, and critical review can 
significantly improve the quality of causal inference(147).   
There is a lot of debate and controversy about combining realist approaches with 
RCT design or quasi-experimental methods(148, 149).  How congruent or not a 
counterfactual is to realist thought is a matter of recent debate due to the 
potential conflation of ‘successionist’ and ‘generative’ causation as RCTs and 
quasi-experiments attempt to isolate cause to that of the intervention alone by 
controlling out context, namely the very things that realists view to be key in 
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explaining an intervention’s success or value(150).  The strength of a realist 
approach is its ability to examine interventions and their outcomes in their 
contexts, irrespective of what form the data are in.  The potentially 
'contentious' issue is that we propose mixing (quasi-) experimental ie positivist 
methodologies to derive data (on average effects) within a realist evaluation 
which works by identifying and explaining differences in effects(151) and which 
is critical of such ‘successionist’ approaches to causation as they supposedly 
ignore the complexity of social causation.  For example, the concept of 
mechanism is used across both paradigms but realists use the term in tandem 
with ‘generative causation’ and ‘ontological depth’ as opposed to from an 
empirical successionist perspective (ie experimental design, dose-response, 
empirically measurable etc)(152).  However, we are of the opinion that it 
matters less how the data were generated, we are sense making about why and 
how outcomes are produced so that our epistemology is still in keeping with 
realism. 
Quasi-experimental methods more likely to be suited to the evaluation of HTA is 
the application of those which would enable us to find variation in uptake or 
implementation of hta decisions over time, and where aggregated (as opposed to 
individual level) data suffice.  ITS is particularly useful when an intervention is 
implemented at population level and when there is a clear time point of 
introduction.  Such methods would allow us to explore any temporal change of 
the uptake of a technology following an hta, using either uncontrolled or 
controlled pre- and post- measures.  This quasi-experimental approach would 
ask does HTA have an effect/impact which, in turn, we quantify as NHB in our 
proposed framework (Chapter 4). 
However, there are limitations to quasi-experimental methods.  A major threat 
to internal validity with most single time series designs is the possibility that 
forces other than the intervention came to influence the dependent 
variable(133).  Another threat is how data are classified, requiring a constancy 
of definition that the data may not always reflect(133).  Seasonal variation also 
needs controlled for if known.  Delayed effects are also difficult to interpret 
especially if there is no theoretical specification of how long a delay should 
elapse before an effect is expected(133).  In this regard, no treatment control 
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groups are generally indispensable(133).  Questions can be also raised about 
external validity, for example, would the same results be obtained in another 
country?  Contextual causal factors are likely to be at play other than just the 
intervention – and this is where we propose theory-driven approaches will help 
with providing greater explanatory power.   
To this end, whilst both realism and ToC attempt to understand the role of 
context (albeit in slightly different ways), rather than attempting to exclude 
contextual influences through controls(153), we have chosen to use realist 
inquiry as complementary to the ToC approach taken by iDSI.  Combining TOC 
with RE can be useful(153).  Both help researchers to think through sets of issues 
but ToC does not usually address mechanisms, and its strength is the level of 
detail which help to identify how it may apply or differ in a new context.  In 
realism, the power of the approach is not in the detailed understanding of entire 
programmes but rather the opportunity to ‘cumulate’ specific Context-
Mechanism-Outcome Configurations (CMOC) [Chapter 5] across different 
programmes since similar processes of generative causation may apply across 
different policy areas(153, 154).  Moreover, ToC approaches can provide an 
analysis of programme theory within which realist approaches can be employed 
to examine the role of particular causal mechanisms and the contexts within 
which they operate to generate outcomes(153, 155).   
Finally, it is worth stating that much of this resonates with some economists 
(see, for example, Tony Lawson) who work the ideas of critical realism into 
economics(156) and whose social ontology is concerned with understanding 
society (what it actually is) before proposing and measuring the effect of 
interventions.  They reject the neoclassical conception of society as consisting of 
atomistic independent agents interacting in the rational (mechanical) manner 
envisaged by Walrasian general equilibrium models(157).  Society has to be 
understood as more than just the sum of its parts.  They are essentially 
interdependent, with the concept of ‘emergence’ recognised where components 
of a system interacting together may produce effects qualitatively different to 
what they could alone(157).  Lawson critiques mainstream economics for relying 
predominantly on (mathematical) predictions in economics despite repeated 
failures and that the underlying theory behind these models of ‘rational 
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behaviour’ is flawed and not reflective of the real world.   Indeed, John Maynard 
Keynes observed that economics was to understand how results were ‘generated 
through the behaviour of real human agents, facing an uncertain future and 
operating under existing institutional conditions, agents whose actions are 
motivated by hopes, fears, expectations..’(157).  Their social ontology is such 
that macro-micro interaction be brought into economics to more appropriately 
take account of the nature of social reality.  We should give up any attempt to 
explain macroeconomic phenomena simply in terms of ‘micro foundations’ - the 
reality is that they cannot explain everything (for instance, the paradox of thrift 
/ fallacy of composition - what is true of the individual's action is not true of 
that of the whole group)(157).  Also causation may run from the general (macro) 
to the micro - crowd psychology determining individual behaviour(157) ie there 
is a causal power that emerges from social structures which cannot be reduced 
to explanations at the individual level.   
3.6 Conclusion 
In the literature retrieved on HTA impact evaluations (Chapter 2), the 
counterfactual is often acknowledged but disregarded as being too challenging 
to establish given the difficulty of observing what would have happened anyway 
without the HTA process.  As randomisation is infeasible by the nature of our 
intervention, we conceive our drawing upon quasi-experiment methodology, as 
well as involving an attempt to understand the generative mechanisms entailed 
in the intervention, its natural and social context, and those possessed by the 
actors involved, will provide greater ontological depth.  We take a complexity-
informed approach, acknowledging that we cannot control the agency of those 
who implement.  So that, in addition to measuring impact, we believe a realist 
approach could be fruitful.  In our framework, we employ these different 
methodological approaches which offer alternative interpretations to causation.  
Exploring how these successionist and generative paradigms may work in tandem 
is a novel aspect to this research(158). 
3.7 Next steps 
Our methodological HTA impact framework, a key output of this research, is 
presented in Part 2.    
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Part 2: Conceptualising, measuring and valuing the 
impact of HTA. 
The objective of Part 2 is to present the mixed methods HTA impact framework 
including the quantitative ROI and the realist review (or synthesis) and to 
illustrate the contribution it makes to the current literature on conceptualising, 
measuring and valuing the impact of HTA.  Our framework aims to quantify 
impact in terms of a Net-Health Benefit Return on Investment (NHB-ROI) but 
this, of itself, offers little explanatory power.  Hence, the realist synthesis – a 
theory driven approach - to unearth how favourable conditions are created for 
the uptake of hta decisions as efforts to rationalise the use of resources are only 
valuable if recommendations are implemented in practice ie everything we are 
focusing on here is a step on from HTA dissemination.   We choose a realist 
synthesis as a complementary and congruent approach to the iDSI ToC in 
explaining how HTA is impactful.  Implementation is context specific, and 
realism as an approach to developing programme theory is particularly relevant 
because it focuses specifically on the influence of context as causal mechanisms 
are activated only in favourable conditions.   This second part comprises 
chapters 4 - 6 as described below.  
Chapter 4: presents our NHB-ROI Framework for quantifying the impact HTA and 
how it addresses limitations discussed in Chapters 2 and 3.  We believe this is 
important as a lack of, in particular, longer-term impact assessment, may 
undermine the importance and value of HTA.  We describe our mixed methods 
approach to quantify the value of investing in HTA as well as to explain how 
outcomes and impact is achieved.  This framework addresses one of the most 
overlooked yet, one of the most critical aspects of evaluation, namely the 
opportunity costs associated with the capital investment and ongoing running 
costs required to sustain an HTA infrastructure at the systems level(37).  If we 
think priority setting should be better informed by evidence, and use tools such 
as HTA, this necessarily implies institutional change to establish a sustainable 
system.  Consequently, we have to consider the opportunity costs which are 
needed for its establishment and ongoing running(38).    
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Chapter 5 is the realist protocol describing our proposed process of theory-
building and refinement.  In adopting a realist perspective, we treat the process 
of HTA as a complex intervention in itself but also as one that is introduced into 
existing complex systems and contexts.   
Chapter 6 is the realist review.  A realist review is a theory-led approach to 
knowledge synthesis that provides an explanatory analysis aimed at discerning 
what works, for whom, in what circumstances, how and why.  Analysis of all 
data retrieved was undertaken using realist evaluation principles of extracting 
CMOC of variables at play, and iterative, participative and collaborative 
approaches to interpretation.  
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4 The Impact of HTA: a Net Health Benefit-Return 
on Investment Framework 
4.1 Introduction 
In this chapter, we present the quantitative part of our HTA impact framework 
which uses quantitative data to capture an empirical and credible measure of 
uptake (or stopping) of a technology following an hta recommendation.  This is 
interlinked to an ROI framework which uses this data to estimate the return in 
investment in HTA.   Specifically, this framework will measure the net health 
benefit (NHB)-ROI in HTA, capturing its health and efficiency impact, and 
establishing whether the benefits gained are estimated to be greater than the 
benefits expected to be forgone as a result of other services in the system 
having to be displaced (opportunity costs).   
As explained in Chapter 1, we distinguish between HTA as a process at the 
systems level to inform decision-making, and hta as an assessment of an 
individual technology (or technologies).  In order to get to the value of investing 
in health technology assessment at the systems levels (hereafter, referred to as 
‘HTA’), we need to look at what the process is delivering.  In other words, we 
need to quantify and aggregate the value of individual health technology 
assessments (hereafter, referred to as ‘hta’).   Central to understanding the two 
levels is the ‘value of implementation’ (VOImp)(159).  VOIimp can be defined as 
the value realised when health technologies are implemented 
appropriately(160).  Dixon(160) recommends payers must invest in 
implementation activities for each set of guidance they issue, and manufacturers 
need to set their prices to give payers a margin to invest in this.  As otherwise, 
the current implementation of guidance results in a loss of value to society(160).  
VOIimp relates directly to individual htas but in aggregating these analyses, we 
can get to the value of HTA at a systems level.  We use case study design with 
purposive sampling to populate the quantitative framework as illustrative 
examples (Part 3) as well as a realist synthesis (Chapters 5 and 6) to help 
theorise the generative forces or mechanisms that lead to health outcomes.  The 
main components or ‘building blocks’ of the framework are presented in Table 
4.1.  The quantitative components are discussed in detail below.    
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Table 4-1  The main building blocks of the proposed HTA impact framework 
Building blocks of 
HTA impact 
framework 
Methods Data requirements Potential data 
sources 
Data challenges 
Return on investment 
(ROI) to measure the 
impact of HTA in 
terms of Net Health 
Benefits (NHBs) 
ROI, modelling. Capital and running costs of 
investing in HTA at a systems 
level.  Realised NHBs of 
individual htas. 
 
Ministry of Health 
or local government 
audit sources.  
Decision analytic 
models to combine 
/supplement 
routine admin data 
with economic 
modelling 
techniques (into 
cost-effectiveness, 
NHB).   
Dependent on aggregating 
NHB for all hta decisions 
made.  Willingness-to-pay 
threshold assumed if an 
explicit value does not exist. 
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Realist synthesis  
Quantitative  
Value of 
implementation 
(VOI). 
Quasi-
experimental 
methods to 
provide measure 
of uptake (realist 
outcome).  
Longitudinal data on 
utilisation / drug volume 
pre- and post-an hta decision 
to monitor implementation 
or uptake; total eligible 
population; disease 
prevalence.  
Administrative 
health systems’ 
monitoring or audit 
data. 
Need existence of routine 
monitoring systems to be 
able to show temporal tends 
in uptake (stopping) of a 
technology following an hta 
recommendation; 
prevalence of disease often 
unknown or uncertain, 
especially in LMIC.    
Realist 
synthesis/evaluation 
Qualitative  
Realist synthesis; 
realist interviews 
using case study 
design. 
Qualitative data to identify 
potential mechanisms to 
produce outcomes and 
impact. 
Relevant 
stakeholders in 
HTA. 
Availability and willingness 
of stakeholders to 
participate; ability to 
provide insights to help 
refute or refine candidate 
theories. 
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4.2 Assumptions 
Key simplifying assumptions made in the framework are stated upfront as 
follows: 
• Whilst we recognise HTA is a process that may include several activities 
(for example, horizon scanning, pricing), we consider its overall purpose 
is to inform decision-making and priority setting.   
• The hta decision is always the ‘better’ one on the basis of cost-
effectiveness. There is, however, always the inherent uncertainty of any 
decision wrongly adopting or rejecting a technology, consequently leading 
to net benefits forgone [Figure 4.1].  
• Uptake of a technology is linear so that any change in uptake following 
an hta recommendation is modelled as a step function. With time lags for 
implementation, the diffusion of technologies is more realistically known 
to follow an S-shaped curve [Section 9.2.3]. 
• We allocate NHBs proportionately in line with implementation which 
assumes NHBs are equitably distributed across the eligible population. 
This, however, does not consider how the NHBs are distributed across the 
eligible population.  For example, it may be that difficult-to-reach 
populations who may have the most to gain, are more likely to often be 
the last to take up the intervention [Section 4.5]. 
• We assume uptake and stopping of a technology to be equivalent in our 
conceptual framework in so far as there might be some natural diffusion 
of a technology pre- an hta.  However, stopping of a technology here is 
not equivalent to disinvestment.  By ‘stopping’ we refer to a negative hta 
recommendation rejecting to invest in a technology in the first place (ie 
the ‘stopping’ of a technology that is not actually yet in the system).  We 
differentiate between this and ‘disinvesting’ in a technology that is in 
current usage and/or in clinical practice.  Our framework deals with the 
former, not the latter [Section 9.3]. 
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• We assume the value of HTA at a systems level is quantitatively the 
aggregate of that of individual htas.  Whilst we are applying our analysis 
to the individual hta, the OECD have published on estimating the value of 
HTA directly at country level (Chapter 2). 
4.3 Net Health Benefits 
We start by introducing NHB, our proposed measure of impact.  A healthcare 
technology is considered beneficial if it provides more overall health than it 
displaces as a result of its additional cost diverting resources away from other 
interventions or services.  To ensure that the funding of a new intervention is 
consistent with the objective of maximising health gains subject to a budget 
constraint, new health care technologies must provide an incremental cost per 
Quality Adjusted Life Year (QALY) or Disability Adjusted Life Year (DALY) 
compared to current care less than the cost-effectiveness threshold(161). The 
calculation of this incremental cost effectiveness ratio (ICER) expressed as 
QALYs is shown in Equation 4.1, where  (𝜆𝜆) represents the cost-effectiveness 
threshold. 
Equation 4-1 Cost per QALY decision rule 
 
In LMIC, WHO GDP per capita-based ‘thresholds’ have been widely used to assess 
cost-effectiveness but empirical evidence suggests these are likely to be 
significantly higher than actual health opportunity costs(162, 163).  
NHB are simply a rearrangement of the more usual cost per QALY or ICER which 
we compare with our willingness to pay for a QALY.  We rearrange the above 
equation to define net health (or monetary) benefits (NHB/NMBs).  Expressing 
costs in terms of their health equivalence by dividing through by the threshold 
(𝜆𝜆), allows costs (C) and effect to be combined into a single metric.  Equation 
4.2 represents the net gain to the healthcare system from introducing a 
technology.  It captures the health gains directly from the technology and 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑝𝑝𝑝𝑝𝑝𝑝 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑠𝑠 𝑠𝑠𝑝𝑝𝑑𝑑𝑑𝑑𝐶𝐶𝑑𝑑𝐶𝐶𝑠𝑠 𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝: 
 𝜆𝜆 >
∆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝐶𝐶
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compares it to the health loss from any technologies displaced elsewhere within 
system to fund the new technology(161).  The concept of opportunity costs as 
expressed through the threshold is central to NHB.   
Equation 4-2 Net health benefits 
 
The current value to the health system of the healthcare technology is the value 
from all the patients who currently receive it and is determined by the NHB (or 
NMB) of treating each patient ie the health gains minus the opportunity costs.  
The net population health benefit of introducing a technology is, along with 
setting a threshold and a function of its incremental costs and effects in 
comparison with alternative guidance or standard care, the duration of its usage 
or validity and the size of the patient population served(164).   Equation 4.3 
represents the value to the healthcare system of patients currently treated with 
the technology, where 𝒏𝒏 is the total patient population eligible for treatment 
and p is the current utilisation rate of the technology(161). 
Equation 4-3 Value to the healthcare system 
 
As such, the advantage of using NHB is that they can measure the scale or 
magnitude of the health benefits at a population level as offered by the 
intervention(165).   
4.4 Return on Investment  
We then define ROI.  ROI can be expressed as shown in Equation 4.4. Gains are 
typically measured in monetary terms (financial ROI), or can also be expressed in 
terms of social values which are then monetarised (a social ROI - SROI); costs 
remain the same in both cases(166). 
𝑁𝑁𝑝𝑝𝐶𝐶 𝐻𝐻𝑝𝑝𝑠𝑠𝑟𝑟𝐶𝐶ℎ 𝐵𝐵𝑝𝑝𝑠𝑠𝑝𝑝𝐵𝐵𝑑𝑑𝐶𝐶𝐶𝐶 =  ∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝐶𝐶 −  
∆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
𝜆𝜆
 
𝑠𝑠 ∗ 𝑝𝑝 ∗ 𝑁𝑁𝐻𝐻𝐵𝐵 = 𝑑𝑑𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝐶𝐶 𝑣𝑣𝑠𝑠𝑟𝑟𝑟𝑟𝑝𝑝 𝐶𝐶𝐶𝐶 𝐶𝐶ℎ𝑝𝑝 ℎ𝑝𝑝𝑠𝑠𝑟𝑟𝐶𝐶ℎ𝑑𝑑𝑠𝑠𝑝𝑝𝑝𝑝 𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝑝𝑝𝑠𝑠 
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Equation 4-4 Return on Investment 
 
If we were to apply the concept of a financial ROI to HTA with its focus on 
maximising financial returns, this would necessarily mean a preference for 
investing only in cost-saving treatments.  Treatment costs stemming from the 
technology would need to be offset by any net disease cost-savings over the long 
term.  This is not always the case with cost-effective treatments, with new 
treatments usually leading to incremental costs and effects at the margin.  Thus, 
were we to apply a traditional method or focus of HTA, we may never arrive at a 
positive financial return, even over a lifetime.   
Instead, if we were to apply a SROI, the values of HTA could be maintained and 
it would be more broadly applicable to HTA.  Rather than monetarising these 
benefits as is the norm in a SROI(167), we  propose the use of NHB, expressing 
costs – as described above - in terms of their health equivalence by dividing 
through by the willingness-to-pay threshold for a QALY, thereby combining costs 
and effect into a single metric.  By employing a net benefit approach, our 
framework allows for the explicit consideration of costs and benefits.   A 
technology is considered beneficial if it provides more overall health than it 
displaces as a result of its additional cost.  Currently, NICE takes this value to be 
between £20,000 - £30,000 per QALY, though research would indicate it is 
considerably lower(163).  This concept of opportunity costs as expressed through 
the threshold is central to NHB but is also integral to any ROI.  Slotting the NHB 
metric into the original ROI equation, we can express a NHB-ROI in Equation 4.5. 
Equation 4-5 NHB-ROI 
 
𝑅𝑅𝑅𝑅𝑅𝑅 =  
𝐺𝐺𝑠𝑠𝑑𝑑𝑠𝑠 𝐵𝐵𝑝𝑝𝐶𝐶𝑠𝑠 𝑑𝑑𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶 − 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑑𝑑𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑑𝑑𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶
 
𝑁𝑁𝐻𝐻𝐵𝐵 𝑅𝑅𝑅𝑅𝑅𝑅 =  
∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝐶𝐶 +
 �∆𝐶𝐶𝑆𝑆𝑠𝑠𝑣𝑣𝑑𝑑𝑠𝑠𝑆𝑆 − ∆𝐶𝐶𝐶𝐶𝑝𝑝𝑑𝑑ℎ𝑠𝑠𝐶𝐶𝑟𝑟𝐶𝐶𝑆𝑆𝑠𝑠 �
𝜆𝜆 − 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑅𝑅𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶/𝜆𝜆
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑅𝑅𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶/𝜆𝜆
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4.5 Realist Synthesis - quantitative 
4.5.1 Value of implementation – individual hta   
We define the impact of HTA to be achieved through increasing the uptake of 
net beneficial technologies and decreasing the uptake of non-net beneficial 
technologies.  There is, of course, the inherent uncertainty of any decision not 
being the ‘better’ one.  We assume cost-effectiveness is the basis but there is 
always the outside chance the technology recommended was not cost-effective, 
with that decision not being a true positive (or negative) but rather one which 
wrongly adopts or rejects a technology, consequently leading to net benefits 
forgone.  Such opportunity cost losses due to the adoption of a ‘wrong’ decision 
can be estimated by integrating the distribution of the NHBs associated with an 
hta with the loss function [Figure 4.1](159, 168).   
Figure 4-1  Net Benefit and Loss Function 
 
Source: Reproduced with permission from A Briggs. Briggs A, Sculpher M, Claxton K. 
Decision Modelling for Health Economic Evaluation: Oxford University Press; 2006 
 
Nevertheless, by employing a VOImp analysis, the objective is to convey the 
concepts of potential population NHB and realised population NHB.  This is 
depicted in Figures 4.2 and 4.3, and shows that HTA is about both the uptake of 
cost-effective/beneficial inventions and a decrease in use of those which are 
not.  Implementation is shown across the top and equates to NHB running along 
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the bottom.  The potential population NHB associated with full implementation 
of a technology is quantified from the use of decision-analytic modelling into 
long term health and cost outcomes which would normally be undertaken as part 
of the assessment process of an hta, using the best available evidence at that 
time.  As stated above, the net population health benefit of introducing a 
technology is, along with setting a cost-effectiveness threshold, a function of its 
incremental costs and effects in comparison with alternative guidance or 
standard care, the duration of usage or validity, and the size of the patient 
population served(164).   Realising a net population health benefit then requires 
using available evidence or assumptions on the degree of uptake (or stopping) of 
the technology (at any point in time) in order to calculate the value of current 
implementation.  A shortfall between potential and current implementation 
provides evidence that current care is sub-optimal.  Inefficiencies exist in 
healthcare from the under- or over-use of beneficial interventions as less than 
optimal adherence implies net benefit forgone.    
To what extent we can attribute to the hta the uptake (or stopping) of a 
technology requires a counterfactual as to what the level of uptake (or stopping) 
might have been without this.  There might have been some natural diffusion or 
decline in usage anyway which would reduce the overall value and impact of the 
hta.   To estimate the extent to which implementation would have happened 
without the hta, we propose drawing on methods increasingly applied to natural 
or quasi-experiments where randomisation is similarly unfeasible(169, 170).  We 
would also propose that randomisation is not just unfeasible; it may not always 
be the most appropriate approach given the failure of counterfactuals to 
account for complexity – or for it to be understood (see Chapter 3).    
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Figure 4-2  The value of implementation (Net beneficial technology) 
  
Figure 4-3  The value of (non)-implementation (Non-net beneficial technology) 
 
In the literature, VOImp relates at the level of implementing an individual 
technology.  We build on this to employ VoImp at a systems level.  We want to 
measure uptake, for example, the volume purchased of a drug for a specific 
indication or the adoption of policy or guidance into practice, both following an 
hta recommendation and, without going through any hta process.  By 
aggregating these htas, we can get to the value of HTA at the systems level.   
This is described below.
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4.5.2 Value of implementation – HTA at the systems level  
By aggregating the realised NHB of all hta decisions given the current level of 
implementation, or as we propose, by taking into account a level of 
implementation attributable to the hta process itself as measured against a 
counterfactual, we are able to offset these total benefits against the costs of 
investing in HTA at a systems level.  Such costs would include investing in the 
HTA infrastructure and the running costs associated with personnel and 
resources involved in undertaking the assessment and appraisal of each hta.   
Figure 4.4 depicts the ROI-NHB impact framework for HTA.  Reading from left to 
right, the first column shows the fixed costs of investing in HTA.  In the next, we 
identify individual htas undertaken as, in order to get to the overall value of 
investing in HTA at a systems (or country) level, we need to look at what the 
process is delivering.  In other words, we quantify the value stemming from each 
individual hta.  The 3rd column lists the costs of undertaking the assessment and 
appraisal process for each hta numbered 1-K.  Moving onto benefits, the ‘level of 
implementation’ relates to the uptake of a technology further to an hta 
recommendation.  Full implementation (potential NHB) is everyone who is 
eligible receiving it; current implementation (realised NHB) relates to the 
number of patients actually receiving the treatment; and the counterfactual is 
what we reckon the situation might have been had the hta not been undertaken.  
In this way, we can establish what we can attribute to the hta.   We show the 
NHB stemming from each hta, numbered 1-K, associated with full, current and 
attributable levels of implementation.  The summed NHB associated with 
‘current’ and ‘counterfactual’ levels of implementation are circled as relate to 
the realised and attributable benefits of the hta (attributable benefits being 
current NHBs minus the counterfactual). The fixed costs (CFC) of investing in 
HTA and the running costs (C) are also summed and expressed in terms of their 
health equivalence by dividing through by the willingness-to-pay threshold (𝜆𝜆). 
The aggregated costs and benefits of HTA, both expressed in their health 
equivalence of NHBs, can be directly offset against each other.  Net gains or 
losses can be expressed as a percentage of the initial investment to obtain the 
ROI. 
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Figure 4-4  The ROI-NHB Framework for HTA impact 
 
 
4.6 Discussion 
We present here a methodological framework to quantify the impact of HTA 
expressed in NHBs.  The objective is not to rank or score HTA bodies but 
recognise that evaluation should help to improve (optimise) HTA in a given 
context.  The focus of our framework is on countries where HTA currently exists 
and on those countries transitioning out of donor support as to what institutional 
models might be appropriate.  If we think priority setting should be better 
informed by evidence, and use tools such as HTA, this necessarily implies 
institutional change to establish a sustainable system.  Consequently, we have to 
consider the opportunity costs which are needed for its establishment and 
ongoing running but which are often overlooked(38).  We propose this framework 
should help with this.  Linking to opportunity costs, our proposed use of NHB 
measures the impact of HTA in terms of health and efficiency gains at a systems 
level and, importantly, reflects the opportunity costs of investing in individual 
technologies though the use of a threshold.  We recognise most countries do not 
operate with explicit thresholds and that there is much debate as to how they 
are to be measured and estimated (either using willingness-to-pay or the 
marginal productivity of the healthcare system).  Where none exist, we would 
propose doing scenario analyses around plausible values - see for example, 
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Woods et al(171).  Yet, we believe there is learning still to be had for countries 
where HTA is not currently institutionalised or developed at all, due to limited 
capacity and lack of awareness of its potential amongst policy makers, by 
assessing the costs and benefits of different (discrete) processes and 
mechanisms versus investing in full HTA processes.  It should also help build 
needed political support for improved priority setting processes(172). 
We aim to address some of the methodological limitations identified in Chapters 
2 and 3; we do not stop at full implementation, we include ‘negative’ decisions 
ie not just those which could offer benefits if introduced, and critically, we 
construct a counterfactual in order to facilitate isolating or disentangling the 
impact of an hta on outcomes from what would have happened without it.   
Ideally, we would find a sector or jurisdiction unaffected by an hta to make such 
a comparison but as groups get increasingly non comparable, threats to internal 
validity become more plausible.  Alternatively, we draw on quasi-experimental 
methods to construct a ‘no hta’ control.   Quasi-experimental methods, such as 
ITS or simpler forms more suited to analysing routine data such as segmented 
regression (see Part 3), can be used to analyse impact at a population level over 
a defined time period by measuring the adoption of a technology after an hta 
recommendation against its pre-existing trend of adoption (the counterfactual).  
We apply this quasi-experimental approach to an individual hta, and propose 
aggregating the htas to get to the value at a systems level [Figure 4.4].  Note 
that the OECD have published on the value for money of HTA at a country level 
on population health outcomes and public spending(48) [see Chapter 2].    
Whilst ITS was successfully used previously to assess the implementation of NICE 
guidance(135), it no longer makes sense to use this on contemporary NICE 
guidance as these processes have now become institutionalised with hta 
recommendations made predominantly on newly licensed technologies.  This 
means there are fewer data prior to the hta on prescribing levels or volume 
against which to measure the influence of the hta recommendation.  However, 
in countries transitioning out of donor support, the intended focus of our impact 
framework and where HTA processes have not yet been institutionalised, there 
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should be more data to be able to apply such methods – indeed, as Sheldon et al 
did when NICE was still only advisory(135).  
Finally, as the standard form of cost-effectiveness analysis is indifferent to the 
distribution of outcomes, there is a need to take account of equity in any value 
of HTA framework.  The QALYs would be modelled as is the norm in any cost-
effectiveness analysis as part of an hta, either extrapolating from endpoints in a 
trial and/or using decision-analytic techniques.  However, their distributional 
impact is of importance in an impact evaluation.  Recent methodological 
developments allow cost-effectiveness considerations to be combined with 
assessments of equity impacts(173).  Extended cost-effectiveness analysis (ECEA) 
was developed to address both the health and financial consequences of public 
policies(174).  Distributional cost-effectiveness analysis (DCEA), similarly looks 
at the distribution of costs and benefits but it additionally accounts for the 
distribution of opportunity costs and weights the trade-off between health and 
the inequality reduction objective(175).    Instead of a traditional CEA, the 
potential incorporation of ECEA or DCEA could better account for equity(176).    
4.7 Limitations 
We acknowledge that implementation does not equal impact – but here, impact 
is given as modelled so we focus on what level of that impact is realised.  We 
purposively do not consider other spillover effects arising from the HTA process 
itself in order to limit the scope.   We do recognise though there are likely to be 
other externalities to arise from this process including, for example, better 
bargaining power on price negotiations.  However, our understanding is that the 
impact of HTA on health outcomes is the major gap in the literature.  A realist 
approach [Chapter 5] should help capture other potential outcomes. 
A key limitation of using the NHB approach is its reliance on the value of the 
cost-effectiveness threshold as a representation of the true opportunity costs of 
resource allocation within a health system.  The conceptual basis of thresholds 
can be either classified as ‘supply side’ (what the health system is ‘able’ to 
provide given resource constraints) or ‘demand side’ (based upon expressions of 
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the value of health).  The former requires assessment of the opportunity costs of 
scarce healthcare resources.  We recognise most countries do not operate with 
explicit thresholds and that there is much debate as to how they are to be 
measured and estimated, either using willingness-to-pay or the marginal 
productivity of the healthcare system.  Where none exist, we would propose 
doing scenario analyses around plausible values using, for example, published 
country estimates by Woods et al(171). 
Operationalising the framework to assess the ROI of an entire country’s HTA 
programme is unlikely to be feasible.  Practically, we can only undertake 
illustrative case studies.  RAND restricted its evaluation to 10 HTA-funded 
projects framed within, presumably, the more clearly defined boundaries of an 
audited research programme(19).  However, we can scale-up case studies to 
calculate how many htas may need to be undertaken in order to get a positive 
ROI.   
Finally, the background to this framework in relation to the iDSI ToC has been 
discussed [Chapter 1].  The iDSI ToC was developed in full consultation with 
stakeholders and partners in the countries concerned.  For our framework, we 
have taken this forward after its development with stakeholders to undertake 
illustrative case studies [Part 3] and we propose a future application of the full 
framework [Part 4]. 
4.8 Summary and conclusion 
The NHB-ROI framework is presented.  Ultimately, we hope this ROI-NHB 
framework will contribute to demonstrating the value of HTA by quantifying the 
NHBs and opportunity costs of investing in these processes.  In turn, we hope this 
will contribute to generating political will and financial investment in these 
processes.  What our framework adds to existing models and why this is 
important is summarised in Chapter 10.   
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4.9 Next steps 
We present the realist synthesis in the next two chapters.  We envisage this 
research, by synthesising economic and more qualitative methods, will provide a 
framework to quantify the value and impact of HTA on health and economic 
outcomes, as well as evidence informed theory to produce recommendations as 
how to do HTA by context in order to optimise its impact. 
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5 The Value of HTA: protocol for a realist 
synthesis  
5.1 Introduction 
We present the protocol for a realist synthesis of evidence of HTA value, 
describing our proposed process of theory-building.  Theorisation allows a 
greater understanding of how interventions work.  In adopting a realist 
perspective, we treat HTA as a complex intervention in itself but also as one 
that is introduced into existing complex systems and contexts.  Indeed, the 
systems in which HTA will operate already have policies, procedures, 
communications, cultures, histories and ‘ways of doing things’.  As in the 
quantitative framework, we distinguish between hta as an individual assessment 
of a technology (or technologies) including evidence-based interventions, 
practices or policies and, HTA at the systems level to inform priority-setting and 
decision-making.  Both are potentially complex, operate at different levels and 
are likely to interact. The constructs of a realist approach provide a framework 
to capture and address the complexity and multi-dimensionality of HTA: at the 
individual technology level, at the systems level and in their interactions.  The 
realist synthesis will follow the steps and procedures outlined in RAMESES 
publication standards(98, 177).   
5.2 Implementation of HTA findings 
Efforts to rationalise the use of resources are only valuable if recommendations 
are implemented in practice(178), as it is only when those decisions result in 
practice change can better health be achieved.  Yet, we know that 
implementation of HTA findings is variable(19-23).  A recent review(179) has 
highlighted the need to look beyond the development of HTA guidelines to the 
mechanisms through which guidelines can be implemented.  According to this 
review, HTA has focused on the development of products such as quality 
standards, guidelines and care pathways but there is less evidence of a 
systematic approach to thinking through the various institutional mechanisms 
through which they might be implemented and the associated incentives to do so 
– thus avoiding a situation where, for example, any change might be short lived 
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as unless there is investment and commitment to enact upon hta 
recommendations, any new practices or protocols could ‘snap back’ to the old 
norm.     
A review by Hailey et al (112)on the influence of HTA found that ‘the literature 
on assessment of HTA influence is still quite limited and there is little on longer 
term effects on clinical practice and health outcomes’.  This is also a likely 
consequence of a lack of routine administrative monitoring and evaluation data, 
leading to poor data capture and reporting.  A lack of longer-term impact 
assessment may undermine its importance and value, as hinted by Hailey et al.  
Assessing the real-world monetary, health and broader societal effects of HTA as 
currently implemented in countries around the world will require not only the 
expertise of traditional HTA practitioners but also the unique perspectives of 
social science(180).  By synthesising some of the vast theoretical literature from 
the social sciences, we aim to promote a better understanding of the 
implementation of HTA recommendations(181). 
5.3 Research aims and objectives 
This realist synthesis aims to produce tested and data-driven theory that 
considers individual, interpersonal, institutional and systems-level components 
and their interactions on the mechanisms by which HTA impact can be 
optimised.  Our specific research questions are: 
• What are the mechanisms that encourage the implementation of hta 
findings? 
• Do the injected resources have the leverage to trigger these mechanisms 
and counter contextual deficiencies (transform the context)?   
• What are the common predicting mechanisms that transcend contexts? 
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5.4 Methodology 
Realism is a new conceptualisation of programme theory (see Chapter 3), 
valuable for addressing the complexity of programmes(141).  It is a form of 
theory-driven evaluation based on realist philosophy and which is becoming 
increasingly used in the evaluation of complex interventions.  There are many 
types of theory driven evaluation but realist evaluation can be differentiated as 
being underpinned by realist philosophy which makes explicit that there are 
underlying mechanisms, thus acknowledging different levels or layers of 
knowledge ie ontological depth(141).  This means at the empirical level there 
are commonly observed outcomes and, at a deeper layer, there are explanatory 
underpinnings of such outcomes.  A realist logic to inquiry attempts to provide 
an explanatory analysis aimed at discerning what works, for whom, in what 
circumstances, how and why(141).      
Realist theory starts with the basic premise that underlying mechanisms, 
operating in particular contexts, generate outcomes.  Explanation-building using 
a realist lens is operationalised through investigating CMOC(182).  We shall 
produce CMOC based on the literature and assess to what extent any pre-existing 
theories fit with these CMOC to produce our preliminary programme theory.  
Implementation of a programme is dependent on both the context and the 
intrinsic properties of the intervention itself.  A realist perspective treats 'other 
resources' ie those not introduced by the programme, as context for the 
programme mechanisms(183).  Such contextual elements (values, competencies, 
assets, deficits, infrastructure) have an impact.  It conceives of programme 
mechanisms as 'reasoning and resources' ie the (new) resources, opportunities or 
constraints that the programme theory or intervention – here, the hta – 
introduces, and 'reasoning’ (for example, trust-building, motivation to act, 
realisation of knowledge) as to how people react in response to those 
resources(184).  As such, there is always an interaction between context and 
mechanism [Figure 5.1](185).  Outcomes arise from a combination of the 
stakeholders’ choices (reasoning) and their capacity (resources) to put these into 
practice(139, 141, 184). 
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Figure 5-1  Context-Mechanism Interaction 
 
Source: Reproduced with permission from Jagosh J (June 2018). Incorporating Middle-
Range Theory in Realist Evaluation and Synthesis. [Webinar]. CARES Webinar Training 
Series with permission from Justin Jagosh, June 2020. 
 
Whilst iDSI are focusing on institutional aspects around achieving ‘better’ 
recommendations/decisions (the ‘initiation’ context), this realist synthesis will 
target those institutional characteristics involved in getting hta 
recommendations into practice (the ‘implementation’ context) – although 
clearly there will be some overlap.  Barriers and facilitators to implementation 
can arise at multiple levels - patient, provider, organisational, policy (see 
Chapter 2).  Whilst much research has established what factors influence 
improved decision-making including good governance structures, expertise, 
political and institutional factors, resources and participation (41-44), it is less 
understood how such influences interact with local context and health systems, 
leading to the improved implementation of evidence-based recommendations 
and guidance.  Indeed, the data for studies of the implementation of 
reimbursement decisions have been found to be scarce but available evidence 
indicates that there is a gap between decisions and implementation, resulting in 
an inefficient use of new technologies and thus a loss of value(24).  Our research 
theorises those elements of the context that are critical to the intervention 
‘functioning’.  At this stage of the hta, there is generally no further injection of 
resources and instead the reliance is on pre-existing resources for the 
implementation of recommendations.  To what extent can an hta produce a 
variety of new resources that can leverage against contextual barriers, triggering 
those mechanisms which optimise uptake of a technology following a 
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recommendation?  Realist inquiry helps to understand the leverage hta/HTA has 
and this paradigm of realism can help bring new insight to optimise its impact.  
To illustrate this, we overlay the iDSI ToC with realist terminology: ‘context’, 
‘outcome’ and the intervention ‘HTA’ [Figure 5-2], mechanisms being found in 
an interaction between the context and the HTA resources/responses. 
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Figure 5-2  iDSI Theory of Change overlaid with CMO configuration 
 
Source: Adapted from report on NICE’s engagement in China, 2015(179) and https://www.idsihealth.org/blog/changing-a-theory-of-change-six-important-
lessons-from-our-work-with-idsi/ with permission from Itad Ltd.   
CONTEXT HTA OUTCOME
.
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5.5 Identifying potential theories 
A realist search focuses on the theory underpinning the intervention or it can 
also look for existing evidence how interventions work, building on stakeholders’ 
knowledge of the area or subject to inform the programme theory.  By drawing 
on an iterative analysis of the literature and formal theories, we seek to 
generate, test and refine explanations for the (non-)implementation of hta 
recommendations.  These formal theories are not specified in realist terms ie 
with respect to contexts, mechanisms and outcomes.  The degree to which hta 
recommendations are 'taken up’ is observable, and therefore lies at the 
empirical level.   Mechanisms, in the sense that realists use the term, are 
‘underlying’ causal processes that cannot usually be directly observed.   
An initial scoping of the literature was undertaken to identify existing HTA 
evaluation or impact frameworks [Chapter 2] as well as theories related to 
uptake to inform our initial candidate theory.  The latter involved a relatively 
unstructured scan focusing on formal knowledge translation and implementation 
readiness theories [see Figure 1.3].  We also drew on the growing body of 
literature on the barriers and facilitators to the implementation of cost-
effectiveness recommendations [Chapter 2].  An extensive body of literature 
identifies various barriers and facilitators to implementing clinical guidelines in 
general and evidence-based guidance more specifically.  Whilst the literature 
usefully explains implementation in terms of barriers and facilitators, this 
approach only provides antecedent factors of uptake.  By adopting a realist 
approach, we provide a dynamic framework that offers explanatory power, and 
thus has the potential to be utilised in evaluation.   Finally, as stated above, we 
are dealing with both hta at the intervention and HTA at a systems’ level.  Both 
are potentially complex, operate at different levels and likely to interact.  We 
consider theories at both levels. 
5.5.1 Realist approach – individual ‘hta’ 
To make a broader assessment of the role of HTA in an entire health system, we 
need to understand the value of what that process is actually delivering.  Given 
the value of HTA is dependent on the implementation of a technology itself, this 
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is about understanding how well an hta works in any given context.  How far 
along the implementation path we get [Figures 4.2 and 4.3] depends on this 
theory element.   It is likely there is relevant theory in a range of different 
sectors that could be combined or adapted and applied as to how a technology is 
taken up (or stopped) following an hta recommendation (or rejection) in order 
to produce an initial programme theory or hypothesis(183).  For example, we 
drew on knowledge translation theories as to how knowledge is utilised as well 
as the research on the barriers and facilitators to the implementation of cost-
effective interventions as useful starting places to theorise the uptake (or 
stopping), and thus impact, of an ‘hta’ (41, 42, 84, 90, 114-116).  
Implementation science,  which is ‘the study of methods to promote the 
adoption and integration of evidence-based practices, interventions and policies 
into routine health care and public health settings’(186), emerged in the wake 
of evidence-based medicine.  It relates, in our case, at the level of 
implementing an individual technology following an hta recommendation(187).   
Formal theories from this field could include, for example, those of socio-
cognitive behaviour change. 
5.5.2 Realist approach – HTA at the systems level 
A realist lens is equally valid applied to HTA as a process at the systems’ level.    
Policy implementation is the process of carrying out a government decision(188) 
and formal theories from this field which apply to more macro or meso 
institutional levels to inform our theorising could include ‘the Diffusion of 
Innovations’, Governance Theory, Institutional Theory and network governance 
(187).  In applying Diffusion of Innovations theory, Yates(189) highlights the 
importance of both ‘macro theory (systemic adoption, that is, organisational and 
structural change) and micro theory (individual change)’(139), a useful 
distinction we make here too.  Such theories are broadly about the interplay and 
tensions between knowledge, power and social control, the premise being that 
organisations do not make decisions but people with biases, motives and 
histories make the decisions but are required to do so within the confines of 
power structures (like organisations and governments).  This is congruent with 
the philosophy of realist evaluation. 
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An overview of the many knowledge translation and implementation theories was 
facilitated by retrieving existing reviews of frameworks, models and theories(190, 
191).  Key theories considered included the Consolidated Framework for 
Implementation Research (CFIR)(192), the Critical Realism and the Arts Research 
Utilization Model (CRARUM)(142), the Ottawa model of research use (OMRU)(193), 
the Context and Implementation of Complex Interventions (CICI) framework(194), 
and another from organisational readiness theory(195).  The CICI comprises three 
dimensions of context, setting and implementation.  The OMRU includes six key 
elements: evidence-based innovation, potential adopters, the practice 
environment, implementation of interventions, adoption of the innovation, 
outcomes resulting from implementation of the innovation. The CFIR consolidates 
multiple different conceptual frameworks relevant to implementation research 
and proposes that implementation is influenced by intervention characteristics, 
the outer setting, the inner setting, the characteristics of the individuals involved 
and the process of implementation. The CRARUM was interesting as an adaptation 
of the OMRU but borrowing elements from critical realism including the concept 
of generative mechanisms – and thus relating to our realist inquiry.  The CRARUM 
incorporates critical realism into their knowledge transfer model “to shed light 
on the structures, powers, generative mechanisms, and tendencies that 
characterise clinical settings and the agential reflexive capabilities of health care 
practitioners”(142).   
 
Building on iDSI’s ToC which is at a broad macro level, this helped to narrow our 
realist synthesis to also draw upon theory at an organisational level.  In the 
CRARUM, the unit of analysis is at the individual level, whilst a theory at an 
organisational/institutional level would keep the focus on HTA at a systems 
level.  Weiner’s theory relates behaviour of individuals to knowledge 
mobilisation at a macro or systems level, reconciling the structural 
(organisational resources) and psychological (motivations, values) views of 
organisational readiness which could be seen to relate to the 
HTA/hta/technology implementation interaction(196). It is noted the application 
of organisational theory in implementation has to-date been limited(197).  Yet, 
as it is usually government policy which sets the scene for adoption, this public 
policy/macro perspective is important to uptake.   
107 
 
 
 
We consider the Promoting Action on Research Implementation in Health 
Services Framework (PARiHS)(198-200) model of implementation alongside 
Weiner’s Theory of Organisational Readiness(196), to establish a more thorough 
framework for expressing our candidate theory. Whilst the CFIR, CICI and OMRU 
focus is on characteristics of the intervention, PARiHS identifies characteristics 
of evidence as its focus of implementation.  We opted for the latter as whilst we 
assume the principles of HTA will be the same in LMIC and HIC, a main 
difference may relate to the availability of evidence.  The original PARiHS 
Framework has been used which proposed that successful implementation is a 
function of the relationship between evidence, context and facilitation.  A later 
version, the i-PARIHS(201), incorporates the addition of recipients.  Although 
this subsequent inclusion as to how individuals interact with context reflects the 
realist mechanism of ‘reasoning and resources’ ie individual’s behaviour, 
intentions and actions, we kept to using the original framework with its focus on 
evidence as described above. 
Together, these theories (PARiHS and Weiner’s Theory of Organisational 
Readiness) provide a model for examining how the uptake of hta 
recommendations occur successfully. The PARiHS model offers the contextual 
and intervention perspective, and the theory of organisational readiness 
considers more fully individuals are agents of change.  In so doing, we 
acknowledge a political/national, organisational and individual spectrum to the 
model.  They are described in more detail below.   
5.5.3 PARiHS model 
Knowledge translation (KT) is a term increasingly used in healthcare to represent 
a process of moving what has been learned through research to the actual 
applications of such knowledge in a variety of practice settings and 
circumstances(202).   KT encompasses all steps between the creation of new 
knowledge and its application, and there are a large number of related models 
and theories(203).  However, the final component of the process, the actual use 
and implementation of knowledge, is not included in all.  We reviewed those 
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models which specifically included implementation and propose the use of the 
PARiHS model(199, 204-206).   
PARiHS is an implementation framework which takes into account the role of 
context and, therefore, aligns well with a realist approach.  Furthermore, the 
model can operate at an institutional or systems level and contemplates the 
interplay of evidence, context, and facilitation(207, 208).  Whilst we assume the 
principles of HTA will be the same in LMIC and HIC, a main difference may relate 
to the availability of evidence.  The PARiHS framework was used to help define 
our initial programme theory by diagnosing the context into which HTA is being 
introduced.  PARiHS can be operationalised through grid-plotting to assess 
‘readiness’.  Each element can be assessed for whether its status is weak or 
strong with a negative or positive influence on implementation.  The PARiHS 
logic is thus that strong ‘Context’ plus ‘Evidence’ results in successful 
‘Implementation’(202).  Our hypothesis is that high- and low-income countries 
will be positioned in different quadrants of the framework [Figure 5.3].  We shall 
look for variation in these contexts to test if the theory is transferable.  As it 
stands, the PARiHS model tells us ‘why’ implementation is achieved but a realist 
approach will build on this to tell us ‘how’.   We will interrogate and develop the 
PARiHS model by adding mechanistic concepts to it.   
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Figure 5-3  The PARiHS Diagnostic and Evaluative Grid 
 
Source: Kitson A, Rycroft-Malone J, Harvey G, McCormack B, Seer K, Titchen A. Evaluating 
the successful implementation of evidence into practice using the PARIHS framework: 
theoretical and practical challenges. Implement Sci. 2008;3(204). Use of this image is 
supported by the Creative Commons CC BY https://creativecommons.org/licenses/ 
 
The later addition of the construct of ‘recipients’ to the framework (201) 
illustrates how individual level factors, as well as political and structural factors, 
are also included as influential.  
5.5.4 Weiner’s Theory of Organisational Readiness 
We integrate the individual perspective by drawing upon Weiner’s Theory of 
Organisational Readiness(196) which proposes that ‘implementation readiness’ 
depends on collective behaviour change linked to change commitment (wanting 
to change) and change efficacy (ability to change), thereby making a key 
distinction between capacity and readiness.  Organisational readiness for change 
varies as a function of how much members value the change and how favourably 
they appraise implementation capability ie task demands, resource availability 
and situational factors.  When organisational readiness for change is high, 
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organisational members are more likely to initiate change, exert greater effort, 
exhibit greater persistence, and display more cooperative behaviour.   The result 
is more effective implementation(196).  The theory offers a means of reconciling 
the structural and psychological views of organisational readiness found in the 
literature and draws specifically on motivation theory and social cognitive 
theory(196).  Research by Herscovitch and Meyer(209) [cited in(196)] found that 
organisational members whose commitment to change was determined by 'want 
to' motives rather than 'need to' or 'ought to' motives, exhibited not only more 
cooperative behaviour but also championing behaviour ie ‘promoting the value 
of the change to others, thus creating spread of innovation and ultimately, new 
cultural practices’.  Resources and other structural attributes of organisations 
are not automatically categorised as features of readiness.  Instead, ‘they 
represent an important class of performance determinants that organisational 
members consider in formulating change efficacy judgments’(196).  Thus, 
‘organisations with the same resources, endowments and organisational 
structures (capacity to implement) can differ in the effectiveness with which 
they implement the same change depending on how they utilise, combine and 
sequence organisational resources and routines’(196).  
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Figure 5-4  Weiner's theory of organisational readiness 
 
Source: Weiner BJ. A theory of organizational readiness for change. Implement Sci. 2009;4 (196) Use of this image is supported by the Creative Commons 
CC BY https://creativecommons.org/licenses/
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When the PARiHS model of implementation is considered alongside Weiner’s 
Theory of Organisational Readiness, we establish a more thorough framework for 
expressing our candidate theory.  The PARiHS model offers the contextual and 
intervention perspective, and the theory of organisational readiness considers 
that causal mechanisms cannot always be usefully understood in terms of 
individual reasoning, since they are operating at the level of the organisation 
(153, 196).  Together, they provide a model for examining how the uptake of hta 
recommendations occur successfully. 
5.6 Search strategy 
The search strategy proceeded iteratively as follows: 
Firstly, a detailed search focused specifically on HTA and ‘health outcomes’, our 
impact measure of interest but also HTA and ‘uptake/implementation’ as a 
proxy measure given the lack of literature on impact on health outcomes.  
Search terms, therefore, covered two key domains: 
Health Technology Assessment – using MESH terms and expanding this for all 
relevant terms which could include ‘decision-making’, ‘priority-setting’; 
Outcomes – and expanding this for all relevant terms which could include 
‘uptake’, ‘diffusion’, ‘adoption’, ‘implementation’, ‘health outcomes’, ‘patient 
outcomes’, ‘Net Health Benefits and/or Net Monetary Benefits’. 
Secondly, ongoing reference, citation and author tracking to identify the most 
theory-relevant studies available; and finally, refined searches, operating 
concurrently with the overall synthesis process, to collect additional materials 
that may be required to elucidate particular aspects of theory. 
Search terms were applied to Ovid MEDLINE and EMBASE databases (see Annex 
B).  Articles were limited to the English language but not limited by timeline or 
any methodological design.  Titles and abstracts were reviewed first, then full 
papers based on the selection criteria below.  Searches of grey literature 
included the websites of HTA agencies.  For example, the UK’s National Institute 
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for Health and Care Excellence (NICE) has databases on shared learning and the 
implementation of evidence containing ‘real-life’ examples of how organisations 
have put NICE guidance into practice (see Annex C).   
5.6.1 Study selection criteria 
Inclusion criteria were studies that included a measure of implementation of hta 
decisions or impact on health outcomes.  We adopted a definition of evidence of 
implementation as follows: ‘studies that reliably reported consideration by 
decision-makers of HTA findings and/or recommendations; comparative studies 
that included relevant measures related to use of a health technology before 
and after dissemination of an HTA; and studies that reported changes in one or 
more features that could be credibly linked to information provided by an HTA.  
Those features were policy related to a health technology, use of a health 
technology in a healthcare system, relevant health outcomes associated with use 
of a health technology, and an increased level of research or initiation of 
research’(112).  Studies that reported either a qualitative or quantitative 
measure of the implementation of HTA findings or its impact on health outcomes 
were included.  We excluded studies that did not provide any measure of 
implementation or health outcomes or, did so without providing any contextual 
information thus lacking realist material on contexts or mechanisms.  We 
updated the review undertaken by D Hailey et al, 2016(112) to present day.   All 
their included papers were also reviewed using the theoretical framework. 
5.7 Data extraction 
For each paper identified as relevant, we extracted contextual data and 
mechanisms to inform our analysis.  Data were extracted from all sections of 
articles.  In appraising the quality of evidence, we critically reflected on all 
evidence and determined its relevance and robustness for the purposes of 
answering the review question.  The Realist and Meta-narrative Evidence 
Syntheses: Evolving Standards (RAMESES) group poses two questions in this 
regard: (1) can the section of data in a given document be used to contribute to 
theory building/testing (relevance)? and (2) were the methods used to generate 
this section of data credible and rigorous?  
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Excel was used to capture the data.  Often, the nature or form of data for 
Contexts (here, of the hta) and Outcomes (here, health outcomes and proxy 
measures of uptake or implementation) are descriptive and quantitative 
respectively, and qualitative data allow us to identify potential Mechanisms 
(currently unknown, and subject to the identification of usable candidate 
theories).  We expected this to be the case in this study, although all data were 
fitted in the programme theory based on their concept or meaning, not their 
form.  Indeed, the strength of this approach is its ability to examine 
interventions and their outcomes in their contexts, irrespective of what form the 
data are in.  In addition, assumptions implicit in the expression of authors about 
HTA may provide useful realist evidence.  Thus, the study generated data which 
could populate the design of an explanatory framework to help optimise the 
implementation, and thus impact, of hta decisions. 
5.8 Data synthesis and theory refinement  
Analysis of all the data was linked to the programme theory.  Analysis was 
undertaken using realist evaluation principles of extracting CMOC variables at 
play, and iterative, participative and collaborative approaches to interpretation. 
We also considered pre-conditional as well as unintended outcomes.  This 
brought in, for example, issues around quality, uptake by whom – practitioners 
versus patients, and awareness and acceptance of HTA decisions as stages or 
pre-conditions before uptake – as well as the accumulation of intellectual, 
technical and social capital.  Using the CMOC to identify (semi-) predictable 
patterns or pathways in the data, known as demi-regularities, we produced 
theory to explain the influence of context and mechanisms as to how hta 
findings are better implemented(141).   
5.9 Discussion 
We use a realist synthesis as a complementary and congruent approach to our 
quantitative framework [Chapter 4] to theorise those contextual factors and 
mechanisms that play a role in the last step of IDSI’s ToC.  In so doing, we aim to 
provide greater insight into how ‘better decisions’ translate into ‘health 
outcomes’.   As stated previously, realist synthesis is a relatively new approach 
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to evaluation in health and an innovative way to review the literature pertaining 
to HTA outcomes as this is the first time, to our knowledge, that such an 
approach has been applied to this field.  The basis of adopting a realist approach 
is that we start and end with a theory, thus supposing that the final overarching 
theory can be translatable to other similar contexts.  Our unit of analysis is HTA 
at the systems level, and we apply a realist lens to HTA at this by looking to 
theories which apply to more macro or meso institutional levels ie systemic 
adoption, and organisational and structural change.  Such theories offer analysis 
of the interplay and tensions between knowledge, power and social control, the 
premise being that organisations do not make decisions but people with biases, 
motives and histories make the decisions and are required to do so within the 
confines of power structures (like organisations and governments).  This is 
congruent with the philosophy of realist evaluation which recognises such 
tensions at different levels.   
HTA should seek to harness mechanisms to improve the implementation of 
findings.  In realism, often it is the ‘resource’ aspect of the mechanism that 
becomes central to understanding how programmes work. (210)  So, for 
example, in triggering a response/reaction of ‘motivation to enact decision’, 
how does the HTA deliver this ‘resource’?  And, how does that resource manifest 
differently in different contexts?  What are the specific types of resources that 
are introduced and meaningful that support implementation?   The development 
of robust and evidence-informed products needs to be balanced with work to 
ensure that there are mechanisms and pathways for implementation and use of 
products – and without demand for these type of products from many clinicians, 
and indeed patients, it is unclear how and whether guidance will be 
implemented once developed(179).  While demonstrating the value of guidelines 
etc may be enough, there seems to be a need to look beyond this to more formal 
mechanisms of implementation.  As such, there is still a recognised need to have 
better insight into how the parties ‘on the front line’ - those who have to carry 
out policy - respond to the policies and guidance that ‘come down the line’ to 
them, as well as ‘on the ground’ service configuration issues.   Street level 
bureaucracy(211) describes the role of discretion in implementation ie the role 
of agency in delivery. This filtering of policy can inevitably result in differences 
116 
 
 
 
between government policy and policy in practice.  As these quotes below 
indicate, there is a need to get to the reasoning of stakeholders ie mechanisms 
in realist terms:   
‘Bringing about effective policy change does not simply require good technical 
design or using evidence to generate policy but must always involve clear 
attention to the processes by which change is brought about, including concern 
for the values and interests of the actors with potential to block or subvert 
policy development and implementation, and for the discourses surrounding 
policy change processes’(114).  This suggests ‘the need for policy managers to 
have a better understanding of the processes of policy development, including 
insight into the roles of stakeholders, their interests, and interactions with the 
health system context. However, analysis of health policy is rarely recognized 
and applied in developing countries’ academic institutes and health 
administrative authorities’(114, 212). 
There is much diversity in the role and application of HTA and it could take 
different forms depending on purpose and context.  Such differences reflect not 
only differences between health systems and their financing but also how well-
developed country-specific HTA institutions and processes are, as well as other 
wider contextual issues such as values and culture.  In using a realist 
perspective, we treat the process of HTA as a complex intervention which is 
intended to make a change, and would/should take different forms depending 
on purpose and context.  As HTA works differently in different contexts - context 
being more than locality but embodies, for example, health care systems, 
resources and stakeholders - and impact is likely to be achieved through 
different change mechanisms, it is unlikely that the same intervention (ie HTA 
assessment and appraisal processes) can be replicated from one context to 
another and achieve the same outcomes. Good understanding about what works, 
for whom, in what contexts, and how – are, however, portable. We will test 
these theories with empirical testing using country case studies.  We hope this 
might provide a better understanding as to how HTA needs to (better?) connect 
and interact with ‘context’ in translating into health outcomes so that the use of 
HTA can be optimised as well as understanding the value for money of HTA. 
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Finally, in HICs, there has been perhaps an element of taking for granted that a 
fully functional system will pick up hta recommendations and adapt accordingly 
with little effort required to ensure implementation given our health systems 
and regulations.  For LMICs, we hope this research will offer a forward-looking 
model that LMICs can point to as a reference for their own implementation.  A 
robust analysis of the context-mechanism association can serve to innovate and 
transform interventions(213).  For example, should elements of the context be 
determined to be critically important to the successful implementation of hta 
findings, these may be re-theorised as an intervention component.  We aim to 
produce ‘policy-friendly outputs’ or guidance in terms of ‘what works, where, 
for whom, and how’ – as well as promoting improved monitoring of the adoption 
of hta recommendations. 
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6 Realist synthesis 
6.1 Introduction 
A realist synthesis focuses on the underlying mechanisms and the contexts in 
which they fire that lead to outcomes.  To have impact, hta recommendations 
need to be realised which requires the opportunities and resources to enact 
those decisions.  HTA is necessarily customised to context and, like all 
interventions, will introduce both new resources but also catalyse pre-existing 
resources(182).  The question there is ‘has the hta suitably harnessed the 
resources and overcome any deficits to ensure that implementation of its 
recommendations can occur?’ We explore patterns of outcomes and use the 
evidence to develop and refine our programme theory.   
6.2 Articles retrieved 
The search was an iterative process across the different themes of HTA and 
‘health outcomes’, ‘uptake and implementation’, ‘governance and knowledge’.  
The results are shown in the PRISMA flow diagram [Figure 6.1] by search theme 
as well the updating of a review on the influence of HTA(112).  The articles were 
retrieved from Ovid MEDLINE(R) without Revisions 1996 to November Week 3 
2018 and Embase 1996 to 2018 Week 47 then updated to Ovid MEDLINE(R) 
without Revisions 1996 to June Week 1 2020 and Embase 1996 to 2020 Week 23.  
Annex B details the search terms.  Grey literature searching was also undertaken 
and Annex C provides details on information retrieved and sources searched.   
Many of the articles retrieved were useful in terms of evaluation more generally.  
Articles, mainly descriptive, on facilitators and barriers were found across all 
themes.  Whilst many of these articles did not necessarily provide suitable 
material for CMO extraction, these data were usefully mapped to diagnose 
‘context’ as described below. 
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Figure 6-1  PRISMA flow realist search 
 
6.3 Document characteristics, data extraction and coding 
6.3.1 Diagnosis of implementing context  
As a first step, we mapped ‘barriers and facilitators’ to the implementation of 
hta recommendations onto the PARiHS model to diagnose important aspects of 
the implementation context [Table 6.1].  These barriers and facilitators were 
retrieved also from our initial review of the literature to identify existing 
frameworks or models to measure the impact of HTA [Chapter 2].  Key 
contextual information was extracted from articles, and mapped to the 
constructs of ‘context’, ‘evidence’ and ‘recipient’ by their sub-domains as 
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referred to in the PARIHS model.  As failure to implement hta recommendations 
has been found to emerge from a combination of system (macro), organisation 
(meso) and individual (micro) factors, this approach to understanding context 
also determined what sources of data we should include such that the research 
remained contained.   
The mapping to the PARiHS framework identified sub-dimensions under ‘context’ 
to be the most frequently cited in terms of barriers and facilitators (these often 
being the same in reverse) to the uptake of hta recommendations, followed by 
the constructs of ‘evidence’ and ‘recipient’ [Table 6.1].  From a realist 
perspective, ‘evidence’ would be considered an element of context whereas 
‘recipient’ refers to the beliefs, attitudes, motivations and values of those 
implementing, and influenced by, hta recommendations.  Evidence, as a 
context, was informed by the PARiHS model, acting as a (partial) programme 
theory and analytic framework. The mapping might infer that overcoming 
deficits in the implementing context pose the greater challenge regarding the 
uptake of hta decisions rather than the ‘buy-in’ of those implementing the 
recommendations.  However, frequency does not necessarily equate to what 
matters most from a realist perspective in terms of generating outcomes.  We 
explore this further through the CMOs.   
Table 6-1  Barriers and facilitators mapped to PARIHS 
Barriers and facilitators PARIHS mapping 
Costs of implementation, resourcing and 
inflexibility of budgets and resources(22, 90-
92, 95). 
Context - finances 
Uncertainty, weak governance, political 
constraints(90) including the role of 
accountability and regulation in affecting 
behaviour and uptake, leadership(91). 
Context – 
political/leadership 
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Poor quality of communication and 
dissemination(61, 91); too few mechanisms to 
inform; users’ (mis)understanding(22, 99). 
Context - culture 
Learning through collaboration and exchange of 
experience; skills, ability(94); formal links 
between producers and users(42); stakeholders 
are involved and support decisions(61, 95-98) 
with front line engagement, champions(22, 80, 
91). 
Evidence – 
research/experience 
Timeliness(61, 96, 99, 100). Evidence - research 
Accuracy and validity(61, 94, 99); evidence 
comes from a trusted source (95). 
Evidence - data 
Relevance(22, 94-96, 99, 100). Evidence - data 
Design of health system(90, 95) and broader 
organisational context(80, 94, 96, 101), 
including health information systems (102), 
payment mechanisms (90) and alignment of 
incentives and support from the top (61, 91). 
Context – culture/leadership 
 
Interaction at the human level. Knowledge 
translation (96, 102). 
Recipient construct (PARiHS 
later version)(200) 
 
6.3.2 Extract of articles and CMO data extraction 
In addition to the articles retrieved from our search, we analysed all the studies 
included in a review on the influence of HTA(112) from a realist perspective and 
also brought this review up-to-date to June 2020.  We examined the conclusions 
made by Hailey et al(112), extending their review by focusing on mechanisms 
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explaining how HTA is impactful.  Hailey et al found few publications assessed 
the contribution of HTA to changing patient outcomes and, given the limited 
number of studies following change in clinical practice and health outcomes, 
suggested that these areas needed much more attention in the future.  Taking a 
realist approach, we aimed to move beyond the useful description presented in 
their systematic review to interpretation, optimising the evidence about the 
impact of HTA by examining mechanisms and applying theory to critically 
appraise the literature.  We focused first on those studies employing 
quantitative methods to measure the implementation of HTA guidance.  This 
related back to our interlinked NHB-ROI framework by using a quantitative 
measure of uptake.  Analysing quantitative data in a realist way often threw up 
limitations of the data and the reporting given the need for more qualitative 
detail in the realist synthesis.  However, CMOs were able to be identified, 
especially mechanisms, from several papers [Table 6.2].  These quantitative 
evaluations included before-and-after study designs, ITS, retrospective 
longitudinal studies and prospective clinical audits to measure the 
implementation of interventions pre- and post-hta decisions.  All studies were 
observational in design. The outcome measures were related to the uptake of 
the technology, compliance with guidance, changes in prescribing rates etc.  
Data were extracted and entered into Excel under the headings of ‘context’ (of 
decision-making), ‘mechanisms’ (reactions), ‘intermediate outcomes’ and final 
outcomes which we refer to here as ‘impact’.  This enabled a better unpacking 
of longitudinal outcomes wherever possible(126).  Note that Table 6.2 lists 
‘reactions’ under mechanisms only; unless otherwise stated, the hta resource is 
always in the form of ‘evidence’ or 'information'. 
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Table 6-2  Extract of articles and data extraction. 
Article / study details Context [in PT, capability is part of context] Mechanisms Outcomes 
Article reference 
[setting] 
Study design hta Initiation context  Implementation 
context 
Reactions [in PT, 
willingness is a 
key mechanism] 
Intermediate Impact 
Mooney (2011) 
[2 hospitals] 
(214) 
Retrospective 
before and 
after 
NICE guidance on 
emergency head 
imaging 
. Lack of access to 24 
hours CT 
necessitates the 
adaptation and 
evolution of radiology 
service provision for 
this to be available in 
order to comply. 
 
Consultant-led 
publicity programme 
around the guidance, 
teaching sessions 
Weigh up of risk 
versus benefit and 
parent preferences 
by physicians. 
 
Where both CT 
available 24/7 and 
consultant publicity 
undertaken, 
practitioners’ 
change efficacy 
increases. 
 
 
Reluctance to adhere 
to guidance in children. 
 
Formal implementation 
strategy increased 
compliance more than 
site with no formal 
strategy. 
Number of CT scans 
increased in adults 
significantly but not in 
children. 
Thavarajah (2012) 
[1 hospital] (215) 
Prospective 
audit – before 
and after 
NICE guidance on 
risk assessment 
for venous 
thromboembolism 
Some issues with the 
guidance itself / sometimes 
impractical 
 Distrust / scepticism 
/ compromised 
autonomy 
 Proportion of patients 
assessed fell short 
Bennie (2012) 
[Scotland] (216) 
Longitudinal Prescribing 
efficiency of 
proton-pump 
inhibitors and 
statins 
 Quality & Outcomes 
Framework targets + 
demand side 
measures - 
education, 
economics, 
engineering, 
enforcement 
Cumulative effect 
on positive 
influence  
 Expenditure and 
number of drugs 
Goeree (2006) 
[Canada 
provincial health 
system] (217) 
Analysis of 
admin data 
Stents Relevant, responsive and 
dynamic process as 
opposed to a static report - 
handles uncertainty by 
turning the process into an 
iterative data collection, 
 Enhances credibility 
and trust as findings 
are more 
responsive to needs 
Acceptance of 
recommendations 
Reduced time lag 
between knowledge 
translation and 
uptake 
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updating and knowledge 
translation process. 
Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’ Initiation context Implementation 
context 
Reactions [in PT, 
willingness is a 
key mechanism] 
Intermediate Impact 
Schluessman 
(2009) 
[Switzerland 
national coverage] 
(218) 
 
 
Analysis of 
registry data 
Arthroplasty  Establishment of a 
registry to follow 
patient outcomes 
Creates new 
attitudes and 
motivation for HTA 
through the 
generation of 
evidence on 
outcomes  
Transparency / 
evidence generation 
Coverage 
Jonsson (2001) 
[Swedish public 
hospital] (219) 
Analysis of 
admin data 
Screening 
(various) 
Strong cultural acceptance 
of HTA.  
Emphasis on 
dissemination to 
utilise results and 
budgets for this.  
Believe that 
dissemination would 
be enhanced further 
with links to quality 
assurance activities 
too. 
Generate greater 
influence. 
Greater utilisation of 
results. 
Decisions and 
practice patterns 
following HTA 
recommendation 
Zechmeister 
(2012) [Austria 
public health care 
system] (220) 
Analysis of 
admin data 
from hospital 
and health 
insurance 
funds 
69 hta’s  No legally binding 
mechanisms to use 
results. Media 
reporting plays a role. 
Trigger for change 
motivation is as 
likely to be as much 
due to the 
admin/org changes 
as acceptance of 
the HTA findings – 
impact lies at 
organisational level 
of health system 
rather than with the 
individual. 
 Cost savings 
Bennie (2011) 
[Scotland] (221) 
Analysis of 
admin data – 
before and 
Medicines 
rejected by SMC 
Delays between 
medicine launch and initial 
SMC advice, the 
publication of conflicting 
 Complex 
relationship 
between HTA 
advice and clinical 
Variable adherence, Drug 
volume/prescribing 
not always showing 
change in clinical 
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after study 
design 
advice from different 
national bodies. Failure to 
engage with relevant 
clinical experts early in the 
medicine review process. 
practice change – 
inconsistent and 
conflicting 
professional advice 
causing confusion 
to prescribers 
practice following 
HTA recommendation 
Dietrich (2009) 
[UK] (222) 
Analysis of 
prescribing 
costs 
Medicines 
rejected by NICE 
Lack of education of 
patients and physicians as 
to rationale of guidance. 
Non compliance not 
sanctioned. Lack of 
incentives rather than 
penalties to adhere. 
No incentive or 
awareness to 
change practice. 
Non acceptance Prescriptions 
dispensed (mostly no 
change) 
Rosen (2014) 
[Sweden] (223) 
Documents, 
before-after 
surveys and 
time series 
register data. 
26 hta’s Involvement of experts 
from early on - 
effectiveness depends on 
HTA agency’s 
trustworthiness. 
Ability to disseminate 
information and 
implementation 
strategies. 
Confidence in HTA 
body and evidence 
via colleagues’ 
involvement 
Conviction of reliability 
of the HTA findings 
Changes in use and 
clinical practice 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Platt(224) [UK] Retrospective 
multi-site audit 
Childhood UTI 
NICE guidance 
 Inadequate IT systems – 
flexible computerised 
clinical systems needed to 
support implementation 
Complexity of 
guidance leading to 
subjective 
interpretation 
Variability in 
compliance 
Under-diagnosis 
Sheldon [UK](135) ITS, audit and 
interviews 
20 NHS 
hospital trusts 
Identification of a lead 
clinician early in the NICE 
guidance development and 
involvement of clinicians in 
the guideline development 
process 
Implementing deficit 
emerges from a 
combination of system, 
organisational and 
individual factors. 
 
A commitment to a 
process for 
implementing 
guidance brought 
about by trust in the 
evidence. 
 Trusts with high 
compliance to 
NICE guidelines 
had these 
common 
characteristics 
subject to 
contextual 
deficits. 
RAND [UK](19) Economic Net 
Health 
Benefits 
NIHR research Lack of practitioners’ 
involvement 
Capacity/expertise 
insufficiently accounted for 
Implementation costs not 
considered in UK health 
system 
 
Existing views and 
habits of 
practitioners, 
personal experience / 
patient preference 
not overcome 
Poor 
understanding of 
research findings 
Delays/waiting 
times in 
implementation 
NICE CVD impact 
[UK] (225)  
Before/after NICE guidance  Lack of identification of 
appropriate patients / lack 
of local referral pathways 
triggered pro-active 
networking at local level 
(via community 
groups/charities/pharmacy 
led) 
 
Mechanisms 
triggered to identify 
those at risk / local 
pathways established 
and/or supported - 
systems wide 
approaches 
Increase in those 
who can be 
diagnosed 
Increased uptake 
NICE Cancer 
impact [UK] (226) 
[this is a series of 
NICE reports]. 
Before/after NICE guidance Not always timed with 
marketing authorisation as 
well in UK as in other 
countries but changes now 
to produce earlier draft 
guidance 
 Demand generated 
for such new drugs is 
‘always’ high/exists 
by patients and 
clinicians’ needs/ 
"cancer alliances" 
Uptake slower 
than in other 
countries 
Increased uptake 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’ Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
NICE Maternity 
impact [UK] 
(227) 
Before/after NICE guidance  
 
Additional resources such 
as training, new 
equipment or pathway 
reconfiguration required. 
 
Bespoke action plans 
and support 
packages / audits 
(using charities /NHS 
partnerships / 
systems partners) to 
educate/inform/reach 
out to patients 
Patients at risk 
informed 
 
Thai HITAP 
[Thailand](212) 
Interviews, 
review of 
documentation 
Cervical 
cancer 
screening 
 
 
Financial support 
provided and good 
infrastructure existed. 
 
Political motivation 
alienated clinical 
experts and health 
professionals in the 
process of scaling up 
implementation 
Stakeholders' 
interests and 
interactions with 
health system 
not harmonised. 
Top down driven 
implementation 
failed  
Rosen 
[Sweden](223) 
Before/after, 
time series 
 A context where 
confidence in the HTA 
agency is high and 
engaging clinicians is key. 
 Confidence/trust 
among health 
professionals.  
Confidence in the 
HTA agencies' 
evidence creates 
value among leading 
healthcare 
professionals. 
 Change in clinical 
practice 
Britton 
[Sweden](228) 
7 SBU reports Various  Collaboration is in 
evidence. 
 Ownership is 
generated. 
Generally strong 
influence 
SBU reports on 
moderately 
elevated blood 
pressure, use of 
neuroleptics, 
stomach pain, 
smoking 
cessation, and 
preoperative 
routines have 
had an impact on 
clinical practice. 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Axelsson 
[Sweden](229) 
Survey SBU guidance 
on tobacco 
prevention 
Accessible, translatable 
guidance 
 Awareness and 
knowledge increased 
of practitioners 
Clinical practice 
changed 
Positive 
outcomes on 
smoking 
cessation but to 
what extent is this 
attributable to the 
guidance? 
Solans(230) 
[Spain] 
Interviews COPD  The barriers and 
facilitators identified were 
mostly organisational - in 
research management, 
and clinical and 
healthcare practice 
 
Good collaboration 
led to increased 
credibility – with 
relationships linked to 
facilitators and 
barriers 
Increased 
funding (for 
research, 
implementation?) 
Positive change 
in healthcare 
practice 
Hanney  
[UK - 
Research](231) 
 
Payback - 
interviews 
Various incl. 
NICE 
Technology 
Assessment 
Reports 
Relevance and policy 
collaboration 
 Generated policy 
customers buy in 
 Programme had 
perceived impact 
on policy and to 
some extent on 
practice. 
Guthrie  
[UK - 
Research](68) 
Payback – 
interviews, 
case studies 
Various Involvement of clinicians in 
clinical trials 
 Increased clinical 
skills 
Primary route to 
impact of 
programme-
funded research 
on patients is 
through 
influence on 
guidelines.   
Implementation of 
guidance not 
explored 
Schuller, T 
[Various INAHTA 
member 
organisations] 
(232) 
Narrative 
‘stories’ 
Various Early on stakeholder 
engagement – range of 
stakeholders including 
media, politicians, lawyers 
(+ve) 
Broadening of scope (+ve) 
The management and 
organizational culture do 
Quality monitoring (+ve) 
HTA process and 
information are totally 
separated from budgeting 
and purchasing (-ve) 
Difficult to improve 
adherence to 
recommendations as 
process underlying 
scientific evidence is 
questioned where 
lack of (+ve). 
 
 A risk that HTA 
fails to exert any 
impact on real life 
decision making. 
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not support the use of HTA 
knowledge as an essential 
part of decision processes 
(-ve) 
 
Capability 
constraints. 
Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Frønsdal, K(233) 
[HTAi Policy 
Forum] 
Descriptive Various 
 
 
 
 
 
 
 
 
 
Whole system 
consideration - health 
system structure, tasks 
(function), people (staff, 
attitudes, and knowledge) 
and technology. 
 
 
Whole system 
consideration - health 
system structure, tasks 
(function), people (staff, 
attitudes, and knowledge) 
and technology. 
 
Data from monitoring 
activities informs 
practitioners on 
optimal use by 
adding to the 
evidence base.  
 
Methods to take into 
account 
organisational issues 
or expand breadth to 
do this.  
Evidence 
generated on 
use and 
contextual 
barriers 
overcome using 
whole systems 
approach. 
Augments uptake 
but questions 
whether HTAs 
take sufficient 
account of these 
“organizational 
issues” as 
routine. 
Lowson, K et al, 
2015(234) [NHS 
Trusts] 
Cross-
sectional 
survey 
Interventional 
procedures 
Organisational processes, 
clinician engagement and 
exist as barriers. 
Financing of new 
procedures 
Lack of buy-in and 
ability (time and 
resources) 
 Non 
implementation 
Stemerding D, 
2001 (235) 
[Netherlands] 
Descriptive New serum 
screening in 
maternity care 
HTA does not incorporate 
the ethical, social, cultural 
and political dimensions of 
health technology.   
 By stimulating the 
interplay between 
different perspectives 
and preferences 
among parties 
involved, social 
learning could be 
promoted. 
Tension between 
political and 
clinical 
motivations 
unresolved. 
Unsatisfactory 
outcome to all 
parties of neither 
scale up/or scale 
down. 
Gagnon MP, 2006 
(80) [Catalonia] 
Semi-
structured 
interviews 
Insulin pump, 
cataract 
surgery, 
hip/knee 
replacement 
Hospital-based  Considering the 
dynamics between 
organisational and 
human factors 
generates more 
meaningful 
involvement in hta. 
Greater 
acceptance 
Greater uptake 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Teerawattananon 
Y, 2014(236) 
[Thailand] 
Descriptive National List of 
Essential 
Medicines 
Strong HTA processes and 
infrastructure exist 
 Enforcement of 
NLEM means 
obligation to 
provide/implement 
 Medicines are 
made available 
by law 
Corbacho B, 2019 
(237) [Spain, 
England] 
Regression on 
trends 3 
months post- 
guidance 
Cancer drugs 
(NICE, 
GENESIS) 
Number of external factors 
– not just the guidance in 
isolation 
 The more local the 
decisions, the 
stronger the adoption 
– practitioners 
perceptions key. 
 +ve 
recommendations 
equated to 
increased uptake 
but 
-ve 
recommendations 
did not show drop 
in usage 
Cummings G, 
2007 (238) 
Cross-
sectional 
census 
Nursing  Positive culture, strong 
leadership, evaluation 
feedback are predictors of 
greater staffing support 
and development 
This enhances 
practical support & 
encourages 
autonomy. 
Greater research 
utilisation 
Better quality 
care 
Dent, T 2002 
(239) [UK] 
Descriptive 
 
Various 
 
 
 
 
 
 
3 years after NICE set up.   Lack of mechanisms for 
evaluation to feedback 
and support performance 
Need for being 
informed on what is 
working and how in 
clinical process. 
Increased 
capacity by 
users to feel 
ownership  
Greater uptake of 
NICE guidance 
Fronsdal K, 
2010(233)[Multiple 
countries] 
HTAi 
workshop 
Various  Organisational and whole 
systems approach not 
incorporated into HTAs – 
lack of implementation 
plans 
But regulation, 
funding, monitoring 
can still augment the 
evidence base 
through knowledge 
generation and 
ongoing feedback to 
users 
Greater 
understanding of 
risks, what works 
etc 
Refine 
technology 
utilisation 
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Poder T, 2018 
(240) 
Interviews Various – 20 
reports 
Complexity of changes on 
administrative system 
ignored tying back to HTA 
process and stakeholder 
involvement 
Complexity of changes on 
administrative system 
ignored tying back to HTA 
process and stakeholder 
involvement 
Validation not 
generated early on in 
the process 
Discordance 
between 
guidance and 
institutions 
Non-
implementation of 
HTA guidance 
Sihvo S, 
2017(241) 
[Finland] 
Brief survey Managed 
uptake of 
medical 
methods 
 HTA process, budgeting 
and purchasing separate.   
Organisational 
leaders can generate 
influence and 
monitoring activities 
an appreciation by 
users 
HTA importance 
better 
acknowledged 
Uptake? 
Haslam D, 
2007(242) – see 
all plus Chidgey J 
2007 (243) [UK] 
Descriptive Various Uptake is dependent on 
the HTA process and 
clinical support 
 This generates 
clinical confidence in 
guidance – but alone 
not enough without 
organisational 
change and support  
 Change in clinical 
practice variable 
Gallego G, 
2011(244) 
[Australia] 
Semi-
structured 
interviews 
Medical 
devices 
Fragmented, complex 
health system 
 Uptake is dependent 
on the HTA process 
but only a facilitator – 
other factors 
including context and 
clinicians’ 
perceptions 
 Variable uptake 
Hastings J, 2006 
(245) [Multiple 
countries] 
Survey PET device  Funding linked to 
continuous quality 
improvement 
Additional knowledge 
and monitoring data 
generated to inform 
ongoing evidence 
base 
 Improved uptake 
Rosen R, 1999 
(246) 
Descriptive Various Economic and organisation 
impact needs assessed = 
whole system assessment.   
Process of hta to 
implementation is not 
linear. 
Generates openness 
and interest in 
guidance  
Better 
preparedness to 
implement. 
A receptive 
organisational 
context for 
change. 
Barosi G, 2006 
(247) [UK, US] 
Review 
 
 
 
 
 
Clinical 
guidelines 
Guideline-cycle to address 
current service 
organisation, beliefs of 
staff, monitoring 
 Ability and 
willingness of users 
generated where 
economic and 
professional 
resources supplied 
Compliance Improved patient 
outcomes 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Rosenkotter N, 
2011(248) 
Review Genetic tests Organisational analysis of 
the technology’s interaction 
with health care delivery 
and services undertaken 
plus assessing socio-
dynamics of the technology 
Organisational analysis of 
the technology’s 
interaction with health 
care delivery and services 
undertaken plus 
assessing socio-dynamics 
of the technology 
Acceptability and 
resource feasibility 
enhanced 
Broader and 
earlier hta shape 
technology 
development 
Implementation is 
facilitated 
Cacciatore P, 
2020 (249) 
[INAHTA 
members] 
Review HTA reports  Organisational aspect 
plays key role in 
implementation but under-
represented in HTA – this, 
in turn, influences 
behaviour of users 
Generates better 
understanding of the 
resources required to 
be mobilised and co-
ordinated following 
an HTA 
recommendation and 
interconnects to user 
behaviour 
User acceptance 
and capability to 
implement 
enhanced 
Improved 
implementation 
Owen-Smith A, 
2010 (92) [UK] 
Qualitative Guidance in 
clinical practice 
Various settings  
 
Practicalities of funding Autonomy 
compromised by 
rationing 
 
Use is limited Variable uptake 
Hivon M, 2005 
(250) [Canada] 
and Lehoux P, 
2009 (251) and 
Tucker S, 2019 
(252) 
Qualitative Case studies  Organisational and 
material limitations hinder 
implementation 
Shared responsibility 
/ shared commitment 
between producers 
and users of HTA 
leads to greater 
absorptive capacity 
Greater influence 
over barriers by 
users 
Increased uptake 
Pettersson B, 
2012 (253) 
[Sweden] 
Segmented 
regression 
time series 
Lipid modifying 
therapies 
 New reimbursement 
programme.  initiatives: 
education, engineering 
(organisational), 
economic and 
enforcement 
External demand 
created 
Improved 
adherence 
Change in 
prescribing rates 
Campillo-Artero C, 
2012 (254) and 
Tucker S, 2019 
Descriptive 
 
 
Various Behaviours, systems, 
procedures, resources, IT, 
evaluation all need 
Behaviours, systems, 
procedures, resources, IT, 
evaluation all need 
Investment in change 
strategies / multi-
faceted strategies 
Changed 
behaviour and 
Increased 
implementation 
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(252) and Doherty 
S, 2006 (255) and 
Mayer J, 2019 
(256) 
 
 
 
 
 
 
 
 
addressed in a culturally 
appropriate context  
addressed in a culturally 
appropriate context 
generate change 
required across all 
levels/domains – 
addressing both 
capabilities and 
motivations 
simultaneously 
environmental 
factors  
Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’  Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Tian L, 2017 (257) Before/after 
survey and 
interviews 
Nursing Examined facilitators and 
barriers using PARiHS - 
both practical resources as 
well as staff receptiveness 
to change need addressed 
Practical resources Evidence not enough 
of itself. Strong 
leadership generates 
acceptance, 
confidence and 
competence.  
Context 
conducive to 
change  
Variable 
compliance 
Esmail R, 2018 
(87) 
Theory based Disinvestment, 
de-
implementation 
 Usual contextual factors 
apply as to 
implementation 
Knowledge 
translation theory to 
support change as 
more psychologically 
challenging to stop 
rather than take up a 
technology 
 Variable change 
Saunders H, 2016 
(258) [Finland] 
Cross-
sectional 
descriptive 
design 
Nursing Individual and 
organisational readiness 
explored 
Individual and 
organisational readiness 
explored 
Self-efficacy needs to 
be fostered through 
strong leadership and 
knowledge 
Confidence and 
self-efficacy 
lacking within 
staff 
Evidence-based 
not implemented 
Taxman F, 2014 
(259) 
Trials Social 
services/justice 
Underlying social structure 
of whole organisation 
addressed to affirm value 
of interventions to users in 
a whole systems approach 
Underlying social 
structure of whole 
organisation addressed to 
affirm value of 
interventions to users in a 
whole systems approach 
Education/social 
networking builds 
expertise and 
resilience in staff thus 
improves 
organisational 
readiness to 
implement – less 
about skills, more 
about values 
Staff and 
leadership 
support 
implementation 
Improved 
receptivity to 
change given 
more supportive 
and committed 
environment 
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Article / study details Context  Mechanisms Outcomes 
Reference 
[setting] 
Study design ‘hta’ Initiation context Implementation context Reactions [in PT, 
willingness is a key 
mechanism] 
Intermediate Impact 
Stander J, 2018 
(260) [South 
Africa] 
Systematic 
scoping review 
Physiotherapy Local context and 
behaviour studied 
Local context and 
behaviour studied 
Opinion leaders 
generate consensus 
for change – less 
about knowledge and 
skills 
 Barriers in the 
context overcome  
Grenon X, 2016 
(261) 
[Switzerland] 
Semi-
structured 
interviews 
Hospital-based 
HTAs 
, clinicians’ preferences 
key 
Technical difficulties & 
lack of infrastructure 
Compliance was 
sometimes 
compromised due to 
reduced capability 
and willingness 
respectively 
 Variable 
adherence to 
guidance 
Billsten J, 2018 
(262) [Sweden] 
Naturalistic 
design, 
questionnaires 
Psychiatric 
services 
 Greater institutional 
resources and training 
needs explored 
Organisational 
readiness for change 
is generated via 
employees perceived 
need for change 
Organisation 
readiness to 
change is a 
predictor only for 
implementation 
Institutional 
support and 
relevance of 
intervention also 
required for 
implementation 
Uneke C, 2017 
(263) [Nigeria] 
Cross-
sectional 
quantitative 
study 
Maternal 
health 
 Organisational and 
individual capacity 
constraints 
IT structures are key 
to provide support, 
quality and an 
enabling environment 
– lack of 
organisational 
enabling environment 
has a knock-on effect 
on individuals’ 
motivation 
Staff 
demotivation 
Inability to apply 
evidence-based 
practices 
Sasaki N, 2019 
(264) [Japan] 
Survey CPs  IT infrastructure key Enables accessibility 
to latest evidence 
and to disseminate 
this increasing usage 
of CPs as less time 
spent searching for 
medical info.  
Information and 
CP use 
promoted 
Narrowing of the 
evidence-practice 
gap 
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communication 
promote autonomy. 
Jolliffe L, 2019 
(265) [Australia] 
Before and 
after study 
Brain injury 
rehabilitation 
CPs 
Strong organisational 
supportive management 
and leadership culture 
Strong organisational 
supportive management 
and leadership culture 
Feedback and audit 
empower staff by 
creating shared goals 
 Increased 
adherence 
Grove A, 2018 
(266) [UK] 
Case studies Orthopaedics Increased regulatory power 
 
. 
Targeting users will better 
enable them to 
communicate findings via 
the channels they prefer 
Undermines 
autonomy of users.   
 
Greater 
understanding of how 
knowledge and 
evidence 
accumulated 
 
Micro, meso, 
macro interlinked 
as lived 
experience 
(micro), 
organisational 
constrains 
(meso) and 
regulation 
(macro 
initiatives) 
influence uptake. 
Variable 
adherence 
Wathen B, 2004 
(267) [UK] 
Before-and-
after + 
interviews 
Drug 
prescribing 
 NICE guidance taken in 
isolation 
GP / patient 
experience influences 
prescribing through 
own understanding of 
risks.  Greater 
transparency and 
consideration of 
budget required to 
sustain any effect. 
 Unsustainable 
uptake of 
prescribing. 
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6.4 Main findings 
6.4.1 Programme Theory 
The findings presented below are articulated in the context of the initial 
programme theory which is used to refine our theory into a working model of 
how uptake occurs successfully.  We employ our programme theory, 
combining the two formal theories identified, PARIHS and Weiner’s theories, 
to identify and interpret the CMOC.  Using similar depiction and language as 
in the PARIHS framework, we presented this visually to depict our drawn 
model of theory [Figure 6.2].  Readiness for change is a complex multi-
dimensional construct(196) requiring both a willingness and capability to 
change.  These constructs are noted along the X-Y axis, with HTA shown as a 
direct or indirect facilitator of each.  We considered how the CMOs are 
upheld or challenged by the programme theory.  We themed findings by 
‘capability’ and ‘willingness’, and presented CMOs under each.   
Figure 6-2  Representation of our refined programme theory 
 
6.4.2 Willingness 
Practitioners’ autonomy – CMOs 
In ‘riskier’ or less straightforward situations(214) [C], clinicians are more 
likely to apply their own rationale or judgement [M] despite complying with 
guidance at other times and in other populations (for example, in children) 
resulting in non (consistent) adherence to HTA guidance [O](224, 267).  In 
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situations where the treatment had not resulted in any adverse events or side 
effects for a period of time [C], physicians may still choose to maintain the 
original treatment regimen [O](19).  The point here being that there is 
variation on the part of the clinician to use discretion (M).  Where there is 
seen to be no direct evidence of harm [C], although treatment might not be 
cost effective, there is no change in practice [O] due to the existing habits, 
views, personal experience and patient preferences [M](19, 214, 221, 222, 
224, 237, 244, 267).  This is also likely a consequence too of poor 
understanding of the guidance and/or that the guidance is not suitable in 
scope to be applied across differences in patient behaviours(215, 221, 224, 
232).  
Where non-compliance is not sanctioned [C], health professionals are only 
‘expected’ to take guidance into account together with experience and other 
sources of evidence leading to variable adherence [O](220, 222) – as seen 
above, subject to the perceived importance/value placed on the guidance as 
necessary to inform practice [M].  However, incentives rather than penalties 
[M] were thought to better foster the implementation of guidelines(266) 
(relates to Weiner’s theory on ‘want’ versus ‘ought’) together with 
information at the point of prescribing (for example, providing information 
about results of cost-effectiveness could be included in electronic prescribing 
support systems).  When hta encompasses an iterative data collection process 
ie the ongoing generation of evidence and knowledge [C], it enhances 
acceptance of, and credibility in, the hta [O] through increased motivation of 
practitioners in their understanding of what is working (217, 218, 233, 239, 
245).  Education programmes communicating the medical and economic 
rationale of the guidance can foster the patients’ and physicians’ acceptance 
[O](222), especially when they are provided from an independent institution 
[C] (222) or consultant-led(214) as the credibility of source is taken into 
account by clinicians when ‘deciding’ on its implementation [M].    
Clinician engagement promotes confidence in HTA - CMOs 
Failure to collaborate and engage with clinicians early in the hta comes up 
time and time again in relation to both negative(221) and positive 
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recommendations(19, 68, 135, 223, 228, 230, 232, 240).  Failure to engage 
even impacts negatively where capacity in the form of resources and 
infrastructure are strong (C) (for example, in Thailand with the scaling up of 
cervical cancer screening(212)).  When clinicians have been involved in the 
production of guidance via an expert advisor(223) or guidance consultee role 
for NICE [C](135), they and their colleagues are likely to be more engaged (M) 
with implementing the guidance. More generally, identifying the lead 
clinician responsible for implementation of guidance prior to guidance 
publication was reported to aid in clinician engagement(135).  However, it 
was not reported why prior notification aids engagement but, given previous 
reports of time constraints, it is plausible that knowing about the guidance in 
advance allows for resources to be better planned.  In the case of negative 
decisions, omittance to consult early on with clinicians [C] led to inconsistent 
professional advice [M] resulting in confusion by prescribers [O](221).  
Furthermore, the most important means found by one agency (223) for 
implementing its findings, is the involvement of experts in its project groups.  
Attending meetings for 2–3 years, reading and assessing relevant articles and 
reaching agreement on findings and conclusions all serve to create effective 
advocates for the final report. So, involvement in development of guidance 
(C) means practitioners have increased ownership and attachment (M) and 
engagement (M)(234).   
Drawing on Weiner’s theory of organisational readiness as to how to interpret 
and articulate all this as a CMOC:  Forewarning of the intervention (C) allows 
planning of resources and leadership (C), which in turn triggers ownership, 
attachment, and acceptability (M) of the recommendations and increases 
motivation to implement (O).  This is perhaps because an intervention that is 
implemented in a well-resourced context fosters confidence (including 
consistency of message, as per above) and encourages staff to get behind it.  
Moreover, healthcare professionals are more likely to change their behaviour 
if their colleagues are convinced of the reliability of findings.  Rather than 
this being a practicality about time constraints, we would suggest that where 
such engagement is carried out [C], legitimacy in the findings is instilled as 
well as peer trust-building amongst practitioners in the hta [M] leading to 
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more successful uptake of guidance [O].  It enables practitioners to feel a 
change is appropriate, as the critical mass reinforces its appropriateness and 
value.  Weiner’s theory would suggest that when readiness for change is high 
ie with high levels of collective change efficacy and commitment, 
practitioners are more likely to initiate change, exert greater effort, exhibit 
greater persistence in the face of obstacles or setbacks and display more 
cooperative behaviour.  The key point here is about whole team change, or a 
climate of agility resulting in more effective implementation(135, 196, 223, 
232, 268).   Practical means found in the literature used to increase 
confidence/trust etc include early engagement and external validation (in 
some contexts). 
6.4.3 Capability 
Supportive measures must span individual- and system-level- CMOs 
Although analysis of routine health administrative data showed clear positive 
changes in uptake in many instances [O], stakeholders felt that where 
organisational and administrative changes are triggered and/or justified by 
hta reports [C], this is more likely to have been the influencing factor rather 
than health professionals’ awareness or acceptance of the htas [M] (220).  
Contextual change in terms of additional organisational and implementation 
support accounts for variance in uptake just as much – or more than(220) - 
professional buy-in (19, 135, 220, 223, 230, 232-234, 240, 242-244, 246-252, 
254-256, 261).  Several studies identified robust IT systems within the 
healthcare system as being a key step to improving implementation of 
guidance (224, 263, 264).  Here, HTA is possibly more influential at a 
(healthcare) systems level rather than at the individual level with IT being an 
important tangible aspect of an organisation’s infrastructure that must be 
considered; as readiness is gauged, the influence of IT support over-rides the 
influence of (lack of) individual preference/agency/action.    
Although HTA provides resources in terms of guidance, knowledge and 
sometimes training, additional supportive resources including data 
management systems(264) and organisational wide processes(252, 254-256) 
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were often lacking resulting in variable implementation.  Similar to the 
above, this again indicates that knowledge/information-based resources held 
at the individual level were not enough to produce uptake: context-level 
resources were required to augment the knowledge and information.  A 
shared responsibility/collaboration between producers and users of hta in 
addressing the wider causes of, for example, over/under- diagnosis or 
prescribing, would promote a greater harmonisation of interests among 
stakeholders across multiple levels of the system [C](230), triggering 
motivation [M](263) and greater acceptance of the guidance [M](248, 249) 
and ultimately, greater absorptive capacity(250-252).  Supportive measures 
are seen to be not just about providing capacity in terms of resources; it 
enables practitioners to feel capable of making the change successful, with 
greater preparedness and more influence to overcome barriers ie collective 
change efficacy (M)(230, 246, 249-252).  Monitoring systems [C] also 
reinforced this change efficacy [M] for both practical reasons around the ease 
of information retrieval but also by continually augmenting the evidence-
base(233, 247, 263, 264).  Where the process of compliance is turned into an 
iterative data collection and knowledge translation process(217) [C], there is 
greater acceptance of recommendations [O] given its perceived relevance 
and responsiveness by clinicians [M].  Similarly, where monitoring is 
undertaken [C], this in itself increases coverage [O] as it creates new positive 
attitudes [M](218).   
Furthermore, evidence shows where demand-side measures co-exist in 
addition to guidance [C], prescribing increases [O] due to a combination of 
education, economic incentives and enforcement [M](221).  Similarly, where 
there is emphasis on dissemination and budgets for implementation plus links 
to quality assurance activities (C], implementation of services is likely to face 
less barriers [O] due to a combination of practical support and enforcement 
[M] (219).  However, the latter example was found in preventative services 
which may have more influence than other clinical measures.  This 
embellishes the argument about resources being necessary from different 
levels to leverage collective support to act.   
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This is again underpinned by Weiner’s organisational theory (196) on critical 
mass at the organisational rather than individual level where the effect is 
greater when there is shared resolve and a common understanding and 
valence of change.  Weiner’s theory is at the supra-individual levels of 
analysis because many promising approaches to improving healthcare delivery 
entail collective behaviour change in the form of systems redesign - that is, 
multiple, simultaneous changes in staffing, work flow, decision making, 
communication, and reward systems.  It depends on collective, coordinated 
behaviour change. The greater the degree of interdependence in change 
processes and outcomes, the greater the utility of supra-individual theories of 
readiness(196).  It would appear that where HTA is accompanied by joined up 
systems-wide approaches (IT, monitoring and administrative structures, 
funding etc) (C), the change efficacy and change commitment of 
practitioners is increased (M) leading to their adherence of evidence-based 
guidance [O].  The above all argue for a complexity-informed approach ie the 
need to operate across individual, systems/process, and organisational level.   
6.4.4 Drawing lines between CMOs and the Programme Theory 
Our starting premise is that everything we are focusing on here is a step on 
from HTA’s impact on decision-making.   HTA is an input to decision-making 
but “XYZ” is required for implementation of that decision; HTA supports 
decisions but not (directly) the implementation of them. This is why this work 
extends the reach of HTA by an appreciation of the context (‘capability’ 
being part of context) and individuals’ drivers (willingness, scope in role, 
change efficacy etc).  These can also reinforce or strengthen one another, 
and thus better transfer decisions into actions.  Our focus is, therefore, on 
specifically looking for mechanisms that link decisions to actions (outcomes).  
In addition to looking for mechanisms that link decisions to actions, we also 
consider the characteristics of the recommendations.  We can categorise an 
‘hta’ into 3 types(32) [see Chapter 1]: 
• Micro: appraisal of individual technologies (or related groups thereof)  
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• Meso: clinical practice guidelines to manage patient care pathways 
within a healthcare system 
• Macro: efficiency, organisation and strengthening of the healthcare 
system  
The CMOC are tabulated below to demonstrate the links and hypotheses.  We 
also themed these by ‘willingness’ and ‘capability’ and indicate where there 
is an interaction, leading generally to a positive change in implementation.  
Regarding saturation of the literature, we were finding that mechanisms 
identified could be broadly placed under our theory around willingness and 
capability but could be continually modified by new contexts.  Finally, we 
show at which level the hta and any supportive measures were operational 
[Table 6.3]. 
 
 
143 
 
 
 
Table 6-3  Linking CMOs and Programme Theory 
Theme Context Mechanism Outcome Level References 
Willingness* 
capability 
Risky situations – and also the 
governance/accountability 
environment in which they are 
in 
Clinicians apply own 
rationale – and also may not 
feel they can make these 
decisions if context 
restricts how supportive 
they feel their 
infrastructure/ 
environment is 
Non-adherence to HTA Meso (214, 232, 
267) 
Willingness* 
capability 
Evolving alignment of 
healthcare system practicalities 
combined with stakeholder-led 
publicity.  
Change efficacy of 
practitioners increased 
Significant increase in 
compliance 
Meso + 
Macro 
(135, 214, 
227, 233) 
Willingness Long term treatments Poor patient acceptability 
and understanding of 
Non acceptance/ potential for 
medical disputes  
Micro (19, 222, 
267) 
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rationale for change, 
preferences 
Willingness No evidence of harm Lack of perceived incentive 
and motivation/perception 
of ‘need’ 
No change in practice Micro/meso (19, 232, 
262) 
Willingness Non-compliance not sanctioned Guidance adds little value 
to existing knowledge 
Variable adherence  Micro /Meso (220, 222) 
Willingness* 
capability 
Organisational buy-in/ 
convinced of independent, 
evidence-based need: 
Education communicating the 
guidance origins 
Clinician acceptance of 
guidance. 
Increased adherence Meso + 
Macro 
(238, 246) 
Willingness Relevant, responsive and 
dynamic / monitoring processes 
Credibility and trust as 
findings are more 
Reduced time lag between 
knowledge translation and 
uptake  
Micro / 
meso 
(217, 218, 
245) 
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responsive and relevant to 
needs – on an ongoing basis 
Willingness Low trust settings require 
external validation (conversely, 
in existing high trust settings of 
HTA) 
Guidance has perceived 
legitimacy and credibility  
Better communication between 
patient/practitioner/consultant 
on patient care 
Meso (214, 222, 
240) 
Willingness Co-production of guidance and 
engagement with end-user 
(clinician)  
Increased ownership / 
Increased trust  
Better implementation/ 
successful uptake  
Meso (230, 250-
252) 
Capability * 
willingness 
Forewarning of guidance with 
capacity to plan 
organisationally 
Increased acceptability as 
perceived increase in 
feasibility of enacting upon 
findings 
Change efficacy and 
commitment of practitioners 
increases  
Meso + 
Macro 
(80, 240, 
248, 249) 
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Willingness Lack of early consultation with 
clinical experts (conversely 
involvement of experts from 
early on) 
Inconsistent professional 
advice (confidence in HTA 
body and evidence) 
Confusion by prescribers / 
distrust / scepticism 
(conviction in reliability of the 
HTA) 
Micro (19, 135, 
215, 221, 
223, 232, 
234, 266) 
Capability * 
willingness 
IT / infrastructure reforms / 
systems-wide support 
integrated with stakeholder 
engagement (or a recognised 
need for) 
Alignment with clinical 
needs and organisational 
systems 
 
Change efficacy and change 
commitment of practitioners 
increases  
Meso + 
Macro 
(19, 135, 
224, 227, 
232-234, 
240, 242, 
244, 246-
249, 252, 
254, 256, 
261, 263, 
264) 
Willingness Non - identification/address of 
problem (despite good 
infrastructure) 
Non harmonisation of 
interests, motivation  
Non-acceptance of guidance  Meso (212) 
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Capability No legally binding mechanisms 
to use HTA results. 
Organisational changes in the 
system triggered by HTA 
(converse to the above) 
Increased motivation to use 
HTA resulting from 
structural changes (rather 
than acceptance of HTA 
findings)  
Health systems strengthening  Macro (220) 
Capability * 
Willingness 
Demand-side measures co-exist 
with HTA guidance – 
organisational readiness needs 
to be supplemented by uptake 
on the patient side 
Education, economic 
incentives, enforcement 
Increased reach / coverage Meso (216, 253) 
Capability Resources - budgets, quality 
assurance etc 
Combination of practical 
support and enforcement 
Fewer barriers to 
implementation  
Macro (24, 232, 
245) 
Willingness Compliance process becomes 
data collection and KE / 
monitoring 
Increased perceived 
relevance and 
responsiveness / new 
Greater acceptance of 
recommendations  
Meso/macro (217, 218, 
238, 239, 
245, 247) 
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attitudes through the 
generation of evidence  
Capability * 
Willingness 
Strong leadership / cultural 
acceptance of HTA and support 
for dissemination of HTA 
Increased influence Increased utilisation of results Meso & 
Macro 
(219, 232, 
238, 241, 
257, 258, 
260, 265) 
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Finally, for ease of visual presentation, we adapt Figure 6.2 by plotting here 
some papers from the realist synthesis as to where they fit regarding the 
interplay between contextual elements and mechanisms of action.  When 
presenting findings, rather than extensive lists of CMOs, we have presented our 
programme theory diagrammatically as shown into a ‘mid-level of abstraction’. 
Figure 6-3  Capability & Willingness - Context & Mechanisms 
 
 
 
6.5 Discussion 
The NIHR HTA Programme and NICE’s guidelines have, according to the authors 
of an impact study, neglected the final common pathway, namely the HTA and 
implementation interaction(269). ‘The NIHR HTA Programme strives to provide 
the NHS with the best possible evidence. NICE strives to provide it with the best 
possible guidance.  The interactions of these processes seem to work. What is 
missing is information on how new evidence or guidance impacts on patient care 
and what factors influence the implementation of clinical guidelines. These 
relationships are not nearly so well understood and could be rich areas for future 
research’(269).  We have attempted to explore this through a realist inquiry. 
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We started by mapping implementing barriers and facilitators to the PARIHS 
framework.  This showed that most facilitators are to do with evidence, with the 
barriers more likely to be in the context.  The CMOs would suggest that 
willingness (or change commitment) may be predominantly influenced via the 
hta if the hta process is carried out in accordance to good practice(42, 270).  
Relating this back to iDSI’s ToC with its elements of ‘evidence’ and ‘process’, 
this ToC might be more influential in terms of creating willingness but, of itself, 
this may not necessarily be sufficient to overcome contextual deficits with 
regards to the implementation of those decisions.  
Weiner refers to a shared resolve to implement a change (change commitment) 
and a shared belief in collective capacity to do so (change efficacy)(196).  He 
sees this as a function of how practitioners’ value the change and determinants 
of implementation capability (task demands, resource availability and situational 
factors).  As such, it spans both psychological and structural terms.  Through the 
CMOC extracted, we evidence that where there is an interaction between 
willingness (change commitment) and capability (change efficacy), so that one 
reinforces the other, we see a more successful change in practice and 
implementation of hta guidance, decisions, recommendations etc – and that 
both are necessary but not necessarily sufficient on their own to facilitate the 
uptake of those decisions.  A receptive context in terms of either capability or 
willingness is not necessarily sufficient by itself.  Furthermore, whilst 
mechanisms (the response/reaction of people to resources) might seem obvious - 
value, trust, motivation etc all being relatable aspects of the human condition, 
what is less so is how they are activated by specific resources in specific 
contexts(213).  Again, we attempt to reveal this through the CMOC as to how 
these mechanisms leading to outcomes can be achieved through different means 
in different contexts.   
Consideration of funding research on the short-term costs of the implementation 
of new health technologies was a recommendation in a recent NIHR HTA impact 
evaluation(68).  In its HTA process, France takes into consideration other 
transition costs related to infrastructure modifications for getting the 
intervention into routine use.  The CMOC would indicate it is more complex than 
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funding alone.  NICE started the Health Technologies Adoption Programme in 
2014(185)4 which supports the uptake of new recommended technologies.  They 
facilitate the adoption of prioritised medical technologies across the NHS by: 1) 
engaging with clinical teams, commissioners, patient groups and industry; 2) 
gathering real-world experiences from health and social care organisations; 3) 
identifying adoption barriers and solutions.  Their supporting documentation 
recognises ‘readiness’.  In assessing readiness, the care pathway is mapped and 
potential systems effects, the anticipated costs and savings of adoption, change 
in delivery requirements and monitoring data are highlighted.  Whether this 
mapping of the care pathway adequately addresses complexity is unclear, 
especially when adopting a whole systems perspective.  Such mapping can often 
result in a set of linear assumptions which will always perpetuate the gap 
between evidence and delivery/implementation [see Figure 1.3] because the 
implementation is so context and response dependent.  Unless the complexities 
that our CMOC highlight are accounted for, such linear care pathway mapping 
will likely keep falling short. 
The CMOC support an argument for HTA being seen in a wider systems or 
organisational context.  An organisational level is a useful unit of analysis as 
collective behaviour change is needed to enact upon hta decisions in order to 
lead to impact at a population level.  Similar findings were found in an 
evaluation of the Building Capacity to Use Research Evidence (BCURE)5 where 
change at one level (for example, organisational) created conducive contexts for 
change at other levels (individual) and vice versa.  This interaction or two-way 
effect is also highlighted by Currie et al(271) who state that business intelligence 
structures are necessary but not enough as the mobilisation of knowledge is 
‘peopled’.  Indeed, the CMOC indicate that data infrastructures can facilitate 
learning where people embed and use this intelligence (rather than just a focus 
on data per se).  In organisational development, socio-technical theory refers to 
 
4 https://www.nice.org.uk/about/what-we-do/into-practice/adoption-team 
5 https://bcureglobal.wordpress.com/ 
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such interaction between human behaviour and technology in the 
workplace(272, 273). 
Over 20 years ago, Rosen & Gabbay(246) called for technology assessors to 
branch out from their current focus on clinical outcomes and study outcomes 
such as staffing implications, impact on related services and set up costs - 
making their evidence more directly relevant to the decision-makers at whom it 
is aimed and thus more likely to be used.  Whilst guidance exists as to how to 
understand and address what impact a complex intervention will have in the 
implementing context(194), this focuses on the technology (rather than the hta) 
and ends with the hta decision rather than its implementation.  A robust analysis 
of the context-mechanism association can serve to innovate and transform 
interventions as elements of the context, if determined to be critically 
important to the successful functioning of the intervention, and may be re-
theorised as an intervention component in further iterations of the 
intervention(213).  We suggest HTA frequently needs to come with 
complementary components to ensure it has value, with examples found of 
supportive and integrated measures at all levels of the system (organisation, 
structure, incentives at individual level).  Equally, the costs of systems change 
and service configuration cannot be ignored. 
Referring back to the research objectives of the realist synthesis [Chapter 5], we 
suggest that: 
1) the mechanisms that encourage the implementation of hta findings have been 
themed under willingness (relating to Weiner’s collective change commitment) 
and capability (relating to Weiner’s collective change efficacy).  The CMOC 
depict how such responses can be triggered to a greater or lesser extent in 
different contexts.  Understanding these multi-dimensional and multi-level 
aspects of readiness should help give a more complete picture of readiness to 
implement(274).    
2) The CMOC would indicate that an hta often does not have the leverage to 
trigger these mechanisms and counter contextual deficiencies without additional 
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supportive measures.  The literature and our CMOC would indicate that whilst 
acceptance, trust, motivation etc can be influenced by the hta, the systems-
wide or organisational domain is under-represented in an hta.  The opportunities 
and resources to enact those decisions are needed but this systems-perspective 
is often lacking - with a resulting disconnect.  This would suggest that the 
interface between HTA and health delivery systems needs more attention – 
especially in resource limited contexts, as LMIC face greater complexity when it 
comes to implementation of evidence(275).  We call for greater integration 
between HTA and health systems strengthening to optimise impact.  There is not 
a clearly defined boundary between HTA and questions relating to service 
delivery and organisation.  Indeed, some would argue that it is a false distinction 
to make, as technical and organisational or social considerations are so 
interwoven that they should not be studied in isolation. 
3) Common predicting mechanisms that transcend contexts are found in an 
interaction between collective change efficacy and change commitment or 
willingness and capability.  We evidence that this generally leads to a positive 
change in implementation of an HTA.  Both are necessary, and crucially, one can 
reinforce the other.   
In Chapter 10, we discuss the implications of these findings and make 
recommendations for stakeholders.  To tailor this to LMICs in particular, we 
suggest this could mean a focus on greater connectedness between HTA and 
health systems.  A practical way to do this, we suggest, is a refocus on meso HTA 
(for example, guidelines to manage patient care pathways within a healthcare 
system) or macro HTA (efficiency, organisation and strengthening of the 
healthcare system).  We also support greater use of early (or development-
focused) HTA.  In so doing, this research provides a framework for HTA’s reach 
to extend to both readiness and impact – thus stretching both at the beginning 
and at the end. 
154 
 
 
 
6.6 Conclusion  
Through the CMO, we explored the mechanisms and pattern of outcomes in the 
literature on the implementation of hta decisions.  Rather than simply 
summating the literature, by taking a realist approach, we moved beyond a 
description of facilitators and barriers to an interpretation of uptake in order to 
produce tested and data-driven theory on the mechanisms by which HTA impact 
can be optimised.  We have analysed and synthesised CMOC, using the 
programme theory to progress knowledge as a theory or framework.   
6.7 Next Steps 
In Part 3, we bring together the different paradigms (quantitative and theory 
driven) into one framework and test the theory with case studies.  We look at 
whether this further evidence supports, refines or refutes the theory developed 
here.  
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Part 3: Case studies 
This part presents illustrative case studies using the ROI-NHB impact framework 
[Chapter 4].  In order to get to the value of investing in HTA at the systems 
level, we need to look at what the process is delivering, in other words, the 
aggregated value of each individual hta.  In both case studies, by offsetting the 
attributable benefits against the associated costs, we evidence value for money 
from simply introducing a single ‘hta’. We are very grateful to iDSI who helped 
facilitate access to CNHDRC, and to colleagues in China who kindly agreed to us 
using their case study.  The SHTG case study was facilitated by colleagues at 
NHS Healthcare Improvement Scotland after I presented on this research at their 
annual conference.  This led to connections being made with the Scottish Health 
Technologies Group (SHTG) and their recommendation of Freestyle Libre as a 
potentially impactful case study according to their own impact work.   
Chapter 7 presents an hta case study from China.  The uptake of new clinical 
pathways (CP) on stroke management was measured by taking the results of a 
quasi-experimental analysis carried out by colleagues at the Chinese National 
Health Development Research Center (CNHDRC), Beijing.  We converted this into 
realised NHB at the population level for the areas of China where the guidance 
was piloted.  We compared those benefits attributable to the hta with the 
estimated costs of undertaking the process.   
Chapter 8 presents an hta case study from Scotland.  This case study quantifies 
the value of investing in HTA using an illustrative case study from the Scottish 
Health Technologies Group (SHTG).  Freestyle Libre (FL) is a technology to 
enable those with diabetes to continuously measure their glucose levels.  Uptake 
of FL was based on an analysis of routinely collected longitudinal prescribing 
data.  The longer-term impact on health outcomes and resource use was 
modelled by SHTG as part of the hta.  We use these data to estimate realised 
population NHBs and what we can attribute to the hta recommendation.  We 
compare those benefits to the estimated costs of undertaking the hta.   
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Chapter 9 reconciles the programme theory with the two case studies.  We test 
our theory using the case studies to provide a continuing test of the same theory 
with two quite different bodies of data(276).  We bring together the qualitative 
and quantitative methods; quantitative to capture an empirical and credible 
measure of uptake (or stopping) of a technology following an hta 
recommendation plus qualitative data to understand what it is about the context 
that has led to this level of implementation.  Qualitative data were collected by 
itad in the pilot sites in China as part of the project’s monitoring(179).  This 
included site visits and the main mode of data collection during these visits was 
key informant interviews with stakeholders from groups identified as key to the 
implementation of the pilot.  Interviews were conducted according to semi-
structured protocols developed in advance of the visits and translated into 
Chinese.   SHTG had undertaken stakeholder analysis but this was unavailable to 
us, as was the opportunity to undertake our own interviews given the COVID19 
pandemic.  Instead, we discuss our programme theory in relation to our 
quantitative results and SHTG’s impact findings.  These show how the ROI-NHB 
and realist framework look when they are brought together. 
There were several criteria used in selecting the case studies and the rationale 
for each is described below. 
Firstly, there needed to be data on implementation/uptake, for example, 
prescribing data, both before and after an hta recommendation.  This was to 
allow any change in uptake to be estimated drawing upon quasi-experimental 
methods.  Given that the Scottish Medicines Consortium (SMC) undertakes an hta 
upon launch of all new medicines, this requirement of pre-hta data meant that, 
in the case of Scotland, we could only consider non pharmaceutical technologies 
ie technologies appraised by the SHTG.  We note more generally that where HTA 
has been institutionalised, there are fewer data prior to the hta on prescribing 
levels or volume against which to measure the influence of the hta 
recommendation.  Thus, whilst ITS was successfully used previously to assess the 
implementation of NICE guidance (135), it no longer makes sense to use this on 
contemporary NICE guidance as these processes have now become 
institutionalised with hta recommendations made predominantly on newly 
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licensed technologies.  However, in countries transitioning out of donor support, 
the intended focus of our impact framework and where HTA processes have not 
yet been institutionalised, there should be more data to be able to apply such 
methods – indeed, as Sheldon et al did when NICE was still only advisory(135). 
Secondly, a decision model should ideally have been part of the hta. This meant 
that we could incorporate the cost-effectiveness results expressed as cost per 
QALY and/or NHB straight into our framework without having to undertake this 
modelling ourselves.   
Thirdly, accompanying qualitative data relating to the implementation of the 
technology/hta recommendation were sought.  This was to facilitate testing the 
theory developed as part of the realist inquiry.  Ideally, we would have 
undertaken our own realist interviews with stakeholders but being able to draw 
upon existing qualitative data meant we had this option within the boundaries of 
time and other practicalities. 
Finally, we wanted to include both an LMIC and HIC country to represent a 
country where HTA has been institutionalised and one newer to these processes.  
Although we cannot draw comparison from just two case studies, it seemed 
appropriate to aim for this contrast. 
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7 The impact and value of HTA in China:  a 
quantitative case study 
7.1 Introduction 
This case study quantifies the value of investing in HTA using an illustrative case 
study on clinical pathways (CP) from China.  Uptake of the CP was based on an 
analysis of routinely collected longitudinal data and the longer-term impact on 
health outcomes and resource use was modelled.  We drew on an hta and 
evaluation undertaken by colleagues in China to, in turn, estimate realised 
population NHB and what we could attribute to the hta.  By offsetting the 
attributable benefits against the associated costs, we show high returns from a 
single hta.   
Very few studies to-date have estimated the benefits of HTA in terms of net 
health gains.  However, there is growing interest amongst policy-makers and 
donors in the value of HTA, especially given its more recent expansion into LMIC.  
Our literature review [Chapter 2] found the evaluation of HTA to be 
methodologically lacking with scare empirical evidence of the impact of HTA on 
health outcomes and costs.  In this case study, we apply our NHB-ROI framework 
to consider the opportunity costs required to undertake an hta and ultimately, 
to sustain an HTA infrastructure.  Since every resource can be put to alternative 
uses, quantifying the costs and benefits of investing in HTA is important to policy 
makers.  Using this illustrative case study on CP for stroke management which 
was piloted in four regions in China, we quantify the value of investing in a 
single hta.  We drew on a pre-existing analysis by colleagues at CNHDRC of 
routinely collected longitudinal data on relevant clinical practices in order to 
quantify the uptake of the CP.  We converted this into NHB at the population 
level encompassing the four regions of China where the guidance was piloted.  
We compared the benefits attributable to the hta against the costs associated 
with undertaking the process.  We show these costs to be significantly offset 
when estimating the financial investment at the provincial levels.  We suggest it 
would require approximately 30 such htas for costs to be offset if investing in 
HTA at a national level.  
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7.2 Case study background 
Translating evidence into policy and implementation ‘on the ground’ remains a 
persistent challenge.  Policy decisions derived from HTA include drug 
reimbursement decisions, development of health benefits packages as well as CP 
design.  Clinical pathways are medical and nursing procedures including details 
of therapy and consultations designed to reduce variations in clinical practices, 
optimise patient outcomes, minimise resource utilisation, maximise the clinical 
effectiveness of process of care, accommodate communication between patient 
and healthcare professionals and, to improve quality of documentation(277-279). 
CPs are being increasingly recommended and used in various health settings 
internationally and are recognised as an effective instrument to facilitate 
healthcare reform(280, 281). 
CNHDRC supported by NICE International recently introduced a CP for stroke 
covering prevention, treatment and rehabilitation guidance for clinicians at 
different levels of healthcare delivery(282).  In China, non-communicable 
diseases (NCDs) account for an estimated 87% of annual deaths and 69% of the 
total disease burden(282). As the leading cause of adult mortality and morbidity 
in China, the annual stroke death case and mortality rate are approximately 1.6 
million, and 157 per 100,000 respectively(283).  In addition, China has 2.5 
million new stroke cases each year and 7.5 million stroke survivors(284).  
Moreover, recent studies have shown that on the ground, over-prescribing has 
led to dramatic increases in medical costs and an adverse impact upon quality of 
care.  As part of ongoing public hospital reform in China, the development of 
evidence-based CPs has been prioritised as a potential solution by Chinese 
stakeholders to contain medical costs whilst improving quality of care in 
accordance with lessons learned from health sector reforms in other countries.  
CPs intend to improve medical quality, reduce medical service costs and 
increase the cost-effectiveness of overall health resource utilisation.  For those 
reasons, we consider the development of CPs as part of the process of HTA (just 
as NICE has responsibility for clinical guidelines). 
160 
 
 
 
For acute stroke patients, including those receiving treatment for Transient 
Ischaemic Attack (TIA), cerebral haemorrhage and cerebral infarction (CI), the 
CPs promote the increased use of aspirin and statins, advocate swallowing 
assessment and early ambulation and, a reduction or avoidance in the use of 
practice which is ineffective or ambiguous.  The CPs were implemented in four 
pilot counties, a mix of rural and urban areas (Hanbin, Huangdao, Qianjiang and 
Wenxian) in November 2013.  By May 2015, a total of 5,490 patients had been 
managed following the CPs. The CPs were implemented alongside other health 
systems-wide interventions, such as payment reform and the development of 
data management systems and software.  
7.3 Methods 
7.3.1 Markov model 
Net health benefits, our proposed measure of impact, were introduced in 
Chapter 4.  To recap, a healthcare technology is considered beneficial if it 
provides more overall health than it displaces as a result of its additional cost 
diverting resources away from other interventions or services.  To ensure that 
the funding of a new intervention is consistent with the objective of maximising 
health gains subject to a budget constraint, new health care technologies must 
provide an incremental cost per QALY (or DALY averted) compared to current 
care less than the cost-effectiveness threshold(161) [see Equations 4.1 and 4.2]. 
The potential population NHB associated with full implementation of the CP was 
quantified using the results from decision-analytic modelling undertaken as part 
of the hta by CNHDRC.  We converted the lifetime cost per QALY obtained from 
a Markov model of the CPs [see Box 7.1] into NHBs and scaled this up to the 
population level using estimates of the eligible population given the prevalence 
and incidence of stroke(282).  One GDP was assumed as the threshold value.   
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BOX 7.1 Modelling QALYs gained from CPs(285) 
7.1.1 A Markov model is an analytical framework frequently used in the 
economic evaluation of healthcare interventions. Markov models use (mutually 
exclusive and exhaustive) disease states to represent all possible consequences 
of an intervention. Individuals transition between disease states as their 
condition changes over time.  Time spent in each disease state for a single 
model cycle (and transitions between states) is associated with a cost and a 
health outcome.  Costs and health outcomes are aggregated for a cohort of 
patients over successive cycles to provide lifetime cost-effectiveness against a 
comparator strategy(286). 
7.1.2 A Markov health state transition model was developed to simulate the care 
trajectory of a cohort of stroke patients.  The 3-year period of the evaluation 
was divided into cycles of 3 months (40 cycles in total), matching the time 
cycles of the source data. The model was structured into 3 basic modules for 
each cycle: 1) method of care (CP group versus non-CP group), 2) health states 
according to residential status (hospital, home, institutions of rehabilitation, 
death, and stroke-related death), 3) clinical outcome (onset, recurrence, 
rehabilitation, death). The model was built using Treeage Pro 2017 software.  
The base case was assumed to be a cohort of over 1000 CI inpatients, all over 
the age of 60-year-old who were assigned into either the CP group or non-CP 
group according to the inclusion and exclusion criteria and clinician judgment. 
The model used a healthcare system perspective and a time horizon of 10 years. 
The relative risk of stroke-related deaths under the CP was applied as a 
triggering factor to measure the effectiveness of the intervention. Outcome 
measures were costs of health states, QALYs and lifetime ICERs.   
7.3.1 Value of implementation  
As outlined in Chapter 4, we define the impact of HTA to be achieved through 
increasing the uptake of net beneficial technologies and decreasing the uptake 
of non-net beneficial technologies [see Figures 4.2 and 4.3].  To recap, the 
objective is to convey the concepts of population potential, realised and 
attributable NHBs to the hta (as measured against a counterfactual).  We refer 
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to this approach as the VoImp(159).  A shortfall between potential and current 
implementation provides evidence that implementation is sub-optimal.  
Inefficiencies would exist in healthcare from inadequate use of CPs, leading to 
foregone health benefits. The current value to the health system of the CPs is 
the value from all patients currently managed by the guidance.  This is 
determined by the NHB of treating each patient, in other words, the health gains 
minus the opportunity costs.  The population NHB of introducing a technology is, 
along with setting a threshold and a function of its incremental costs and effects 
in comparison with alternative guidance or standard care, the duration of  its 
usage or validity and the size of the patient population served(164).  As such, 
NHB measure the scale or magnitude of the net gains at a population level as 
offered by the intervention(165).  Equation 4.3 defines this value to the 
healthcare system, where 𝒏𝒏 is the total patient population eligible for treatment 
and p is the current utilisation rate of the technology(161). 
Realising the population NHB of the CP required using available evidence on their 
degree of uptake to calculate the VoImp.  We incorporated the findings of an 
evaluation undertaken by CNHDRC on the uptake of the CPs to estimate realised 
and attributable NHBs.  To what extent we can attribute the uptake of the CPs 
to the hta and subsequent changes in clinical practice required a counterfactual 
as to what the level of uptake and change in practice might have been in the 
absence of the hta.  A counterfactual or comparison group enables us to 
estimate changes in outcome that can we can attribute to an intervention, here 
the hta.  There might have been some natural diffusion or decline in usage 
anyway of the various clinical practices covered by the CPs which would reduce 
the overall value and impact of the hta.  To estimate the extent to which 
clinical behaviour change and drug usage as recommended by the CPs would 
have happened without the hta, CNHDRC drew on a range of quasi-experimental 
methods, namely interrupted time series, difference-in-difference and the use 
of matched controls(169, 170).  A summary of the CP evaluation is provided in 
Box 7.2.   
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BOX 7.2 Estimating the level of implementation of the CP 
7.2.1 Evaluation of the uptake of the CPs in 4 pilot sites was undertaken by 
monitoring change in quality of life, resource use, drug usage and clinical 
practice.  This was measured using a variety of methods including interrupted 
time series, before-and-after studies with and without a matched control group. 
7.2.2 Billing data were deemed to be the most detailed source for medical 
expenditure and items prescribed providing the best evidence to summarise 
changes in physicians’ behaviour and expenditure patterns.  Data were collected 
for 24 monthly time points before the CPs and 12 monthly time points after their 
introduction.  Data were randomly sourced from 150 patients’ records for each 
condition, at each pilot hospital, from three groups: pre-intervention 
population, post-intervention population included in CP management, and post-
intervention population not included in CP management.   
7.2.3 Where this routinely collected data allowed, the effect of the CPs on 
selected outcomes was assessed using ITS analysis with segmented regression.  
This can achieve statistical power with a relatively short time series(287, 288).  
Other analyses were conducted using a before-and-after design in comparison 
with a paired control group, and for new quality metrics introduced as part of 
the pathways (ie where there was no routinely collected data prior to their 
introduction), trends in the period since they were introduced was monitored.  
There was no pre-existing information available on the extent of any 
autocorrelation (ie where data items are correlated with lagged versions of 
themselves in the same time series) and the likely effect size.  The Durbin-
Watson test was used to test the presence of first order auto-correlation; if 
auto-correlation was detected in outcomes of interest, a generalised least 
squares estimator was used to estimate the regression. All analysis was 
performed using SAS 9.4.   
The full evaluation report and results are available in a published report(282).   
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7.4 Data  
7.4.1 Lifetime Quality Adjust Life Years and Costs 
The Markov model provided data on the aggregated costs and utilities (based on 
the EQ-5D-3L) of health states, QALYs and the lifetime ICERs.  Only direct 
medical and intervention costs were included; non-medical and indirect medical 
costs were excluded from the analysis.  A pre-requisite for participation in the 
pilot study was the implementation of an electronic prescription system within 
the hospital. The patients’ medical records and patients’ billing data were 
collected electronically for data analysis. Thus, the costs of patients’ 
hospitalisation were generated from the hospital information system, and the 
intervention costs were estimated by the financial department of a local 
hospital. The cost of care of CI patients in a rehabilitation institution unit and 
in-home care was estimated from a literature research. The transition 
probabilities between health states were collected from a literature review.  
Table 7-1 shows the model inputs and the resulting modelled lifetime QALYs, 
costs and ICERs. 
7.4.2 Level of implementation of the CPs 
As the ‘attributable’ parameter is key to our hta impact calculations, we present 
and critique the results of the CNHDRC evaluation which estimated the level of 
implementation of the CPs by looking at changes in clinical practice and drug 
usage before and after the hta.  Analysis of routine clinical data in the pilot sites 
12 months after launch suggested that the utilisation and quality of services 
recommended by the CPs had been strengthened (with fewer significant changes 
in the use of services not recommended by the CPs).  Among the services 
adopted by the CPs, use of statins and brain imaging (within 24 hours of 
hospitalisation) showed the largest increase in utilisation – and are likely to be 
most impactful on health changes.  The CNHDRC evaluation of the CP 
implementation produced the results shown for statins and brain imaging [Table 
7.1].   CT and MRI tests within 24 hours was maintained at a relatively high level 
in both groups.  The CP group’s utilisation of statin-type drugs substantially 
increased as compared with usage both prior to the pilot and with the controls.  
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We show the largest crude before and after change (in bold, Table 7.1).  The 
attributable percentage was calculated as the average of the difference 
between the pathway group and the controls.  The fact that the baseline values 
are the same for both the intervention and control groups is critiqued as a 
limitation below.  We use this uptake of statin as a proxy for the magnitude of 
uptake of the CPs and, in turn, to estimate the realised and attributable NHBs. 
7.4.3 Other data  
Other quantitative data required to establish the potential population NHB of 
the CP included an estimate of the eligible population given the prevalence and 
incidence of stroke, and a cost-effectiveness threshold.  These were taken from 
estimates and assumptions provided by CNHDRC.  We assume the CP to be valid 
for 5 years to enable us to calculate the number of eligible patients reached by 
this one hta.  We estimate the investment costs in HTA at a systems or national 
level to be 0.1% of total healthcare spend.  This is based on a relatively 
consistent percentage spent on HTA across countries(14, 15). 
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Table 7-1  CP Implementation 
 Qianjiang   Hanbin    Huangdao    Wenxian    Before/ Attributable 
 Pre% Post% Post% Pre% Post% Post% Pre% Post% Post% Pre% Post% Post% after % % 
  Pathway Controls  Pathway Controls  Pathway Controls  Pathway Controls  Diff-in-Diff 
TIA statins 25.30 36.37 28.30 34.38      58.00 70.71 76.61 
71.28 10.65 CI statins 84.85 92.67 65.22 56.72 64.39 59.68 24.40 95.68 79.71 64.00 68.24 54.67 
CH brain 
image 89.23 95.45 81.16 73.44 89.55 86.84    70.97 78.52 90.70 
  
CI brain 
image 60.61 79.33 69.57 75.37 60.61 82.26 58.93 89.93 68.12 77.42 81.74 70.59 
Adapted from main report(282) (Table 27).  Appendix: Wenxian (Tables 9,15,20,21); Qianjiang (Tables 10,12,13); Hanbin (Tables 2,7,8); Huangdao (Tables 13, 16) 
Table 7-2  Summary of data 
Inputs Value Data sources           
Prevalence of stroke 2% Chinese Stroke Prevention and Treatment Report 2015           
Population Hanbin  1,010,000 CNHDRC evaluation *to nearest 1000 
 
 
 
 
     
Population Huangdao  1,470,000      
Population Qianjiang  530,000      
Population Wenxian  420,000      
Incidence 
136 – 486 per 100,000 person-years 
(taken average of regional variation) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078629      
Length of time treatment valid 5 years Assumption           
Discount rate 0.035 China Guidelines for Pharmacoeconomic Evaluation           
Cost-effectiveness threshold 54000 RMB 
2014 China GDP per capita (current US $). [Internet]; [cited Dec 2017]. 
Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD.            
Cost of acute hospitalisation 12595 RMB (range 6922—16516) Data from pilot county      
Cost of rehabilitation 10305 RMB (range 2592—12959) 
Thrombolysis Implementation and Monitoring of Acute Ischemic Stroke in 
China      
Cost of intervention 1733 RMB Data from pilot county      
Cost of home care 6773 RMB (range 2028-8639) China National Stroke Registry      
167 
 
 
 
Utilities hospitalisation 0.13 
 
     
Utilities rehabilitation 0.56      
Utilities home 0.92      
Relative Risk_hospitalisation_death (CP v.s. non-CP 
patients) 0.8 
Launois, R., Giroud, M., Mégnigbêto, A. C., Le Lay, K., Présenté, G., 
Mahagne, M. H., Gaudin, A. F. (2004). Estimating the Cost-Effectiveness 
of Stroke Units in France Compared with Conventional Care. Stroke, 
35(3), 770–775. https://doi.org/10.1161/01.STR.0000117574.19517.80.      
Mean cost of acute hospitalisation_CP 14328 RMB per patient Markov model      
Mean cost of acute hospitalisation _Non CP 12595 RMB per patient  Markov model      
Lifetime Costs non CP pathway 114796 Markov model      
QALYs non CP pathway 13.43 Markov model      
Lifetime Costs CP pathway 120855 Markov model      
QALYs CP pathway 13.88 Markov model       
Incremental costs 6059 Markov model      
Incremental QALYs 0.45 Markov model      
ICER 13318 RMB per QALY Markov model      
Change in uptake/practice 70% CNHDRC evaluation: average implementation levels post CP [Table 7.1]      
Attributable uptake 10% CNHDRC evaluation: average difference in CP/non CP group [Table 7.1]      
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7.5 Results 
We present the individual NHB stemming from the CPs [Equation 7.1].  The 
incremental health benefit associated with the CPs compared with usual care 
was, on average, 0.45 QALYs per person.  The incremental costs per person 
associated with the CPs compared with usual care was 6059 RMB.  These costs 
are converted into their health equivalence by dividing through by the 
willingness-to-pay threshold and then subtracted from the health gain.  The NHB 
per person is 0.34 QALYs. 
Equation 7-1 Individual NHB 
 
This individual NHB of 0.34 QALYs was scaled up to the population level given 
new and existing cases [Equation 7.2].   
Equation 7-2 Prevalence and incidence 
 
The total eligible population ie those at risk was based on the estimates of the 
population of the 4 pilot provinces, stroke prevalence and incidence [see Table 
7.2], discounted over 5 years.  The total population at risk was estimated to be 
118325 people [Table 7.3]. 
Table 7-3  Population at risk in the 4 pilots 
Years CP valid Population  Prevalence Incidence  Discounted Cumulative  
Year 1 3426400 68528 10656 79184 79184 
Year 2 3426400  10656 10296 89480 
Year 3 3426400  10656 9948 99427 
Year 4 3426400  10656 9611 109039 
Year 5 3426400  10656 9286 118325 
 
As we scale up NHB to the provincial level of the 4 pilot sites (rather than to a 
national level), we consider the costs of HTA as a percentage of the provincial 
level healthcare spend rather than that at a national level [Table 7.4]. 
𝑁𝑁𝑝𝑝𝐶𝐶 𝐻𝐻𝑝𝑝𝑠𝑠𝑟𝑟𝐶𝐶ℎ 𝐵𝐵𝑝𝑝𝑠𝑠𝑝𝑝𝐵𝐵𝑑𝑑𝐶𝐶𝐶𝐶 =  ∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝐶𝐶 −  
∆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
𝜆𝜆
 
 
   = 0.45 – (6059/54000) 
   = 0.34 
Prev y = Prev y-1 + I Y 
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Table 7-4  Provincial annual healthcare spend 
Pilot 1 1648.65 (unit 100 million) RMB 
Pilot 2 1259.4 (unit 100 million) RMB 
Pilot 3 512.03 (unit 100 million) RMB 
Pilot 4 730.98 (unit 100 million) RMB 
Source: 2013 China healthcare statistics yearbook *more recent versions did not 
disaggregate by region http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2013/index2013.html 
 
The estimated costs of investing in HTA at a regional level based on 0.1% of total 
healthcare spend are expressed in terms of their health equivalence by dividing 
through by cost-effectiveness threshold (𝜆𝜆). Using a willingness-to-pay threshold 
of one GDP, this equates to 7687 NHB. 
Table 7-5  Costs of investing in HTA (RMB) 
Annual healthcare 
spend in 4 pilot areas 
(in 100 million RMB)  
Estimated spend on 
HTA at 0.1% (in 100 
million RMB) 
Expressed in health 
equivalence                         
assuming 1 GDP = 54000 RMB 
4151 RMB 4.15 RMB 7687 NHB 
 
We present the NHB associated with full, current and the attributable levels of 
implementation and offset this against the costs of investing in HTA at a systems 
level.  Full implementation was based on all eligible patients receiving 
treatment.  Current implementation was based on before-and-after results from 
the CP implementation study, and the attributable percentage was taken from 
the difference-in-difference estimates between the intervention group and the 
controls.  This shows that the NHB attributable to approximately three htas 
(assuming similar impact) would offset annual investment costs in HTA at a 
regional level [Table 7-6]. 
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Table 7-6  Results 
Population NHB 
(full 
implementation) 
Realised NHB 
(Current 
implementation) 
70% 
% NHBs 
attributable to 
the hta = 10% 
Costs of 
investing 
in HTA 
expressed 
in NHB 
No. of 
similar 
htas to 
offset 
costs 
= 118325 x 0.34 
= 39970 27979 2798 
 
7687 
 
3 
 
7.5.1 Scenario analyses 
We undertook an illustrative two-way scenario analysis by varying the magnitude 
of uptake and attributable percentages.  This scenario analysis can help to 
examine uncertainty in the implementation and uptake of the CPs [Table 7-7].   
Table 7-7  Scenario analysis – implementation 
Implementation % Attributable % Population NHB No. hta's to offset 
regional HTA costs 
100% 10% 39970 1.92 
90% 20% 39970 1.07 
80% 30% 39970 0.80 
70% 40% 39970 0.69 
50% 50% 39970 0.77 
40% 60% 39970 0.80 
30% 70% 39970 0.92 
20% 80% 39970 1.20 
10% 90% 39970 2.14 
 
We also undertook a scenario analysis using national healthcare spend.  In 2015, 
this was 40975(100 million) RMB(289).  HTA investment costs were estimated 
again at 0.1% of total healthcare spend and would include infrastructure and 
recurring costs of maintaining a sustainable infrastructure.  The results of this 
analysis indicated that around twenty-seven htas (assuming similar impact) 
would be required to offset these costs at a national level. 
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Table 7-8  Scenario analysis –offsetting HTA costs at a national level 
National 
healthcare 
spend (100 
million RMB)  
Estimated spend 
on HTA at 0.1% 
(100 million RMB) 
Expressed in health 
equivalence                         
assuming 1 GDP as 
threshold 
 
40974.64 40.97 75879 
 
Population NHB         
(Full 
implementation) 
Realised NHB 
(Current 
implementation) 
  
% NHBs 
attributable 
to hta 10%  
HTA as 
0.1% of 
national 
spend in 
NHBs 
No. of hta's 
to offset 
HTA costs 
at a 
national 
level 
39970 NHB 27979 NHB 2798 NHB 75879 NHB Approx. 27 
     
 
7.6 Discussion 
HTA is expanding rapidly in China with recent political commitment for its 
coordination at a national level(290).  However, ‘for HTA to be as effective as it 
should be, researchers need to pay equal attention to the transmission of 
research findings to potential users and the translation of research into policies, 
decisions, clinical practice, etc. Without this, HTA is just an academic exercise 
that is of little value to health care and has little impact on society’(291).  For 
HTA to be more impactful in China, knowledge translation is deemed to be 
important(292).  Furthermore, active producers and users of HTA in China should 
take every opportunity to showcase the value of HTA(293). This case study 
illustrates its potential returns by offsetting the benefits of a single hta against 
typical costs associated with regional and national investment in HTA.  The 
results indicate approximately 30 htas annually, assuming similar impact on 
average, would offset costs nationally.  This could approximate to what 
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established agencies such as HITAP in Thailand might now average6, and 
certainly a lot less than what some HTA agencies carry out7. 
Unlike the RAND impact evaluation of the HTA NIHR programme (19), we 
estimate realised and attributable NHBs using methods to establish uptake 
against a counterfactual rather than simply assume full implementation.  To do 
this, we drew upon existing analyses undertaken by colleagues at CHNDRC.  
There are some limitations to the quasi-experimental methods applied.  To 
measure the change in statin usage, they used a difference-in-difference 
approach.  CNHDRC stated that some analyses were conducted using a before-
and-after design in comparison with a paired control group but for new quality 
metrics introduced as part of the pathways (ie no routinely collected data prior 
to their introduction), only trends in the period since they were introduced was 
monitored.  As the baseline measurement for both the intervention and the 
control groups were the same, we took the pooled difference in the post-
intervention measures between the two groups.  Nevertheless, it illustrates that 
a control or comparator is crucial to impact evaluations given the potential for a 
crude before-and-after analysis to lead to erroneous measures and conclusions of 
impact, with attribution which could be wrongly assigned or interpreted. 
Others have estimated the cost-effectiveness of clinical guidelines(294).  
However, they do not measure implementation or bring in the issue of 
attribution/the counterfactual as this is about the CP itself rather than the hta.  
We make the case that this is not just about the CP being cost-effective which, 
indeed, they appear to be: a French study found similar results of 1395 euros per 
QALY = 11299 RMB/QALY, and expert opinion has indicated that CPs in stroke 
units are much more likely to be followed than in other disease areas(295).  Our 
results suggest that the actual hta creates value with benefits of the process 
offsetting the costs.  There is a relatively high level of implementation 
associated with the CP and realised NHB are estimated to be fairly close to the 
potential NHB associated with full implementation.  However, the observed 
change in practice from the quasi-experimental analyses found the control group 
 
6 HITAP list 240 reports on their website over the last 10+ years https://www.hitap.net/en/ 
7 The Scottish Medicines Consortium lists ~100 htas in 2019 https://www.scottishmedicines.org.uk/ 
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also experienced a change in practice to higher levels of compliance with the 
recommended guidance.  The fact that the controls also saw a positive change in 
clinical practice could be due to other factors. This project was implemented 
under the backdrop of healthcare reform. The impact of the project – and thus 
the hta – would have likely been influenced by external factors, such as 
healthcare reform policy, medical insurance policy and hospital management.  
Indeed, the costs of these supporting measures cannot be ignored.  This is 
discussed in Chapter 9. 
We aim to capture here the often over-looked issue of redeploying existing 
resources from alternative uses (the opportunity costs) in order to ensure a 
sustainable HTA system be established.  If we think priority setting should be 
better informed by evidence, and use tools such as HTA, this necessarily implies 
institutional change to establish a sustainable system.  Consequently, the 
opportunity costs that are needed for its establishment and ongoing running 
have to be considered(38).  In order to show the ROI of HTA at a systems level, 
this would require aggregating all individual htas.  By aggregating the realised 
NHBs of all hta decisions given the current level of implementation, or as we 
propose, by considering a level of implementation attributable to the hta as 
measured against a counterfactual, we would be able to offset these aggregated 
NHB against the costs of investing in HTA at a systems level.  A natural 
progression of this case study would be to apply the full framework.  We 
recognise that the data requirements would not be without their challenges and 
would likely require purposeful sampling with data collection and not just a 
reliance on routine administrative systems.   
7.7 Limitations 
In keeping with the assumptions made by CNHDRC in their original hta, we have 
used WHO GDP per capita-based thresholds.  Although widely used to assess 
cost-effectiveness, empirical evidence suggests these thresholds are likely to be 
significantly higher than actual health opportunity costs(162, 171) – and indeed, 
was not a use for which they were ever intended(296). They depict the value of 
a statistical life and is not a reflection of opportunity costs.  A scenario analysis 
using more realistic thresholds could be undertaken. 
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This case study intends to be illustrative only, seeking to use available data and 
information on the cost, effectiveness and implementation levels of a 
technology following an hta.  We scale this up to make an estimate of how many 
htas may be required to offset the costs of investing in HTA at a systems level – 
at both a regional and national level.  As stated above, a natural progression of 
this case study would be to apply the NHB-ROI framework in full or with a wider 
range of case studies. 
The support costs of the payment reforms, IT support etc have not been taken 
into account in the analysis.  Again, a scenario or threshold analysis could be 
undertaken to incorporate a range of values. 
Finally, we recognise we are not capturing spillover benefits of investing in HTA 
beyond NHB.  For example, HTA might facilitate improved monitoring and 
administrative systems.  However, we have used the qualitative data collected 
from stakeholders in the pilot sites in China which should help with 
understanding how social, technical, intellectual and political capital may be 
leveraged by HTA over time as well as the mechanisms underpinning the uptake 
of the CP [Chapter 9]. 
7.8 Conclusion 
Our study goes beyond showing that the stroke CPs are cost-effective.  This case 
study shows that the hta itself offers value for money to the extent that the 
benefits attributable to the process offset a significant proportion of its costs.  
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8 The value of HTA:  a quantitative case study on 
Freestyle Libre Glucose Monitoring System from 
the Scottish Health Technologies Group 
8.1 Introduction 
This research intends to quantify the value of HTA using a case study approach 
from Scotland where HTA has been institutionalised, having been formally 
established approximately 20 years ago.  Using a single illustrative hta on 
Freestyle Libre (FL) for diabetes management as implemented in Scotland, this 
case study intends to quantify the value of investing in HTA as a priority setting 
process.  The potential benefits from introducing FL for diabetes management is 
measured and converted into NHBs at the population level.  We use routinely 
collected longitudinal prescribing data to assess the uptake of FL across all 
fourteen NHS Boards before-and-after the Scottish Health Technologies Group’s 
(SHTG) guidance; using quasi-experimental methods, we more robustly estimate 
the benefits attributable to the hta (as compared with a crude before-and-after 
estimate) by accounting for pre-existing trends in prescribing.  This change in 
uptake is used, in turn, to estimate realised population NHBs – and what we can 
attribute to the hta itself.  We compare those benefits attributable to the hta 
against its associated costs and show these to be potentially offset in full. 
8.2 Case study background 
The SHTG is a national HTA agency.  SHTG provides evidence, support and advice 
to NHS Scotland on the use of new and existing health technologies which are 
not medicines and which are likely to have significant implications for people’s 
care.  The role of the SHTG committee is to advise on and support best use of 
health technology interventions within NHS Scotland. The committee is made up 
of representatives from NHS boards, clinical and professional networks, 
academia, National Procurement and Scottish Government. It also includes four 
volunteer public partners, who represent the views of the Scottish public8. 
 
8http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg/about
_shtg.aspx 
176 
 
The SHTG undertook an hta of FL in 2018.  Diabetes mellitus (DM) is a major 
cause of morbidity and mortality in Scotland with around 300,000 people 
diagnosed with the condition.  Self-monitoring of blood glucose is essential for 
people with type 1 (DMT1), and is used by roughly one in 10 people with type 2 
(DMT2) to manage glycaemic control and adjust insulin or other medications.  
Currently, finger-prick self-monitoring of blood glucose (SMBG) using test strips 
and blood glucose meters is the most frequently used monitoring method(297).  
DM Freestyle Libre® is a flash glucose monitoring system.  The ‘game-changing 
technology’ allows people with diabetes to track their blood sugar levels without 
having to prick their fingers. The flash glucose monitoring system is designed to 
change how people with diabetes measure their glucose levels and ultimately 
help them achieve better health outcomes.  The system automatically reads 
glucose levels through a small sensor that is worn on the back of the upper arm 
for up to fourteen days, eliminating the need for routine finger pricks and user 
calibration.  Two clinical trials and real-world evidence from more than 50,000 
users showed that people who used the FL system scanned their glucose levels 
an average of at least 15 times per day. In real-world use, higher rates of 
scanning to self-monitor glucose were found to be strongly associated with 
improved glucose measures, including decreased time in hypoglycaemia and 
hyperglycaemia(298). 
Regulatory approval for FL was obtained in September 2014 in the UK but was 
available as of then only privately.  It was added to the Scottish drugs tariff from 
November 2017, meaning it would be available for reimbursement across NHS 
Scotland (as well as the NHS in England and Wales, and Health and Social Care in 
Northern Ireland) for people with DMT1 and DMT2 who intensively used insulin.  
The topic was prioritised for inclusion on the SHTG work programme following a 
referral from the Scottish Diabetes Group and the assessment was intended to 
provide information to support decision makers within NHS Scotland.  In July 
2018, an advice statement9 was issued by the SHTG following an Evidence 
Note(299).  Evidence notes are rapid reviews of the evidence surrounding health 
technologies that are under consideration by decision makers in NHS Scotland.  
 
9 
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/topics_a
ssessed/shtg_009-18.aspx  
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They are intended to provide information quickly to support time-sensitive 
decisions, usually within 6 months(297).  The Evidence Note was based on a 
European Network for Health Technology Assessment (EUnetHTA) rapid review of 
published clinical effectiveness and safety literature but also incorporated a 
range of additional evidence sources including: a Healthcare Improvement 
Scotland (NHS HIS) economic evaluation, a patient group submission from 
Diabetes Scotland and NHS Scotland clinical expert input.  The advice for NHS 
Scotland was that flash glucose monitoring with Freestyle Libre® be available for 
individuals with diabetes who are actively engaged in the management of their 
diabetes and who intensively manage their condition with multiple daily insulin 
injections or insulin pump therapy.  NHS Scotland is required to consider the 
SHTG advice but it is not mandatory.  Seven of the fourteen NHS health boards 
in Scotland had already made FL available after launch in November 2017 and 
had put pathways into practice(300) whilst the rest were awaiting the SHTG 
recommendation first before prescribing it. 
8.3 Methods 
8.3.1 Markov model 
Our framework utilises the lifetime health economic results from a Markov 
model [see Chapter 7, Box 7.1] as outlined in SHTG’s evidence note.  We adapt 
the information from the published Evidence Note to estimate potential 
population NHBs [see Chapter 4].  The model is summarised in Box 8.1.  For full 
details, please see SHTG’s Evidence Note(299).    
BOX 8.1 Modelling QALYs gained from FLs 
Economic modelling was undertaken using a Markov Model and considered 
resource utilisation, utilities and 2 main clinical outcomes, namely the impact of 
FL on the testing frequency of blood glucose and on the frequency of 
hypoglycemic events.  FL had a statistically significant impact compared with 
SMBG on both these outcomes using evidence from 2 key randomised controlled 
trials.  A Markov health state transition model was developed to simulate the 
care trajectory of a cohort of diabetic patients. A simple 2-state structure was 
applied, separated into sub-models for T1DM and T2DM. A patient can either be 
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dead or alive in the model (the 2 states), with transition determined by a 
diabetes-specific mortality rate. One year of living with diabetes is associated 
with a direct resource use linked to the consumables involved in monitoring 
blood glucose but also an indirect resource use due to severe hypoglycemic 
events. A key assumption is that FL monitoring results in a decrease in the 
number of blood glucose tests used by a patient.  The evidence also points to a 
potential decreased incidence of hypoglycemia with FL compared with SMBG, 
resulting in an impact on NHS resources for severe hypoglycemic events requiring 
medical attention. These potential savings are offset by an increased cost 
associated with FL.  Two model structures were used: the first was a restricted 
model taking into account the relative cost of monitoring and the direct impact 
of FL on health utility scores; the second (‘full’ model) also incorporates 
hypoglycemic events and the associated impact on utility and resource use.   The 
models used a healthcare system perspective and a lifetime horizon. Outcome 
measures were costs of health states, QALYs and lifetime ICERs(299). 
8.3.2 Value of implementation  
As outlined previously (see Chapters 4 and 7), the current value to the health 
system of the healthcare technology is the value from all the patients who 
currently receive it and is determined by the NHB of treating each patient ie the 
health gains minus the opportunity costs.  To recap, we define the impact of 
HTA to be achieved through increasing the uptake of net beneficial technologies 
and decreasing the uptake of non-net beneficial technologies.   The objective is 
to convey the concepts of potential, realised and attributable (ie as measured 
against a counterfactual) population NHBs.  We refer to this approach as 
VoImp(159).   
In order to calculate the potential population NHB associated with FL, we 
converted the cost-effectiveness results of the lifetime cost per QALY obtained 
from the Markov model of FL versus SMBG care and scaled this up to the 
population level given estimates of the prevalence and incidence of diabetes in 
Scotland.  To calculate NHB, we used the lower bound of £20k as the UK 
threshold.  Realising the population NHB then required using available evidence 
on the degree of uptake of FL as described below.   
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8.3.3 Interrupted time series – segmented regression 
We analysed monthly monitoring data on the prescribing of FL in order to 
estimate realised and attributable NHB.  To estimate the extent to which uptake 
of FL would have happened without the hta, we used ITS with segmented 
regression.  Uptake of FL was recorded by ISD Scotland who monitored 
prescribing rates across all NHS boards(301).  Prescriptions in the community 
dataset(302) contained details of items dispensed in the community by General 
Practices (GP) by NHS Board.  Data monitoring started from November 2017 (ie 
when FL became available on the NHS) and we analysed the data over 24 
monthly time points to November 2019 [Table 8.1].  This, therefore, covered 8 
months prescribing data pre-hta guidance which was issued in July 2018, and 16 
monthly time points post-hta guidance.  
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Table 8-1  ISD monthly practice level prescribing data by NHS Board 
Prescribing 
by Board 
Ayr.  
Arran1 
Borders D&G2 Fife Forth 
Valley 
Grampian Greater  
Glasgow 
& Clyde 
Highland Lanark3. Lothian Orkney Shet4. Tayside Western 
Isles 
Total Mile-
stones  
                      
Nov-17 4 0 0 6 59 4 14 6 1 8 0 0 0 0 102 NHS 
Dec-17 2 1 2 22 207 8 13 4 9 2 0 0 0 0 270   
Jan-18 4 13 9 79 336 18 21 12 18 10 0 0 0 0 520   
Feb-18 6 8 10 93 452 6 20 23 12 45 0 0 0 0 675   
Mar-18 40 142 5 132 692 6 31 26 20 2755 0 0 0 0 3849   
Apr-18 57 182 3 134 878 10 43 22 21 3162 0 0 0 0 4512   
May-18 147 81 83 162 1149 18 47 38 70 3005 0 0 0 0 4800   
Jun-18 260 242 498 51 1341 4 166 35 229 4109 0 0 0 0 6935   
Jul-18 380 140 599 87 1206 15 1245 53 308 4303 0 0 0 0 8336 HTA 
Aug-18 434 98 677 19 1358 8 1610 82 459 4934 0 0 0 54 9733   
Sep-18 504 394 734 138 1339 10 1967 92 516 4433 0 0 0 56 10183   
Oct-18 736 383 826 25 1585 277 2351 119 771 4916 0 4 0 70 12063   
Nov-18 760 318 854 329 1558 345 2312 170 779 4949 0 45 0 164 12583   
Dec-18 915 523 1016 442 1899 718 2460 234 1261 5349 30 58 0 143 15048   
Jan-19 947 397 945 528 1758 631 2430 237 1362 5132 58 56 0 163 14644   
Feb-19 926 525 934 1213 1792 904 2356 333 408 4971 58 47 989 149 15605   
Mar-19 1104 613 1102 1368 2067 973 2668 271 92 5598 49 76 1223 237 17441   
Apr-19 1188 524 1156 1491 2106 1219 2413 577 106 5570 74 61 1132 237 17854   
May-19 1280 658 1249 1689 2253 1429 2914 856 0 6465 78 89 1432 256 20648   
Jun-19 1370 646 1247 1671 2240 1423 3742 840 297 5788 68 71 1453 126 20982   
Jul-19 1473 700 1359 1909 2434 1794 3330 949 0 6645 92 78 1705 288 22756   
Aug-19 1482 724 1381 1767 2496 1621 3982 965 70 6406 101 90 1775 257 23117   
Sep-19 1503 753 1448 1930 2526 1871 3749 1151 419 6586 103 87 1920 294 24340   
Oct-19 1720 732 1548 1882 2751 2040 4667 1210 0 6826 93 118 2051 309 25947   
1Ayrshire and Arran, 2Dumfries and Galloway 3Lanarkshire, 4 Shetland. Units are the number of prescriptions dispensed for which the dispenser has been reimbursed. Glossary-of-Terms.pdf (isdscotland.org) 
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This routinely collected data allowed the effect of the hta guidance on FL 
prescribing to be assessed using ITS analysis with segmented regression.  This 
method can achieve statistical power with a relatively short time series (287, 
288).  ITS studies use routine data collected at equally spaced intervals of time 
before and after an intervention, and do not necessarily require a control site.  
Given the limited number of timepoints over which data were collected, 
segmented regression was a more practical option for analysing and utilising this 
routinely collected data.  The analysis followed the steps as outlined in Lagarde 
et al, 2012(287).  
Equation 8.1 shows the specification of the linear regression. 
Equation 8-1 Linear regression 
 
Where Yt is the outcome variable (ie the number of FL units prescribed) at time 
t; time is a continuous variable indicating time from the start of the study up to 
the end of the period of observation.  In this model, 𝛽𝛽0 captures the baseline 
level of the outcome at time 0 (beginning of the period); 𝛽𝛽1 estimates the 
structural trend or growth rate in utilisation, independently from the 
intervention; 𝛽𝛽2 estimates the immediate impact of the intervention or the 
change in level in the outcome of interest after the intervention; and 𝛽𝛽3 reflects 
the change in trend, or growth rate in outcome, after the intervention. 
The intervention (ie the issuance of hta guidance) is coded 0 for pre-intervention 
time points and 1 for post-intervention time points and, post-slope is coded 0 up 
to the last point before the intervention phase and coded sequentially from 1 
thereafter.  The following independent variables (‘time’, ‘intervention’, ‘post-
slope’, ‘pre-slope’) were created [Table 8.2].   
 
 
𝑄𝑄𝐶𝐶 =  𝛽𝛽0 +  𝛽𝛽1𝐶𝐶𝑑𝑑𝑠𝑠𝑝𝑝 +  𝛽𝛽2𝑑𝑑𝑠𝑠𝐶𝐶𝑝𝑝𝑝𝑝𝑣𝑣𝑝𝑝𝑠𝑠𝐶𝐶𝑑𝑑𝐶𝐶𝑠𝑠 +  𝛽𝛽3𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶𝑝𝑝𝑝𝑝 +  𝜀𝜀𝐶𝐶 
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Table 8-2  ITS Dataset and variables 
Date Outcome 
[Table 8.1] 
Time Intervention Pre-slope Post-slope 
Nov-17 102 1 0 1 0 
Dec-17 270 2 0 2 0 
Jan-18 520 3 0 3 0 
Feb-18 675 4 0 4 0 
Mar-18 3849 5 0 5 0 
Apr-18 4512 6 0 6 0 
May-18 4800 7 0 7 0 
Jun-18 6935 8 0 8 0 
Jul-18 8336 9 1 8 1 
Aug-18 9733 10 1 8 2 
Sep-18 10183 11 1 8 3 
Oct-18 12063 12 1 8 4 
Nov-18 12583 13 1 8 5 
Dec-18 15048 14 1 8 6 
Jan-19 14644 15 1 8 7 
Feb-19 15605 16 1 8 8 
Mar-19 17441 17 1 8 9 
Apr-19 17854 18 1 8 10 
May-19 20648 19 1 8 11 
Jun-19 20982 20 1 8 12 
Jul-19 22756 21 1 8 13 
Aug-19 23117 22 1 8 14 
Sep-19 24340 23 1 8 15 
Oct-19 25947 24 1 8 16 
 
The analysis was undertaken with ‘outcome’ as the dependent variable in the 
regression.  The Durbin-Watson test was used to test the presence of first order 
auto-correlation (where values are statistically correlated with past values of 
the data) using a Prais-Winsten estimator that corrects for data auto-correlation; 
and a generalised least squares estimator was used to estimate the regression. 
All analysis was performed using STATA version 14. The STATA code is given 
below. 
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Figure 8-1  Stata code for ITS segmented regression 
 
Stimport excel ("ITS analysis") firstrow 
reg Outcome Time Intervention Postslope     
tsset Time        
prais Outcome Time Intervention Postslope     
predict fitted_values       
line fitted_values Time        
 
8.3.4 Return on investment 
The ROI equation is outlined in Chapter 4 [Equation 4.1].  Slotting the NHBs 
metric into this original ROI equation, we can express a NHB-ROI [Equation 4.2]. 
8.4 Data  
8.4.1 Lifetime Quality Adjusted Life Years and Costs 
The Markov model provided data on the aggregated costs and utilities (based on 
the EQ-5D) of health states, QALYs and the lifetime ICER.  Only direct medical 
and intervention costs were included, non-medical and indirect medical costs 
were excluded from the analysis [Table 8.4]. 
8.4.2 Level of implementation of FL 
Analysis of the routine clinical data across all NHS boards 24 months after launch 
(and 16 months after the hta guidance) showed that the utilisation of FL had 
been strengthened after the publication of the SHTG HTA Evidence Note.  We 
use these results to inform a magnitude of uptake of FL and, in turn, to estimate 
the realised and attributable NHBs.  The results of the model are presented in 
Table 8.3. 
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Table 8-3  Results of ITS segmented regression 
 
Results indicate a (non significant) increase of 820 FL units per month after the 
issuance of the hta guidance.  We used these results to calculate the relative 
and absolute effects of the guidance by estimating the expected prescribing 
uptake of FL 16 months after the hta (24 months after launch).  We entered the 
values of the explanatory variables at month 24 into the estimated regression 
equation [Equation 8.2]. 
Equation 8-2 HTA effect on prescribing levels 
 
In the absence of a control group, we also used the results of the regression to 
fabricate a counterfactual and estimate what would have been the level of 
outcome of prescribing without the HTA [Equation 8.3]. 
Equation 8-3 Prescribing levels without HTA 
 
Using the estimated coefficients, we found that 16 months after the hta 
guidance there was a predicted monthly prescribing uptake of 25,652 units of FL 
(actual 25,947 units); while, without the hta, the model predicted that uptake 
would only have reached 22,704 units.  Therefore, the absolute effect of the 
intervention was an increase of 2,948 units and the relative effect was a 13% 
increase in prescribing.  We show the fitted results with the outcome of interest 
plotted against time with the hta guidance issued at month 8 indicated by the 
dashed line [Figure 8.2]. 
Outcome Coef. Std. Err. t P>t [95% Conf. Interval]
Time 1027.365 90.95131 11.3 0 837.6443 1217.087
Intervention 820.4716 490.0288 1.67 0.11 -201.7106 1842.654
Postslope 132.8752 95.19409 1.4 0.178 -65.69615 331.4466
_cons -1944.49 456.566 -4.26 0 -2896.868 -992.108
rho -0.18329
𝑄𝑄24 =  𝛽𝛽0 +  𝛽𝛽1 𝑥𝑥 24 +  𝛽𝛽2 +  𝛽𝛽3 𝑥𝑥 16 
𝑄𝑄24 =  𝛽𝛽0 +  𝛽𝛽1 𝑥𝑥 24 
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Figure 8-2  Prescribing trends pre-and post hta 
  
8.4.3 Other data  
Other quantitative data required to estimate the potential population NHB of FL 
included an estimate of the eligible population given the prevalence and 
incidence of diabetes in Scotland, and a cost-effectiveness threshold.  These 
values were taken from the estimates provided in the HTA Evidence Note(299).  
We assumed FL to be valid for 5 years (for example, before another review or 
new diagnostic) to enable us to calculate the number of patients potentially able 
to be reached by this hta.  We estimated the investment costs in HTA to be 0.1% 
of total healthcare spend as a relatively consistent percentage spent on HTA 
across countries(14, 15)10.   
  
 
10 SHTG were calculating their actual costs for this exercise but was stopped due to COVID19. 
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Table 8-4  Summary table of data 
Inputs Value Data sources            
Prevalence of diabetes in Scotland 
5.4% (n = 291,981) of which 
10.6% T1DM 
88.3% T2DM 
<2% other forms of DM 
Scottish Diabetes Survey 2016  
          
Eligible population in Scotland meeting FL criteria in Year 1 
Over 60,000 patients of which 
28,531 have T1DM 
32,342 have T2DM 
2017 figures/SCI-Diabetes  
     
Incidence (crude rate) 
18 cases per 100,000 pop per year (n = 943) T1DM 
316 cases per 100,000 pop per year (n = 16,973) 
T2DM 
Evidence Note 81  
     
Length of time diagnostic valid 5 years Assumption            
Discount rate 0.035 
UK Treasury recommended rates and as 
used in SHTG model 
 
          
Cost-effectiveness threshold £20,000 HIS/NICE usual lower threshold            
Key model inputs- for full details see Evidence Note 81         
SMBG mean no. of blood tests per day 5.5 (T1DM), 3.8 (T2DM) Markov model input - from RCTs       
FL intervention effect on blood tests Reduction of 90.9% (T1DM), 89.5% (T2DM) Markov model input - from RCTs       
FL intervention effect on severe hypoglycaemic events Reduction of 55.0% (T1DM), 52.6% (T2DM) Markov model input - from RCTs       
FL cost £35 each with a lifetime of 14 days use 
Markov model input – Scottish Drug 
Tariff/manufacturer 
 
     
Cost of severe hypoglycaemic event (SHE) £1,034 (£855 - £1,253) 
Rates of SHE obtained from 
RCTs/systematic review by SHTG 
 
     
Full model T1DM base case         
Lifetime costs FL  £18,074 Markov model       
Lifetime costs SMBG  £12,860 Markov model       
Lifetime QALYs FL  9.73 Markov model       
Lifetime QALYs SMBG  7.61 Markov model       
Incremental costs  £5,214 Markov model       
Incremental QALYs 2.12 Markov model       
ICER  £2,459 per QALY Markov model       
187 
 
Full model T2DM base case         
Lifetime costs FL  £10,450 Markov model       
Lifetime costs SMBG  £5,535 Markov model       
Lifetime QALYs FL  6.14 Markov model       
Lifetime QALYs SMBG  5.04 Markov model       
Incremental costs  £4,916 Markov model       
Incremental QALYs 1.09 Markov model       
ICER  £4,498 per QALY Markov model       
Restricted model T1DM base case         
Lifetime costs FL  £17,010 Markov model       
Lifetime costs SMBG  £10,496 Markov model       
Lifetime QALYs FL  13.20 Markov model       
Lifetime QALYs SMBG  12.67 Markov model       
Incremental costs  £6,514 Markov model       
Incremental QALYs 0.53 Markov model       
ICER  £12,340 per QALY Markov model       
Restricted model T2DM base case         
Lifetime costs FL  £9,837 Markov model       
Lifetime costs SMBG  £4,241 Markov model       
Lifetime QALYs FL  7.51 Markov model       
Lifetime QALYs SMBG  7.20 Markov model       
Incremental costs  £5,596 Markov model       
Incremental QALYs 0.31 Markov model       
ICER  £18,125 per QALY Markov model       
Change in prescribing 
From 116 items (November 2017) to 25,947 items 
(October 2019) 
ISD data  
     
Uptake % 25,947 / total eligible Yr 1 n = 60,873 
43% assuming units sold equates to the 
number of patients 
 
     
Attributable uptake 13% ITS using segmented regression       
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8.5 Results 
We present the individual NHBs stemming from FL.  The incremental health 
benefit associated with FL compared with usual care was 0.53 and 0.31 QALYs 
for T1DM and T2DM respectively (restricted model); and 2.12 and 1.09 QALYs for 
T1DM and T2DM respectively (full model).  The incremental costs associated with 
the FL compared with usual care was £6514 and £5596 for T1DM and T2DM 
respectively (restricted model); and £5214 and £4916 for T1DM and T2DM 
respectively (full model).  These costs are converted into their health 
equivalence by dividing through by the willingness-to-pay threshold and then 
subtracted from the health gain.  The NHB per person is 0.2043 and 0.0302 
QALYs for T1DM and T2DM respectively (restricted model); and 1.8593 and 
0.8442 QALYs for T1DM and T2DM respectively (full model) [Table 8.5]. 
Table 8-5  NHBs individual level (base case)   
Restricted 
model 
Incremental 
QALYs 
Incremental 
Costs 
ICER NHBs using 
£20k 
threshold 
NHB 
T1DM 0.53 £6514 £12,340 * = 0.53 – 
(6514/20000) 
0.2043 
T2DM 0.31 £5596 £18,125 * = 0.31 – 
(5596/20000) 
0.0302 
Full model Incremental 
QALYs 
Incremental 
Costs 
ICER  NHBs 
T1DM 2.12 £5214 £2,459 = 2.12 – 
(5214/20000) 
1.8593 
T2DM 1.09 £4916 £4,498 = 1.09 – 
(4916/20000) 
0.8442 
*(rounding) 
This is scaled up to the population level in Scotland taking existing and new 
cases of T1DM and T2DM [Equation 8.4] and discounted over 5 years [Table 8.6].  
 
 
The total population at risk was estimated to be 32593 T1DM and 42291 T2DM 
people [Table 8.6]. 
 
 
Prev y = Prev y-1 + I Y 
Equation 8-4 Prevalence and incidence 
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Table 8-6  Cumulative population at risk 
CPs valid Prevalence  Incidence  Discounted Cumulative  
Year 1     
T1DM 28,531 869 29,400 29,400 
T2DM 32,342 2129 34,471 34,471 
Year 2     
T1DM   840 30,240 
T2DM   2057 36,528 
Year 3     
T1DM   811 31,051 
T2DM   1988 38,516 
Year 4     
T1DM   784 31,835 
T2DM   1920 40,436 
Year 5     
T1DM   758 32,593 
T2DM   1855 42,291 
 
The estimated costs of investing in HTA based on 0.1% of total healthcare spend, 
are expressed in terms of their health equivalence by dividing through by cost-
effectiveness threshold (𝜆𝜆). Using a willingness-to-pay threshold of £20,000, this 
equates to 650 NHB [Table 8.7]. 
Table 8-7  Costs HTA 
National healthcare 
spend Scotland 2018 
(GBP) 
Estimated spend 
on HTA at 0.1%  
(GBP)      
Expressed in health 
equivalence, £20k threshold 
13 billion11 13,000,000 650 NHBs 
 
We present the NHB associated with full (potential), current (realised) and the 
attributable levels of implementation of FL and offset this against the costs of 
investing in HTA at a systems level.  Full implementation was based on all 
eligible patients receiving treatment.  The NHB were scaled up separately by 
T1DM and T2DM, and then totalled.  Current implementation was based on the 
number of currently prescribed units as a percentage of eligible population, and 
the attributable percentage was taken from the ITS analysis.  This shows that, 
using the restricted (more conservative) model, the gains attributable to 2 hta 
 
11 Source: https://fullfact.org/health/nhs-scotland-spending/ 
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(assuming similar impact) would offset the annual investment costs.  Using the 
results of the full model, the costs are offset entirely [Table 8.8].   
Table 8-8  Results 
 Population 
potential NHB 
(full 
implement) 
Realised NHB 
(Current 
implementation 
43%)  
Attributable 
NHB = 13% 
No. of hta's 
(assuming similar 
impact) to offset 
costs @ 650 NHBs  
Restricted 
model 
QALYs 
7,936 NHB                    
= (6,659 T1DM 
+ 1,277 T2DM) 
3,383 439 2  
0.2043 
0.0302 
Full model 
QALYs 
96,302 NHB 
= (60,600 T1 + 
35,702 T2DM) 
 41,049 5,330 Offset ~ 7-fold 
1.8593 
0.8442 
 
Expressing this in terms of an NHB-ROI calculation is shown below [Equation 8.5]. 
Equation 8-5 NHB-ROI 
 
𝑁𝑁𝐻𝐻𝐵𝐵 𝑅𝑅𝑅𝑅𝑅𝑅 =  
𝑁𝑁𝐻𝐻𝐵𝐵 − 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑅𝑅𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶/𝜆𝜆
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑅𝑅𝑠𝑠𝑣𝑣𝑝𝑝𝐶𝐶𝐶𝐶𝑠𝑠𝑝𝑝𝑠𝑠𝐶𝐶/𝜆𝜆
 
 
 
𝑅𝑅𝑝𝑝𝐶𝐶𝐶𝐶𝑝𝑝𝑑𝑑𝑑𝑑𝐶𝐶𝑝𝑝𝑠𝑠 𝑠𝑠𝐶𝐶𝑠𝑠𝑝𝑝𝑟𝑟 =
{439 𝑁𝑁𝐻𝐻𝐵𝐵 − 650 𝑁𝑁𝐻𝐻𝐵𝐵}
650 𝑁𝑁𝐻𝐻𝐵𝐵
=  −32% 
 
 
𝐹𝐹𝑟𝑟𝑟𝑟𝑟𝑟 𝑠𝑠𝐶𝐶𝑠𝑠𝑝𝑝𝑟𝑟 =
{5330 𝑁𝑁𝐻𝐻𝐵𝐵 − 650 𝑁𝑁𝐻𝐻𝐵𝐵}
650 𝑁𝑁𝐻𝐻𝐵𝐵
= 720% 
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This shows the same results as above but expressed as a ROI.  The result would 
need to be positive to show a return on investment.  Using the restricted model, 
it suggests that the NHB associated with one further hta (assuming similar 
impact) would achieve this.  For the full model, it shows the hta yielded a 720% 
NHB-ROI.  
8.6 Discussion 
In order to get to the overall value of investing in HTA at a systems (ie here, at a 
national level), we need to look at what the process is delivering.  We used an 
illustrative example by quantifying the value stemming from an hta of FL.  First, 
we converted the ICER as modelled by SHTG to NHBs and scaled to a population 
level taking new and existing cases discounted over 5 years (an assumption on 
the life of the technology).  This provided an estimate of the potential 
population NHBs ie if everyone who was eligible were to receive it.  
Implementation was monitored by ISD and this routinely collected prescribing 
data indicated a current uptake of 43% (25,947 units sold with over 60,000 
eligible patients in Scotland).  This provided an estimate of realised population 
NHB.  Using segmented regression as a simplified form of ITS, we estimated 
uptake after the issuance of SHTG’s guidance against the pre-existing prescribing 
trend to establish what we could attribute to the hta.  This indicated that, 
although it was predicted that uptake would have increased anyway without the 
hta, uptake was an additional 13% higher after the advice statement was issued 
as measured 16 months later.  Finally, we offset the attributable benefits 
against the costs of investing in HTA (expressed in terms of their health 
equivalence).   
The results of the ITS segmented regression undertaken do not detect a 
statistically significant effect at the conventional 5% level ie it could be 
considered that the result is inconclusive as to whether the increase in uptake of 
the technology was due to the hta or not.  Yet, for the sake of illustrating the 
conceptual framework, we incorporate this point estimate of the mean as real 
and attributable to the hta.  The results of the ROI calculation should, 
therefore, be treated with caution.  This effect parameter could 
be handled probabilistically using the standard error of the estimate from the 
regression so that the final ROI is expressed with a measure of the degree of 
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certainty in the result. Additionally, a threshold analysis could be undertaken to 
establish the minimum level of uptake required in this case study to generate a 
positive ROI.  The latter, however, addresses a slightly different point as results 
already show a positive ROI on the observed (non significant) effect.  Note that 
when no evidence of effect is found, examining the joint distribution of costs 
and effects is still valuable for cost-effectiveness analysis(303).  
We make the case that this is not just about FL being cost-effective which, 
indeed, it appears to be with many studies finding similar results(304) but that 
the hta itself provides value for money – noting the uncertainty discussed above. 
This case study illustrates the high potential returns and value for money of 
investing in HTA by offsetting the benefits of a single hta against typical costs 
associated with HTA investment costs at a systems level(14, 15).  Whilst others 
have estimated HTA impact, they have stopped at the equivalent of what we 
refer to as potential NHB(19).  We estimate impact in terms of realised and 
attributable NHBs using methods to establish uptake against a counterfactual of 
what might have happened without the hta.  Ramsay et al have critiqued the use 
of ITS in HTA and have found it has often fallen short; they recommend time 
series regression techniques when the series is short (305) which we employed.  
Although subject to uncertainty in the ITS point estimate, our results, based on 
this being real, suggest that the hta created value, and that these benefits 
substantially offset the costs.   
Finally, there is extensive data linkage in Scotland for those with diabetes to 
longer term health outcomes.  Data are collected from electronic patient 
records as part of the Scottish Care Information – Diabetes Collaboration12.  
Whilst outcomes have been modelled as part of the hta economic evaluation, 
there is the potential for longer term follow-up using patient records and actual 
health outcomes. 
8.7 Limitations 
Whilst T1DM and T2DM NHBs were able to be split out when calculating 
population NHB (as we have incidence and prevalence by diabetes type), we do 
 
12 https://www.sci-diabetes.scot.nhs.uk/ 
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not have prescribing split out by diabetic type.  This would provide a more 
accurate calculation of realised NHB but for the purposes of this example, the 
case study illustrates the principle and methods which can be applied. 
In converting QALYs into their monetary equivalence, we use NICE’s lower value 
of £20k per QALY.  However, it should be noted that research would indicate it 
is considerably lower still(163).  Deterministic sensitivity analysis could again be 
undertaken using more accurate values using specifically, the supply-side 
estimates by Claxton et al of around £13k per QALY(163).  We have, however, 
refrained from using the upper NICE threshold of £30k or indeed, higher values 
used for end-of-life treatments by NICE. 
In both case studies, the thresholds used have a rationale but both are likely to 
be over-estimates of the true opportunity costs.  Getting the threshold wrong 
has consequences.  The consequences of over-estimating the threshold are 
arguably worse than under-estimating it13.  Too high, and this would result in a 
net reduction in population health as the benefits do not exceed those 
displaced.  Too low, and cost-effectiveness results may recommend 
interventions are not funded when they could generate population health 
benefits. In this case, there would be lost opportunities for health improvement.  
The implications of using too high a threshold in these case studies means the 
impact of HTA is likely over-estimated.  Scenario analysis using lower threshold 
values to more realistically reflect the true opportunity costs incurred by the 
health system would provide more conservative estimates of the impact of HTA; 
the value of NHBs fall and the cost of the hta expressed in health equivalence 
increases.  The ROI is consequently reduced. 
Again, similar to Chapter 7, we recognise that doing this for all htas in any given 
context would be impractical and so we suggest the use of illustrative case 
studies.   A natural progression of this case study would be to apply the full 
framework.  We recognise that the data requirements would not be without 
their challenges and would likely require purposeful sampling with data 
 
13 Acknowledge presentations by Prof Mark Sculpher, NUI Galway 2013 on estimating thresholds 
and Paul Revill, CHE presentation. 
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collection and not just a reliance on routine administrative systems – though this 
case study does utilise routinely collected data.      
Finally, this framework allows time-series analysis by individual boards so we 
could have looked at the impact of the hta on those Boards which had already 
put a care pathway for FL into practice before the SHTG Evidence Note was 
published.  However, this was not entirely clear as the data showed uptake 
against more than the number of expected Boards waiting for guidance before 
prescribing FL. 
8.8 Conclusion 
Our study goes beyond the recommendation that FL is cost-effective by showing 
that the hta process itself offered value for money, showing potentially high 
returns with the introduction of a single hta – albeit against a backdrop of 
uncertainty in the ITS mean value on change in prescribing levels following the 
hta.   To the extent the benefits offset the costs, we quantify the value of 
investing in such processes.  In so doing, we aim to capture the issue of 
redeploying existing resources from alternative uses (the opportunity costs) to 
ensure a sustainable HTA system be established(37). 
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9 Integrating theory-based and quasi-experimental 
methods for impact evaluation 
9.1 Integrating mixed methods 
The UK Government’s Magenta 2020 book(131) which sets out guidance on what 
to consider when designing an impact evaluation, groups methods into three 
types: theory-based impact evaluation methods, experimental and quasi-
experimental impact evaluation methods, and value-for-money methods.  It 
states that good quality impact evaluation evidence will be both theoretically 
driven and provide confidence that the measured outcomes can be attributed to 
the policy and provide an estimate of the size of that impact.  These different 
methods may be better suited to different types of data analysis and study 
designs.  In this case, measuring the impact of HTA, we suggest that a 
complexity-informed approach is appropriate.  Whilst a dominant empiricist 
philosophy has been the conventional approach to evaluation, proving causation 
by quantitative data and statistical relationships, using this alone would not give 
an understanding of how impact is brought about.  Quantitative methods alone 
would not produce insights about how any measured change comes about, or 
whether the same outcome would occur if the intervention is tried in another 
context or at a different scale.  Combining experimental or quasi-experimental 
approaches with theory-based approaches ...can provide this often essential 
insight.(131)  The wider literature also recognises the use of different 
paradigms, calling for economists who share a broadly ‘positivist’ perspective to 
work together with researchers from organisational studies and policy analysis 
with an interpretivist perspective to study the same change in delivery of a 
health service.  Researchers who have traditionally taken a ‘black box’ approach 
focussing on inputs and outputs need to work with researchers who study 
context and processes, and vice-versa(306).   
9.1.1 Applying mixed methods to our research 
We incorporate the use of each of these types of methods outlined in the 
Magenta Book(131) in this thesis to come up with a robust way of quantifying and 
explaining the impact and value for money of HTA.   This ‘joining up of methods’ 
allows researchers to think from different perspectives – and, rather than being 
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a case of either/or, we consider the added value of their combination to be in 
providing a complexity-informed approach.  In our impact framework, the 
quantitative and qualitative research is positioned under an overarching realist 
theory driven approach [Table 4.1].  Our framework acknowledges that, at the 
heart of impact evaluation, is a requirement to explain ‘how’ and ‘why’ causes 
and effects are linked – as well as addressing ‘how much’ and ‘to what extent’.  
Explanatory methods are used alongside quantitative methods to generate, test 
and refine explanations for a gap between potential and realised gains in 
population health further to an hta.  In adopting a mixed methods approach, we 
aim to both demonstrate the value of HTA (quantified in terms of NHB), and to 
progress knowledge as a theory or framework.   
Whilst realist inquiry - and theory-based methods more generally - can be used 
to explore the causal chains thought to bring about change by an intervention, 
they do not provide precise estimates of effect sizes(131).  Furthermore, a 
criticism of realism is that it does not always (or often) provide a quantitative 
effect size(307).  Pawson(308) suggests ‘that quantitative may mean no more 
than the ability to count numbers.’  Rather than adopting a crude before-and-
after count, experimental and quasi-experimental approaches are designed to 
achieve a robust estimate of the average impact of an intervention.  This 
requires a comparison group.  Consideration and quantification of what would 
have happened without the hta is central to our impact framework.  We draw on 
quasi-experimental methods to estimate how much ‘uptake’ can be attributed to 
the hta using (often underutilised) administrative data.   
Our framework also utilises a ROI approach which is rooted in a positivist 
epistemology [Chapter 3].  Some suggest that if methodological issues can be 
addressed in ROI then it may be possible to arrive at a rigorous and reliable ratio 
that is representative of social impact(309-311).  The use of standard linear 
(positivist) economic methods as used in (S)ROI has been critiqued on both 
methodological and philosophical grounds, in so far as it does not account for 
any relational aspects and the result is reduced to a ratio of financial costs and 
benefits(309).  Here, qualitative methods - or a more complexity-informed 
approach - may be ‘important to understand how an intervention’s mechanisms 
197 
 
lead to the desired outcomes as the ratio may take focus away from 
understanding the processes of achieving outcomes’(309, 310).   
HTA is context specific and, realism as an approach to developing programme 
theory is particularly relevant because it focuses specifically on the influence of 
context.  We use quantitative methods to measure outcomes and qualitative, 
descriptive methods to develop theory in order to further knowledge.  Realism is 
a broad methodological church(158) and realist evaluation is profoundly multi-
method.  Hence, the use of the terms realist ‘inquiry, principles or approach’ - 
not methodology - as realism favours methodological pluralism.  Indeed, 
Pawson(308) recommends ‘qualitative data to investigate mechanisms – you 
need to get one way or another to the reasoning of stakeholders; quantitative 
data to get to outcomes…; and comparative data to inspect contexts’.  We use 
the uptake of a technology following an hta as our outcome of interest in the 
realist inquiry (outcome ‘O’ in CMO).  This enables us to work backwards from 
outcomes to explore mechanisms and relevant contextual factors, as causal 
mechanisms are activated only in favourable conditions.  By proposing a quasi-
experimental method (specifically, ITS) to measure outcomes, we go beyond a 
mixed methods approach to synthesising a positivist analysis within a realist 
inquiry. 
9.2 Testing the theory 
Here, we use the ROI-NHB studies as ‘test cases’ and show how the ROI-NHB and 
realist framework looks when brought together.  Whilst a realist review is a 
theory-led approach to knowledge synthesis using secondary sources, realist 
evaluation is a form of primary research.  Although the realist component of this 
thesis is primarily about developing theory, building this theory from data and 
evidence in the literature, we also test our programme theory using two 
quantitative case studies [Chapters 7 and 8] together with accompanying 
qualitative data which are discussed below for both studies.  This provides a 
continuing test of the same theory with two quite different bodies of data.  As 
such, the case studies are acting as the ‘test cases’ of the theory resulting from 
the realist synthesis ie they are an exemplar of how the CMOC work in 
practice.  The case studies show that these approaches can be complementary 
and how this can work in practice.  Through the CMOC, we test the argument 
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that readiness is a complex multi-dimensional construct(196): it requires both a 
willingness and capability for successful implementation [Chapter 6].    
We note it has been observed that ‘HTA reports typically do not define their 
impact objectives, that is – the effects they would like to achieve (for example, 
to influence coverage decisions, support guideline formulation or change routine 
practice)…the stated objectives or research questions are scientific, related to 
the technology being assessed rather than describing the expected role of the 
HTA itself’(78).  We assume that when a positive hta recommendation is made, 
100% implementation is what is aimed for.  When considering the case studies – 
both of which have found the technology in question to be cost-effective (net 
beneficial) - we suggest that as they show a discernible effect of uptake in the 
right direction over and above what would have happened without the hta, and 
that their attributable benefits outweigh the costs, these are successful cases of 
implementation following an hta (as well as providing value for money of the 
hta).   
9.2.1 CNHDRC case study (China) 
The China case study was accompanied by interviews carried out by itad.  This 
qualitative data were collected in the pilot sites as part of the project’s 
monitoring(179).  This included site visits and the main mode of data collection 
during these visits was informant interviews with stakeholders from groups 
identified as key to the implementation of the pilot.  Interviews were conducted 
according to semi-structured protocols developed in advance of the visits and 
translated into Chinese.  The full report is publicly available(179). 
In this case study, the hta was the development of contextually-appropriate CP 
for patients hospitalised for stroke.  Hta resources were guidance, knowledge 
and training.  Over-and under-treatment are common phenomena in China’s 
healthcare system. The causes of such practice not only relate to the absence of 
appropriately developed clinical guidelines but also because of institutional 
issues, such as inadequacies in quality monitoring systems, medical insurance 
reimbursement policies and general compensation mechanisms. The hta was 
referred to as ‘integrated’ CP as additional supportive resources, including data 
management systems and software, the negotiation and development of 
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remuneration systems for medical personnel to increase their support for clinical 
pathways and payment reform, were also employed.  This addressed 
institutional inadequacies in terms of quality monitoring systems, medical 
insurance reimbursement policies and general compensation mechanisms.  In 
particular, robust internal IT systems were identified within the healthcare 
system as being a key step to improving implementation of the guidance and 
sites were chosen where such systems were functioning.  Such information 
systems can provide more reliable and timely information for clinicians, support 
clinical decision-making and medical service behaviour standardisation and 
improve quality of care.  
These meso/macro supportive measures were critical for the uptake of the CP by 
providing the capacity and practical resources to implement but also, in turn, 
for installing motivation and willingness to act collaboratively.  The hta involved 
extensive stakeholder engagement with a variety of actors at national and local 
levels.  The reaction of clinicians to buy into the CPs was triggered through the 
specific delivery of supportive resources (capability) and these resources also 
activated motivation to act and buy-in too (willingness); it enabled practitioners 
to feel capable of making the change successful (collective change efficacy) [M].  
This indicates that knowledge/information-based resources, held at the 
individual level, were not enough to produce uptake: context-level resources 
were required to augment the knowledge and information.  Moreover, the scope 
of training carried out locally was broader than clinical pathways, and included 
the use of management and information systems, costing, billing etc.  By 
addressing the wider causes (of over/under prescribing), greater harmonisation 
of interests [C] among stakeholders across multiple levels of the system, 
triggered motivation [M] and greater acceptance of the guidance [M].  While 
clinical pathways are an important part, they are not, and cannot be, a 
standalone reform. There was broad consensus around the need for an 
integrated solution.  This established mechanisms for collaboration and referral 
across different tiers of the health system – between health insurance, provision 
of health services and clinical behaviour. All this led to positive changes in 
clinical practice, prescribing and costs.   
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There was, in certain situations, nevertheless a display of autonomy and own 
discretion with variable adherence despite generally good compliance overall: 
where patients had been receiving the same treatment for a long time [C], the 
practitioner felt if one was to suddenly change the treatment regimen, patients 
may not accept it [M], easily leading to medical disputes [O].   External 
validation and legitimacy were noted in this case study - a low-trust setting [C] – 
in that external validation was brought about by the hta (as it developed with 
international support) which led to legitimacy [M] and thus better 
communication between patients and practitioners on their healthcare [O].  
Ultimately, greater buy in, changes in attitudes, increased capacity and 
collaboration resulted in improved patient communications.  
From Weiner’s theory of organisational readiness, a shared commitment and 
shared change efficacy are both necessary.  This case study showed that they 
can reinforce each other.  The successful implementation of the integrated CP 
required working in alignment with health systems strengthening initiatives in 
order to overcome contextual deficits.  The pilot managed to effectively bundle 
a number of components together that linked clinical pathways to payment 
reform, management changes and technical support.  The case study shows too 
that a refocus on meso hta [Chapters 1 and 6] (here, guidelines to manage 
patient care pathways within a health system) along with macro interventions 
(here, payment and IT reform to strengthen a health system) leads to a better 
integration between the hta and delivery systems - and thus implementation 
and, ultimately, impact.  We propose that it is this interaction between 
‘willingness and capability’ or between change ‘commitment and efficacy’ that 
creates an outcome ie a change in clinical practice or prescribing.  Thus, we 
argue that the hta and system-level need to interact to create uptake.  A meso 
level hta necessitating the adaptation of service provision to manage patients’ 
care pathways within a health system – and integrating macro approaches 
(efficiency, organisation and strengthening of the healthcare system) reinforced 
the change efficacy of those delivering the services.  It enabled practitioners to 
feel capable of making the change successful ie collective change efficacy was 
increased which led to their willingness to implement the guidance.  It showed a 
concern for the values and interests of the stakeholders with potential to block 
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or subvert implementation and their interactions with the health system, with a 
harmonisation of interests across multiple health system levels. 
9.2.2 SHTG case study (Scotland) 
HTA in Scotland has been institutionalised for many years.  Having found many 
HTA agencies measure processes rather than outcomes, SHTG have made recent 
efforts to measure the impact of its work on decision-making and longer-term 
outcomes.  Previous studies have explored the impact of HTA in Scotland, for 
example, Bennie et al(312) demonstrated the complex relationship between HTA 
advice and change in clinical practice.  Factors identified that may explain the 
patterns of medicine use included delays between medicine launch and initial 
advice, the publication of conflicting advice from different national bodies and 
failure to engage with relevant clinical experts early in the medicine review 
process(312).  SHTG’s current impact monitoring is based on the INAHTA impact 
tool(54) [see Chapter 1] and is largely qualitative.  The work relating to FL 
included stakeholder analysis.  The results of that research by SHTG found that 
the FL hta had a ‘major influence on decisions’.  We, in turn, quantified this 
impact in terms of the costs of the hta and its realised NHB.   
A context analysis of this case study would support our theory of a positive 
interaction between willingness (demand-side, at least) and capability leading to 
successful implementation – indeed, of the hta having ‘a major influence’ 
according to SHTG’s qualitative work.  The topic of this hta was advocated for 
by patient groups and was prioritised for inclusion on the SHTG work programme 
following a referral from the Scottish Diabetes Group.  They collated information 
from patient surveys and focus groups on patient experiences.  Although use of 
this device requires regular contact with healthcare professionals to ensure it 
remains the most appropriate for the patient, it is essentially about patients’ 
home-based management of their diabetes.  As such, prescribing and monitoring 
by the NHS is the main aspect to its implementation.  The former could be said 
to relate to ‘willingness’, the latter to do with ‘capability’ within the system.  
Both appear to have contributed favourably to the implementation of the 
technology.   
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Interestingly, whilst some Boards awaited the SHTG’s guidance, others had 
already established a care pathway for FL in practice before the Evidence Note 
was published.  Moreover, some Boards have been slower than others to 
implement since the guidance was issued.  In November 2018, a year on from 
launch and 3 months after the HTA recommendation, some boards were still not 
prescribing FL or lacked clear guidance(313).  The actual level of prescribing is 
captured in our quantitative case study by the analysis of the data from each 
Board over a period of time before and after the hta but a better understanding 
of the reasons for differences in the timing of implementation could be explored 
further.   
9.2.3 Drawing lines from hta to HTA 
Our understanding is that the impact of HTA on health outcomes is the major 
gap in the literature and thus, the focus of this research.  We recognise though 
that there are likely to be other externalities to arise from HTA including, for 
example, better bargaining power on price negotiations.  Here, we consider 
other spillover effects arising from HTA and the building of capital over time.  
Through the inclusion of intermediate outcomes [Table 6.2], we show how a 
generative causal pathway is created of a series of mechanisms activating and 
interacting in contexts over time(126).  The degree to which hta 
recommendations are 'taken up’ is observable.  However, if we were to conclude 
at the empirical, we risk missing a lot of information about what is working (or 
not) and ‘why’ regarding the effective implementation, and consequent, impact 
of HTA.  Generative causation would additionally ask how does HTA have an 
effect/impact?  For example, there may not yet be a discernible empirical effect 
on ‘uptake’ - perhaps there is a time lag for the implementation and, indeed the 
diffusion of technologies is known to follow an S-shaped curve(314) so that 
uptake is better modelled as a diffusion curve than a step function.  Rather than 
being seen to be failing, is the hta still having a residual effect in terms of other 
outcomes such as awareness and/or acceptance in preparing the ground, and 
what is it about the pre-existing resources in that context and the resources 
provided by the hta that is driving the implementation of recommendations and 
decisions?  It is about making the ground fertile and receptive to the hta, 
creating an environment for adoption of HTA to have the broadest scope.  An 
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emergent analysis of context and mechanistic data may allow us to identify that 
the hta is still having a residual effect in terms of preparatory work and 
transforming the context over time.  Rather than concluding the hta has failed 
or has produced negligible returns in our interlinked NHB-ROI framework, we can 
establish how and to what extent this is building social, intellectual and political 
capital for HTA institutionalisation, capacity and acceptance over time.   
In this regard, economies of scale and scope are critical.  Scale, as sheer volume 
of htas will bring cost down per hta but also the potential of reaping economies 
of scope.  This speaks to critical mass by leveraging the technical, intellectual, 
social and political capital built up over time with each hta.  Social capital is, in 
realist terms, generatively important in that it is adding institutional value 
which is necessary for other outcomes to emerge(315)[Figure 9.1].  For example, 
in China, the hta was found to have provided a basis for others to learn from and 
a policy driven scale-up indicated political support had been developed through 
the initial hta as well as building capability through linking it to other needed 
reforms.  According to one CNHDRC interviewee, ‘overall, the impact of the 
project has been greater than the impact of the pilots: …(and) has had a large 
impact in changing ideas at central/policy levels’(179).  Promoting such a 
converging approach between researchers and political stakeholders for future 
HTA institutionalisation is a key step(316).  Thus, the impact is probably greater, 
and of greater importance than that of the specific pilot experience(179).   
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Figure 9-1  Modelling realist causation over time 
 
Source: adapted from Pawson R, Tilley N. Realistic evaluation. London: Sage publications; 
1997 (141).  Permission sought from JJagosh email June 2020. 
 
9.3 Discussion 
This chapter integrates the NHB-ROI case study findings and their corresponding 
stakeholder interviews.  We do this by testing the programme theory developed 
from the realist review with the key informant data from the China and Scotland 
case studies.  This key informant data were purposefully excluded from the 
realist component in building the programme theory (Chapters 5 and 6) so as to 
then be able to go on to test the theory with these case studies (Chapters 7-9).  
Ideally, realist interviewing would have allowed us to explore aspects of the 
theory in greater depth from perspectives of different stakeholders.  However, 
the existing stakeholder data allowed a continuing test of the same theory with 
two quite different bodies of data - across the theory building and theory testing 
components.  As such, the case studies are acting as the ‘test cases’ of the 
theory resulting from the realist synthesis ie they are an exemplar of how the 
CMOC work in practice.  Furthermore, we use the uptake of each case study’s 
technology following an hta as our outcome of interest (outcome ‘O’ in CMO) in 
both the quantitative and qualitative data.  This enabled us to work backwards 
from the quantified outcomes to explore mechanisms and relevant contextual 
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factors, around uptake.  A diagram illustrates how the different elements of the 
case studies interlink with uptake at its centre. 
Figure 9-2: Integration of methods 
 
Garrido et al (78), state ‘further research is necessary to consider how to 
develop and test theoretical frameworks. Successful HTA impact assessment 
requires the involvement of different disciplines…’.  Realism is about testing and 
refining theory, and as such, the project or intervention is not the object of the 
evaluation in its own right(317).  The basis of adopting a realist approach here is 
that we start and end with a theory, supposing that the final overarching theory 
can be translatable to other similar contexts.  Generalisability comes from a 
positivist paradigm that there is a universal truth which can be scaled up or 
replicated (for example, from a trial) and, as such, can handle contextual 
differences.   Realism, on the other hand, is not looking for the general but 
transferability and portability.  What are the aspects of an intervention that can 
be transferred to other contexts and expect same results?  
Everything we are focusing on in this research is a step on from hta 
dissemination.  If we think of hta as an input to decision making but we need 
‘complementary’ aspects for implementation of that decision to ensure hta has 
value (ie hta supports decisions but not directly the implementation of them) 
then by focusing on the context as well as characteristics of the 
.
How to measure uptake of hta decision
Quantifying a change in implementation 
pre- and post an hta using quasi-
experimental methods in case studies
Quantifying the outcome ‘O’ in CMOs
How to explain uptake of hta decision
Testing theory of uptake using 
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Impact at hta level
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studies against the costs 
of each hta
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case studies to estimate 
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investing in HTA against 
aggregated benefits
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recommendations, we can help transfer decisions into actions.  We tested the 
CMOC, and the case studies showed that whilst ‘willingness’ or ‘change 
commitment’ can be influenced via the hta itself, this is not necessarily 
sufficient to overcome contextual deficits.  We suggest an hta frequently needs 
to come with complementary components to ensure it has impact, with 
examples found of supportive and integrated measures at all levels of the 
system.  Our programme theory, and the testing thereof, would suggest that 
where an hta is accompanied by joined up systems-wide approaches (IT, 
payment structures etc) (C), the change efficacy of practitioners is increased (M) 
leading to their adherence of recommendations [O].  Just as the integration of 
HTA into the regulatory, reimbursement and decision-making processes is 
necessary for its findings to translate into policies or decisions(291), 
implementation of those decisions required a greater interconnectedness 
between HTA and the delivery system.  Our CMOC also evidenced that where 
there is an interaction between ‘capability and willingness’, this generally led to 
a positive change in implementation.  A couple of points following on from this 
are noted below. 
Firstly, it should be noted that positivists would want to test the counterfactual 
situation ie of a specific hta accompanied by systems-wide interventions 
compared with that same hta not accompanied by systems-wide interventions in 
comparable contexts.  As such, they would see this as a case of the missing 
counterfactual.  As previously discussed [Chapter 3], realism supports generative 
causation not causation via a counterfactual.   
Secondly, whether the same programme theory can be applied to a negative hta 
decision (ie not to invest in or implement a technology that is not actually yet in 
the system) and/or disinvestment (ie de-implementation) of a technology is 
untested.  Although there were some articles retrieved on negative decisions or 
disinvestment(87, 222, 237, 312), they were only a few [Table 6.2].  Indeed, 
Esmail et al note that knowledge translation theory is needed to support this 
change as it is more psychologically challenging to stop rather than take up a 
technology(87). 
Finally, in order to assess whether HTA is a good use of resources, we compared 
its costs and benefits.  Whether an intervention represents value for money can 
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be estimated with relative straightforwardness; so long as one can ‘specify the 
inputs and outcomes with sufficient clarity to ensure that changes in resource 
use and benefits can be measured and valued, then it is not necessary to 
understand how the intervention works’(33).  There is a growing body of 
literature on how to address complexity better in economic evaluations and 
implications for health economists(33, 318, 319), in particular, by applying a 
realist approach to resource use and cost-effectiveness(319, 320).  It is widely 
recognised that the use, and therefore cost-effectiveness, of new technologies 
may be adversely influenced by constraints on the demand for and supply of 
health services in which the technology is placed – and that ‘given the extent of 
constraints, complexity needs to be ‘ruled out’ rather than ‘ruled in’, especially  
in economic evaluations in LMICs’(321).  Some have called for health economists 
to improve the relevance of their findings by distinguishing between context-
dependent and context-independent factors in their analysis to close the gap 
between economic evaluations and clinical practice(322).  Vassall et al lay out a 
conceptual framework for identifying the technology and what constraints there 
may be in the context of the care pathway(321) – though, to re-iterate, unless 
complexities are fully accounted for, such linear mapping may fall short. Whilst 
our research focuses on the evaluation of HTA and the adoption of hta 
recommendations, rather than the evaluation of technologies, nevertheless as 
evaluation should be used not just for accountability purposes but also for 
learning, we hope this research might contribute to the debate as to how and 
why health economists should broaden the scope of their work by adopting 
complexity-informed approaches.  
9.4 Limitations 
Ideally, testing the theory would have provided a continuing test of it by using 
primary data as this would have allowed us to explore aspects of the theory in 
greater depth from perspectives of different stakeholders.  Although we do use 
two different bodies of data to develop the theory from that used to test it, we 
continue to draw on secondary sources.  As for the quantitative China case 
study, we drew on information in the public domain, specifically previous 
interviews with stakeholders regarding the hta.  Whilst this provided a rich 
source of material to test our programme theory, undertaking our own realist 
interviewing in China may have enhanced this work.  However, it was agreed 
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that the team had already contributed substantially to monitoring and 
evaluation learning.  Access to the SHTG stakeholder data as well as further 
realist interviewing with NHS staff to refine the theory further are on hold14.   
We aimed to distinguish between HIC and LMIC.  However, there is a dearth of 
LMIC research [Table 6.2].  Should we have wished to pursue realist primary data 
collection in LMIC, Gilmore highlights the methodological challenges of 
undertaking realist research in these contexts(323). 
9.5 Conclusions 
None of the methods we use are novel per se – although realism is a relatively 
new approach to evaluation in healthcare and an original way to review the 
literature pertaining to HTA.   Rather, the innovation comes from their 
combined use, integrating a positivist quasi-experimental approach and an 
alternative to ‘causation via counter-factual’ using realist complexity theorising 
to unpack not only what works but how and why.   
9.6 Next steps 
We discuss implications of the findings from this research and make 
recommendations for stakeholders.  
 
14 Due to the COVID situation and personal circumstances in the last year of my thesis. 
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Part 4:  Synthesis of the research 
This final part comprising of Chapter 10 synthesises the findings of the research.  
We provide practical recommendations for decision-makers and make 
suggestions for potential areas of future research. 
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10 Recommendations and Further Research 
10.1 What our NHB-ROI framework adds 
Many LMIC health systems lack the tools and institutional mechanisms to 
prioritise the interventions and products that generate the most health for the 
money, with less than $4 out of every $100 USD in public funds being spent on a 
health maximising technology(324).  The importance of investing in HTA as a 
means of supporting a better allocation of finite resources and UHC has been 
recognised by the international community [Chapter 1].  Yet, the benefits 
concerning the link between HTA as a process at the systems level and impact in 
terms of net health improvements have rarely been quantified.  Furthermore, 
while there may be long term financial and health benefits to HTA, the need for 
upfront funding is a major constraint(325).  In a similar vein, a recent working 
paper discusses the importance of the ‘impact of impact evaluations’ in building 
a stronger evidence base on effective social interventions in LMIC(326).   
We envisage the use of this research will encourage accountability of spending 
decisions and help to optimise the impact of HTA in an era of investment and 
expansion in particular, for LMIC, through better understanding of HTA’s role in 
delivering health outcomes and value for money at the system level.  This 
research aims to offer a forward-looking model that LMIC can point to as a 
reference for their own implementation.  Ultimately, we hope this ROI-NHB 
framework will contribute to demonstrating the value of HTA by quantifying the 
NHB and opportunity costs of investing in these processes.  Indeed, this 
framework has been cited in the literature(180) as a start to devising empirical 
strategies to study the broader effects of HTA beyond pricing and 
reimbursement.  In turn, we hope this will contribute to generating political will 
and financial investment in these processes.  We summarise what we consider 
our impact framework adds to the literature and why we deem this important 
[Table 10.1]. 
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Table 10-1 What our framework adds 
 
 
Criteria Existing models What our HTA framework adds Why this is important  
Unit of 
analysis 
Evaluation of a specific 
intervention or hta.  
Distinction made between 
impact evaluation of an 
hta and HTA agencies. 
Aggregates the value of each hta to 
get to the value of HTA at a 
systems level. 
Investment is at a systems level and a lack of 
longer-term impact assessment at this level may 
undermine HTA’s importance and value.    
Outcome 
measure 
Impact on decision- 
making, outputs or 
costs/cost savings. Health 
and costs considered 
separately. Limited 
empirical evidence on the 
impact on health/net 
health gains.   
Impact is expressed in terms of 
modelled NHBs (or alternatively, 
NMBs). 
The metric of NHBs/NMBs enables us to maintain 
HTA’s broader value of healthcare efficiency 
rather than just cost-containment.  As it is 
understood that final outcomes are already 
(usually) modelled as potential NHBs as part of 
an hta, this allows the focus to be on 
implementation or uptake of hta decisions – and 
without which there can be no impact on health.   
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Criteria Existing models What our HTA framework adds Why this is important  
Opportunity 
costs 
Rarely considered Opportunity costs are made explicit 
as costs are expressed in terms of 
their health equivalence using a WTP 
threshold, combining costs and 
health into one metric.   
Opportunity cost is a key concept when 
considering efficiency and value for money.  It 
helps policy makers quantify what else they could 
have done with the money. 
Attribution Rarely considered Counterfactual modelled via quasi-
experimental methods.  This enables 
us to estimate an attributable level 
of uptake of a technology following 
an hta to quantify attributable 
population benefit to the process. 
A comparator (even if not observable) is 
fundamental to measuring impact against what 
may have happened with and without an 
intervention, here an hta. 
Theory Rarely used, description 
only of barriers and 
facilitators to 
undertaking HTA and 
uptake of its findings. 
We move beyond describing 
facilitators and barriers in order to 
produce tested and data-driven 
theory on the mechanisms by which 
HTA impact can be optimised. 
Health is impacted only if decisions are 
implemented.  Using theory driven approaches, 
we generate findings with are portable across 
contexts and deals with complexity to understand 
and improve implementation, leading to impact.    
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10.2 Challenges using the framework 
Challenges with implementing our NHB-ROI impact framework at any level are 
predominantly to do with a lack of monitoring data and information.  In order to 
test the framework convincingly requires greater access to monitoring data.  
This includes ensuring the quality and frequency of data collection, and ideally 
data which provides insight into vulnerable populations in order to understand 
the distribution of costs and benefits.  Specifically, this requires administrative 
longitudinal data on the utilisation or drug volume, or change in clinical 
practice, pre- and post-an hta to show temporal trends in the uptake (stopping) 
of a technology following an hta decision or recommendation.  Also required are 
the capital and running costs of investing in HTA at a systems level.  It may be 
that this is currently beyond the data capacity of most countries as part of their 
routine data or monitoring systems.  A 2018 OECD survey of routinely collected 
data on prescribed and dispensed medicines revealed that countries are at very 
different stages of data infrastructure and development.  Some countries 
initiated data collections and established prescription databases in the 1990s, 
while others are only about to start(327).   
Operationalising the framework to assess the ROI of an entire country’s HTA 
programme is unlikely to be feasible any context.  Practically, we can only 
undertake illustrative case studies.  RAND restricted its evaluation to 10 HTA-
funded projects framed within the more clearly defined boundaries of an 
audited research programme(19).   However, we can scale-up the results from 
case studies to calculate how many htas may be needed in order to get to a 
positive ROI.  Rather than utilising data from existing systems, a full application 
of the framework would more likely require a specific evaluation or audit to be 
commissioned to purposely collect the necessary data.  That said, in the case 
studies presented, we have drawn upon existing data and analyses in the public 
domain to undertake our own further data interrogation and to populate the 
framework.  Such data where it exists are often underutilised(327).  
Furthermore, the act of monitoring in itself features in the CMOC as a way of 
creating new attitudes and motivations which can augment the evidence-base 
and uptake of a technology.   
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Finally, we make explicit that we present these case studies as illustrative ie as 
proof-of-method studies rather than for their empirical significance - see key 
simplifying assumptions made underlying the framework which provides reasons 
for which this should be clear (Chapter 4).  We thus acknowledge uncertainty in 
the empirical findings of both case studies.  We outline below sources of 
uncertainty in the analyses and propose suggestions of how uncertainty in key 
parameters could be explored more fully in future research.  
In the framework, there exists uncertainty at multiple levels:  
• the modelling of the cost-effectiveness of the technology as part of the 
hta.  Sources of uncertainty here could include structural uncertainty (for 
example, the extent to which a model depicts the condition, intervention, 
care pathways etc); methodological uncertainty (for example, valuation 
of quality of life and resource use); data sources on costs and effects etc.  
• the reliance of NHBs on threshold values as a representation of the true 
opportunity costs of resource allocation within a health system is 
uncertain and a source of potential bias (Chapter 4).  
• the estimation of realised NHBs using monitoring data on implementation, 
prescribing etc.  The quality of this data including accuracy, timeliness, 
completeness, consistency etc is a source of uncertainty.  
• the modelling of change in uptake (stopping) using quasi-experimental 
methods.  As well as the data quality issues outlined above, the point 
estimate result is subject to statistical uncertainty (Chapter 8).  
• calculating the costs of HTA/hta.  We purposefully avoided a full costing 
exercise in our case studies for sensitivity reasons, opting to use more 
general estimates from the literature.  Sources of costs and assumptions 
made while calculating them are further sources of uncertainty if doing a 
specific costing exercise.  
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10.3 Implications of this research for decision makers 
Our focus has been on developing a framework for evaluating the impact of HTA 
on net health gains but it is only when those decisions result in implementation 
and practice change, that the gains can be achieved.  Whilst ICERs are scaleless, 
NHB allows us to scale up the impact by the population.  Realising these NHBs is 
only possible via the implementation of, and access to, beneficial technologies.  
There has often been a perceived disconnect between the delivery system and 
HTA, with the uneven implementation of cost-effective interventions.  As the 
evidence shows, even in relatively well-resourced health systems and high 
income contexts, cost-effective interventions do not always get implemented 
with recurrent themes around organisational processes, clinician engagement 
and financing being key barriers(234).  Optimisation of health technology 
utilisation is health system- and health technology-specific, and HTA may be 
made more relevant by greater explicit consideration of organisational issues 
(233).   Providing evidence about the expected impact of a technology on health 
system structure, processes and resources might be valuable to inform the 
construct and recommendations of an hta or develop an implementation 
plan(233).  Yet, this aspect of hta is found to be lacking [Chapter 6].  Cacciatore 
et al(249) found the assessment of organisational aspects to understand what 
resources are needed when a new technology is implemented or rejected and 
the impact on the health system to be lacking in HTA reports – even though this 
can influence the behaviour of health professionals and may help to overcome 
barriers to implementation.   
Whilst implementation is not strictly considered an integral part of the HTA 
process, when it is discussed, it is often inconsistent and not formally set 
out(328).  To what extent costs of implementation strategies should be included 
sequentially or simultaneously(164, 329) as well as analysing how conventional 
ICERs can be adjusted using methods such as mathematical programming are 
areas of recent research to take account of specific constraints beyond the 
budget constraint within health systems(330-332).  Hauck, K et al(332) extend 
the principles of conventional cost-effectiveness analysis to identify an optimal 
balance between investing in health system strengthening and expenditure on 
specific interventions.  Whilst the standard focus of CEA is on the addition of an 
incremental intervention, they consider how a range of interventions may 
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depend on a common service delivery ‘platform’ as the costs and benefits of 
interventions are not always independent of each other given this common 
dependency(332).  Revill et al suggest that the field of implementation science 
with its multi-disciplinary nature, could help inform economic models on the 
value and opportunity costs of other resources for implementation(331). 
However, few practical applications of these approaches have so far been 
published(333).  Indeed, it is acknowledged that such constraints itself signal 
that the health system needs strengthening in terms of health care inputs(334). 
Interestingly, some HICs now charge a fee for appraising pharma products 
including NICE.  Rather than adding to this important technical body of work 
outlined above to address implementation constraints in the healthcare system 
where the hta is predominantly that of available / existing technologies, we take 
a different approach.  Drawing on our programme theory, we consider the broad 
practical implications for decision-makers and researchers aiming to achieve 
greater interconnectedness between HTA and health systems, in LMIC in 
particular.  Firstly, rather than maintaining an emphasis on user-focused hta ie 
where a synthesis of clinical evidence and economic evaluation of available 
technologies are the mainstay, we consider the application of development-
focused hta where system constraints are addressed whilst the technology is still 
under development(335).  Secondly, although health products have been its 
more significant focus to-date, HTA could develop to increase its focus on 
‘technologies applied to health care’ ie the regulatory and policy measures for 
managing and organising health care systems and on policies in non-health care 
sectors(78).  We consider a refocus towards meso and/or macro HTA given the 
interdependency of HTA and health systems for HTA impact.  Both are discussed 
below.  
10.3.1 Early or development focused HTA  
For many technologies applied to the system, the question of whether the 
intervention works, and even the design of the intervention, is essentially 
context-specific.  Innovate early stage HTA has been proposed as a way of 
identifying critical aspects early on, including organisational-related factors, 
thus improving and facilitating greater clinical acceptance and implementation 
of cost-effective technologies(336).  Organisational issues are affected by (as 
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well as affect) the implementation of a technology.  Patient-related issues are 
also important for uptake.  A review found these aspects were included rarely 
and inconsistently in htas as compared with technological, clinical and economic 
aspects(337).  Expert and professional opinion, political judgment, the 
interpretation of values and traditions, and views from stakeholders and 
contingencies are all relevant inputs in the decision-making and the formulation 
of policy.  Lomas et al cited in (338) refer to these forms of information as 
‘colloquial evidence’ as opposed to information emanating from the application 
of scientific methods.  Since evidence from research on contextual factors is 
frequently limited, or sometimes entirely lacking, decision-makers most often 
rely on such colloquial evidence.  ‘If HTA does not improve its responsiveness to 
context-dependent issues, colloquial evidence will remain the main source of 
information for decision-makers and HTA will fail to establish a robust bridge 
over this particular knowledge-action gap’(339).   
To address this, we propose a greater use of early or development focused HTA.  
The form of HTA used to inform developers of health technologies has been 
termed ‘early HTA’ in the academic literature (340).  Bouttell et al prefer to use 
the label ‘development-focused HTA’ as it is the audience, rather than the 
timing of the HTA, which drives many of the differences between this and the 
more familiar use-focused HTA(335).  By drawing on a broad range of 
multidisciplinary methods, it aims to inform the developers of the technology 
about a wider range of questions including how the technology should be 
designed, used and/or priced.  As such, it relates to the optimisation of an 
individual technology during development (rather than an evaluation between 
available technologies as in more traditional user-focused HTA) and can be 
considered as contributing to three iterative and interlinked assessments of 
clinical value, economic value and the business case(335).  
A key aspect of development-focused HTA is evidence gathering in the specific 
context where the technology will be used.  By, for example, identifying points 
along the implementing pathway where things might breakdown when a 
technology is still at concept stage is a way of being able to deal with 
contextual-dependent evidence more scientifically, and less 'colloquially'(338) ie 
by considering contextual issues from the outset/ early on in the process.  In 
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realism, context is key and in LMIC, this is even more crucial.  We suggest that 
development-focused HTA can offer scientific, transparent and systematic 
methods (such as epidemiological analysis and qualitative methods) to gain a 
thorough understanding of the human factors, infrastructure and health care 
organisation of the context where the technology is to be deployed(335).  
Furthermore, this should also facilitate greater integration and communication 
between HTA and delivery systems stakeholders as evidence generating methods 
gather and synthesise many perspectives.   
Development-focused HTA is an expanding field, and we believe that the tools of 
development-focused HTA could be usefully employed to prioritise the 
development of technologies which impact most upon achieving UHC.  To date, 
we are aware that the Bill and Melinda Gates Foundation have expressed interest 
in the exploration of these methods.  Indeed, in addressing LMIC’s need for more 
of the ‘right’ new products and fewer ‘wrong’ products, early HTA has been 
promoted as a tool to support this(341).  This has been exemplified by the Covid-
19 pandemic. As LMIC prepare for the COVID-19 outbreak, we propose the use of 
development HTA where developers need to rapidly evaluate and optimise or 
adapt existing technologies(335). Furthermore, because LMIC generally lack an 
effective mechanism to ‘pool’ their disease burden and resources, the attractive 
commercial market for pharma is often lacking.  To overcome this, Chalkidou et 
al(342) propose an innovative market-driven, value-based approach whereby 
richer countries offer advance purchase commitments.  In order to ensure local 
needs and value are reflected in any new technological investments, innovations 
and prices, Chalkidou et al similarly recommend the use of early hta as an 
emerging practice and capability.  They suggest early or development-focused 
HTA can ‘help shape the development of COVID-19 vaccines by signalling 
preferable vaccine characteristics (for example, safety and efficacy profiles, 
mode of administration, number of vaccine doses, vaccine storage requirements, 
target populations, vaccine purchasing, and delivery costs) that can maximise 
the public health impact’(343). 
10.3.2 Meso and macro HTA  
Whilst development HTA is about expanding the breadth of HTA to consider 
health system constraints whilst a technology is still in development, here, we 
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consider expanding the remit of HTA by broadening its scope to inform not only 
technology reimbursement decisions but also health system organisation and 
service delivery.  As Garrido et al state(339), ‘although health products and 
health care services have been its preponderant focus to date, HTA should 
develop to increase its focus on the ‘technologies applied to health care’ (ie the 
regulatory and policy measures for managing and organising health care systems) 
and on policies in non-health care sectors’.   Indeed, the recommendation by the 
evaluators of the China CP was that the hta should be integrated into the 
development of other systems in order to change health system functioning, and 
cannot be a standalone reform(179).  We suggest that it is potentially more 
impactful to focus on hta at the meso and macro level in resource poorer 
contexts as this may be one way to better integrate HTA within healthcare 
delivery systems.  So, a refocus is not just about how we do HTA (methods etc) 
but what we evaluate. 
It is noteworthy that iDSI state(17) ‘HTA is not suitable for addressing all health 
systems problems. HTA will not help with general health system problems 
involving financing issues (for example, domestic resource mobilisation) or 
planning the health workforce’.  We would say this is an opportunity overlooked.  
Towse et al(32, 344) state that macro HTA can support the efficiency, 
organisation and strengthening of the healthcare system, and define macro 
technologies as comprising elements of the architecture or framework such as 
how the system is organised, including number and types of hospitals and 
physicians.  Given the poor infrastructure in many LMIC, ‘macro HTA aimed at 
developing performance in the healthcare system may be of greater importance 
in this context than in HICs where HTA has had a more traditional micro HTA role 
of appraisal of single/related technologies’(32).  The conventional focus of HTA 
on technologies that are marginal or incremental to the system is still relevant 
but a refocus to the process or systems-wide interventions (for example, by 
supporting regulatory measures for managing and organising health care 
systems), may result in an improvement in methods used to deliver an existing 
technology, or help develop innovative ways of overcoming barriers and 
challenges in adoption behaviour or infrastructure(335).  Indeed, the most 
successful examples found in our realist review are of several meso level hta 
necessitating the adaptation of service provision to manage patients’ care 
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pathways within a health system – and integrating macro approaches including 
organisational and structural support.  This combination of integrated support 
provided more than just capacity but reinforced the change commitment and 
efficacy of practitioners.   
Finally, Garrido et al(339) recommend that ‘countries embarking on HTA should 
not consider establishing separate agencies for HTA, quality development, 
performance measurement, and health services development but should rather 
combine these functions and goals into a common knowledge strategy for 
evidence-informed decision-making on health care and the health system’.  
Thomas and Chalkidou(345) discuss the benefits and challenges of applying 
economic evaluation at the macro level.  Nevertheless, HTA’s rigorous and 
transparent way of synthesising evidence should be followed when addressing 
health system issues despite any associated methodological challenges(339). 
10.4 Future research 
10.4.1 More empirical case studies 
There is potential for further illustrative empirical case studies through two 
direct contacts: 
1) INAHTA invitation (June 2018) to follow up for future collaboration on 
impact.  This would more likely veer toward HIC case studies but the 
framework is applicable to all countries looking to measure impact and 
value for money.  INAHTA have recently published a report (February 
2020) on their members’ practices relating to impact assessment(109).  
This offers a potential platform on which to build and take this framework 
forward. 
2) the Agency for Care Effectiveness (ACE), Healthcare Performance Group, 
Ministry of Health, Singapore are exploring the feasibility of using 
aggregated and patient-level drug prescription/dispense data to monitor 
the impact of subsidy decisions.  Our contact is the Lead Specialist 
(Economic Modelling & Outcome Evaluation) and the CEO.  They are happy 
to share more as they progress. 
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In any future case studies, in order to assess the robustness of results, different 
methods could be employed. For the modelling of a technology’s cost-
effectiveness as part of the hta, assumptions on model parameters are typically 
handled probabilistically ie each input parameter is assigned a specific sampling 
distribution.  The framework parameters could also be handled in this way with 
distributions so that the NHB-ROI is expressed as a measure of the degree of 
certainty in the final results.  In order to handle the impact assessment 
probabilistically would require the use of probabilistic assessments of all of the 
underlying htas.  Treating the impact assessment parameters probabilistically 
with fixed underlying cost-effectiveness from the htas would not fully represent 
uncertainty.  Aggregate statistics for probabilistic NHB of each underlying hta 
could be used to simplify this in the (likely) event of not having a fully 
probabilistic model for each hta.   
However, a full probabilistic assessment is unlikely to be feasible – hence a focus 
on the use of standard deterministic sensitivity analysis to represent uncertainty 
in the overall system level HTA could be more straightforwardly used.  One-way 
or multi-way deterministic sensitivity analysis could be utilised to explore the 
impact of parameters on the NHB-ROI result either by varying the parameters 
one at a time or analysing how combinations of variations affect the results 
respectively.  This could include varying parameters on the value of the 
threshold, uptake of the intervention, costs of the hta etc.  The use of tornedo 
diagrams showing the relative importance and impact of different variables 
could be used to then depict the results visually.  Scenario analysis, based on 
subsets of these analyses, can be presented.  A threshold analysis to establish 
the critical value/s of a parameter or parameters for a positive NHB-ROI could 
also be identified.  
10.4.2 Full application of the ROI framework 
A natural progression of the case studies would be to apply the full framework to 
a given jurisdiction.  For example, HITAP in Thailand, has considered lending 
itself as an application of the wider framework whereby a representative sample 
of htas could be evaluated.  Operationalising the framework to assess the ROI of 
an entire country’s HTA programme is unlikely to be feasible in any context.   
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10.4.3 Data linkage  
Data linkage to health outcomes could be explored to validate this work.  A 2018 
OECD survey on routine data collection states the richest data sources extend 
beyond prescribing and dispensing to information on utilisation of health services 
and outcomes of treatment(327).  Although this survey identified at least 25 
OECD and EU Member States that collect routine data on prescribed and 
dispensed medicines, linkage with other health or health care datasets is less 
common.  The OECD recommends that methods to generate evidence from 
routinely collected data….need to be further developed and gain greater 
legitimacy and recognition from HTA agencies(327).  Countries with good data 
linkage and the established use of HTA might be Scotland (linkage to Scottish 
Morbidity Records), or possibly Taiwan.  This is only likely to be available in 
HICs.  Nevertheless, it still comes with wider learning opportunities to other 
countries.   
10.4.4 Realist evaluation 
Realist interviewing could help to further test and refine theory by collecting 
primary qualitative data.  A continuing test of the same theory using primary 
data would allow us to explore aspects of the theory in more depth with 
different stakeholders.  This could tie into further empirical case studies.   
10.4.5 Expansion to Health Systems Strengthening 
Health systems strengthening (HSS) is very central in global health discussions.  
In theory, this NHB-ROI framework could be extended to apply not just to 
assessing HTA impact but also a way of capturing the impact and value for 
money of HSS initiatives with the same focus on efficiency and health outcomes.  
Our impact framework measures impact as potential, realised and attributable 
NHBs.  These could be written up as a typology of HSS estimates.  A potential 
starting place might be collaborating with iHEA special interest group, and could 
complement existing methods to measure health systems efficiency(345). 
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10.5 Final reflections 
In this chapter, we outline the main strengths (Table 10-1 “What our framework 
adds”) and challenges (Section 10-2).  We also draw out implications of this 
research for decision-makers and researchers (Section 10-3) and 
recommendations for future research (Section 10-4).  Rather than risk repeat 
what is stated, here I take a more reflective review of the main strengths and 
weaknesses of the whole body of research. 
Our framework uniquely brings together the costs of HTA/hta as well as 
quantifying and understanding impact of HTA/hta as a process or complex 
intervention of itself – and thus, goes beyond the impact of the costs and 
benefits of the technology in question.  Whilst simplifying assumptions were 
required, we consider these to go beyond those made by others in that we have 
attempted to address the counterfactual, attribution and actual implementation 
which we express as realised and attributable NHBs.  Furthermore, expressing 
impact in NHB (or NMB) allows us to go beyond thinking solely in terms of cost-
savings but to capture health and efficiency gains - with the realist approach 
capturing other potential outcomes. NHB importantly reflect the opportunity 
costs of investing in individual technologies as well as in HTA at a systems level.  
Using modelled health outcomes allows us to focus on improving implementation 
over which we have direct influence and thereby, to realise health gains. 
As a researcher, I have learnt a huge amount about different disciplines and 
methods across the evaluation spectrum over the course of this work.  Expanding 
on the usual health economist’s repertoire has been invaluable.  Undertaking a 
realist synthesis as a complementary and congruent approach to iDSI’s ToC and 
then drawing on quasi-experimental methods and finally, linking this to an ROI 
framework mirrors the evaluation method groups as set out by the Magenta 2020 
book(131).  These are namely, theory-based impact evaluation methods, 
experimental and quasi-experimental impact evaluation methods and value-for-
money methods.  As such, the novel aspect could be seen to be less about using 
mixed methods but rather that we combine positivist and quasi-experimental 
approaches with complexity theorising. 
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The strength, however, of developing a new conceptual framework has led, 
perhaps, to a weakness in this research in that illustrations of its application are 
proof-of-methods case studies only.  A natural progression of these applications 
would be to apply the recommendations made around handling uncertainty in 
the framework as well as to apply the full framework in collaboration with a 
specific HTA agency or agencies.  As stated before, we recognise that the data 
requirements would not be without their challenges.  However, this would be an 
opportunity to take this framework forward with stakeholders.  The iDSI ToC was 
developed in full consultation with stakeholders and partners in the countries 
concerned.  A weakness is that our framework might be seen as a somewhat 
academic exercise but we have potential for collaborations to take this forward 
with our HTA partners.  Furthermore, the recent INAHTA Impact report 
(February 2020)(109) provides a relevant and timely platform upon which to 
build. 
As I was writing this section, I received two relevant emails.  One was on REF 
and the latest thinking and evidence on effective impact assessment.  The other 
was NICE’s newsletter, entitled “Making a difference: the impact of NICE's 
work”.  To quote NICE’s December 2020 newsletter: “Over the last 20 years, 
NICE has established itself as a global leader in the development of evidence-
based guidance for health and social care, using robust, transparent 
methodologies and processes. We have one of the biggest guideline programmes 
in the world, with topics covering a range of clinical conditions, social care and 
public health. But it is only by putting this advice into practice that it will make 
a difference to real people, to health outcomes and to equitable access to 
services”.  NICE discuss their National Clinic Audit Programme, a new version of 
their Innovation Scorecard which reports on the use of medicines and medical 
technologies in the NHS in England which have been positively appraised, NICE 
Impact Reports now covering 17 topics, and shared learning case studies.  The 
latter two especially contain a wealth of quantitative data on uptake following 
guidance and qualitative data on implementation.  Indeed, these were reviewed 
as sources of information for this research and offer potential for future case 
studies.   
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Furthermore, commentary and analysis on CGD’s website (30 November 2020) 
highlights that with the onset of COVID-19, SSA countries face economic 
contraction compounding existing pressures on healthcare budgets. 
Institutionalised priority setting processes are needed to ensure that investments 
in health continue to strive for improving overall population health, protecting 
citizens from impoverishment, and enhancing the quality of services.  Leveraging 
expertise and resources across the global movement of priority setting in health 
to help support all countries in their COVID-19 recovery is paramount15.  
These current excerpts illustrate the importance of measuring and optimising 
HTA’s impact in the current climate.  Highlighting the implications drawn from 
this research on macro and development-focused hta to strengthen health 
systems and embed implementation issues in hta from the outset respectively 
can, hopefully, be seen as timely and useful contributions to this field.  
 
 
  
 
15 Afro-European Partnerships in Health: Accelerating Better Efficiency of Health Spending | Center 
For Global Development (cgdev.org) 
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Annex B: Realist Synthesis Search terms and strategy 
 
The search strategy proceeded iteratively in four phases:  
1. Initial search to identify existing frameworks or models to measure the impact of HTA [as per Chapter 2] and a relatively 
unstructured scan to develop tentative theories on HTA impact.  Search terms for this initial search were first run with the terms 
shown in Box 1 but given the large number of articles returned, it was re-run with the adjacent term “adj5 health technolog$ or 
HTA” in lines 4 and 5 (Box 2).  Box 2 results will be a subset of the results retrieved in Box 1. 
Run on Ovid MEDLINE(R) without revisions, Ovid MEDLINE In-Process & Other Non-Indexed Citations, EMBASE 1996 to 1st June 2020. 
       
Box 1 
1. exp Technology Assessment, Biomedical/ 
2. ((health technolog$ adj3 assessment$) or HTA).mp. 
3. 1 or 2 
4. ("evaluat$" or "method$" or "framework$" or "model$" or 
"concept$" or "empirical research" or "theor$" or "cost benefit 
analys$").tw. 
5. ("impact$" or "value" or "gain$" or "benefit$" or "influence$" or 
"return$ on investment" or "ROI" or "social adj3 return$" or 
"economic adj3 return$").tw. 
6. 4 or 5 
7. 3 and 6 
Box 2 
1. exp Technology Assessment, Biomedical/ 
2. ((health technolog$ adj3 assessment$) or HTA).mp. 
3. 1 or 2 
4. (("evaluat$" or "method$" or "framework$" or "model$" or "concept$" 
or "empirical research" or "theor$" or "cost benefit analys$") adj5 
(health technolog$ or HTA)).tw. 
5. (("impact$" or "value" or "gain$" or "benefit$" or "influence$" or 
"return$ on investment" or "ROI" or "social adj3 return$" or "economic 
adj3 return$") adj5 (health technolog$ or HTA)).tw. 
6. 4 or 5 
7. 3 and 6 
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2. Detailed search to identify literature that could be used to elucidate, test and refine those tentative theories.  This focuses 
specifically on i) HTA & health outcomes; ii) HTA & ‘uptake/implementation’ as a proxy measure given the identified lack of 
literature on impact on health outcomes; and iii) governance and knowledge transfer/utilisation theories with respect to HTA. 
Run on Ovid MEDLINE(R) without revisions, Ovid MEDLINE In-Process & Other Non-Indexed Citations, EMBASE 1996 to 1st June 2020. 
 HTA and health outcomes         HTA and uptake 
1. exp Technology Assessment, Biomedical/ 
2. ((health technolog$ adj3 assessment$) or hta).mp. 
3. (("health" or "patient") adj5 (gain$ or outcome$ or benefit$)).mp. 
4. ("evidence" adj5 ("implement$" or "uptake" or "diffusion" or "utilis$" or "utiliz$" or "adopt$" or "practice")).mp. 
5. 1 or 2 or 3 or 4 
6. (governance adj2 (theor$ or model$ or concept$ or framework$)).mp. 
7. (knowledge adj2 (theor$ or model$ or concept$ or framework$)).mp. 
8. 5 and (6 or 7) 
 
1. exp Technology Assessment, Biomedical/ 
2. ((health technolog$ adj3 assessment$) or hta).mp. 
3. 1 or 2 
4. (("health" or "patient") adj5 ("gain$" or "outcome$" or "benefit$")).tw. 
5. ("net health benefit$" or "net monetary benefit$" or "NMB$" or "NHB$").tw. 
 
6. exp Health Impact Assessment/ 
7. "Outcome Assessment (Health Care)"/ 
8. 3 and (4 or 5 or 6 or 7) 
 
1. exp Technology Assessment, Biomedical/ 
2. ((health technolog$ adj3 assessment$) or 
hta).mp. 
3. 1 or 2 
4. ("implement$" or "uptake" or "diffusion" or 
"utilis$" or "utiliz$" or "adopt$" or "practice").tw. 
5. 3 and 4 
 
HTA, or health outcomes or evidence and theory of governance/knowledge 
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3. Ongoing reference, citation and author tracking to identify the most theory relevant studies available. 
4. Finally, very refined searches, again operating concurrently with the synthesis process, to collect additional materials that may 
be required to elucidate particular aspects of theory.  This included expanding the search to other areas, for example, in 
organisational theory where it was inferred that similar mechanisms around willingness and capability might be activated. 
  
1. exp Technology Assessment, Biomedical/ adj2 (("knowledge" or "governance") and (theor$ or model$ or concept$ or 
framework$)).mp. 
2. (((health technolog$ adj3 assessment$) or HTA) adj2 (("knowledge" or "governance") and (theor$ or model$ or concept$ 
or framework$))).mp. 
3. (("health" or "patient") adj5 (gain$ or outcome$ or benefit$) adj2 (("knowledge" or "governance") and (theor$ or model$ 
or concept$ or framework$))).mp. 
4. ("evidence" adj5 ("implement$" or "uptake" or "diffusion" or "utilis$" or "utiliz$" or "adopt$" or "practice") adj2 
(("knowledge" or "governance") and (theor$ or model$ or concept$ or framework$))).mp. 
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Annex C: Grey literature search results 
The following list of websites were searched using the keywords: HTA impact and implementation 
Website  Webpage url if specific sections were searched Downloaded 
NICE ERNIE 
database 
http://webarchive.nationalarchives.gov.uk/20080611115838/  
http://www.nice.org.uk/usingguidance/evaluationandreviewofniceimplementationevidenceernie/ 
niceimplementationuptakecommissionedreports/ nice_commissioned_surveys_and_reports.jsp 
http://webarchive.nationalarchives.gov.uk/20080611122835/                         
https://www.nice.org.uk/usingguidance/evaluationandreviewofniceimplementationevidenceernie/ 
niceimplementationuptakecommissionedreports/nice_implementation_uptake__commissioned_reports.jsp 
All NICE internal 
and externally 
commissioned 
reports 
downloaded – see 
table below 
 NICE shared 
learning 
https://www.nice.org.uk/localPractice/collection 
  
Case studies 
 EUnetHTA / 
Evidence 
Database on 
New 
Technologies 
Database part of EUnetHTA Joint Action on HTA 3  EVIDENT Not 
accessible 
 CADTH Strong emphasis in latest strategy on implementation Latest strategy 
documentation 
TRIP HTA impact and implementation No access to 
advanced search 
INAHTA HTA Impact and Influence https://www.inahta.org/hta-tools-resources/hta-impact-influence/#IAStudy  HTA impact 
framework & 
Report 2020 
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ERNIE Database 
Report Key findings 
Pettit, JL et al.  Assessing the 
implementation of NICE guidance: 
is there a correlation between 
recommendations and uptake in 
clinical practice? 
Uses ERNIE uptake against NIICE projections and finds in the whole a correlation.  This is a 
before/after study. 
NICE Implementation – 
Breakthrough Breast Cancer 
Lack of forward planning, resources, awareness, general need for monitoring systems. 
Variation in usage of Cancer drugs 
approved by NICE.  Report of the 
Review undertaken by the 
National Cancer Director. 
Capacity issues, clinical factors.  Solutions – information, prospective audit and feedback. 
Implementation of NICE Guidance 
– An ABPI perspective 
Generally compared data on uptake against NICE targets.  Guidance and implementation planning 
should be linked, accountability, awareness, education, audit, monitoring, and incentives. 
Audit in the implementation of 
NICE Guidance for Roche Drugs 
Compared audit data on uptake against potential eligible patient population.  Challenging to do 
so. 
Implementation of NICE Guidance 
# 49 
Abacus International posted questionnaire to anaesthetists.  Disclaimer that ‘no statistical analysis 
has been conducted as this survey is simply designed to give a top line picture of the impact and 
implementation of guidance #49’.  Illustrates not all practitioners agree/concur with guidance.  
46% had no access/little access to the required technology required to implement the guidance.  
Barriers included infrastructure issues like training ie not just funding and access to necessary 
equipment.  Some no change to practice as they were already complying. 
Implementation of NICE Guidance 
# 24  
Abacus Int and disclaimer as above.  Not all felt guidance had an impact and sometimes things in 
place anyway but had not been implemented as a result of NICE recommendations.  Guidance 
been read, understood but not brought about a major change.  One of the issues was that the 
guidance did not make specific recommendations and was described as woolly: “there is nothing 
new in it”, guidance too narrow in scope or simply matched current practice and would therefore 
not expect any dramatic changes. 
Abacus International developed a 
methodology to measure the 
Identify data, consult with NICE to establish the expected change in HTA utilisation against what 
NICE had predicted.  Infrastructure barriers, training and resources, guidance sometimes endorsing 
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impact of 28 pieces of NICE 
guidance. 
current practice.  “It is difficult to interpret the impact of NICE guidance because it was issues at 
time of X launch”.  Some show pre-guidance uptake and post-guidance uptake but may have been 
on an up/downward trend anyway.   Predominantly before/after studies. 
A survey measuring the impact of 
NICE Guidance # 11 Abacus Int 
68% found not easy to implement.  Some disagreement with recommendations usually due to a 
lack of perceived evidence base.  Belief that it is a financial not clinical perspective driving these 
recommendations. Should be some element of flexibility.  Lack of funding/pressure.   PCT has 
competing priorities.  Majority felt they were already implementing some of the key priorities 
prior to guideline publication.  62% felt that the Govt pressures had a high/very high impact on 
the implementation of this guideline.  Less than half of all PCTs reported patient group pressure 
having the same level of impact.  Other external pressures – patients, consultants, public health, 
legal depts., SHA, media, local taskforce and professional best practice.   
NICE Guidance – Ritizole Pre/post uptake shows an upward trend anyway.  ITS would have provided estimates of significant 
change in trend. 
NICE Guidance – Cox II Provide national trends and activity 
NICE Guidance  - insulin glargine Uptake greater than anticipated in NICE guidance as now more/better data on prevalence. 
NICE Guidance – Attention Deficit 
hyperactivity Disorder 
“It is not anticipated that this guidance will result in a major increase over current trends in the 
rate of prescribing for ADHD” – data shows steadily increasing as part of a longer term trend. 
NICE Guidance – Insomnia: newer 
hypnotic drugs 
The long term downward trend in this continues.  Both trends pre-date the publication of NICE 
guidance.  Whilst trend lines drawn on, no ITS undertaken.  General lack of contextual detail 
available in these reports though some attempt to provide contextual info from a sample of 
patients’ records from GP to gain insight into hypertension prescribing by age. 
NICE Guidance – epilepsy: newer 
drugs 
“Guidance expected to have a neutral impact on prescribing trends”.  The newer drugs are 
increasing at a faster rate than the older drugs. 
NICE Guidance – lithium Latest trend show that the prescribing rate is steady and in line with expectations.  Lithium is an 
established treatment and continues to be widely prescribed.  So a change in uptake not always 
expected. 
NICE Guidance – statins Estimated an additional 1.7million people will present for treatment as a result of guidance.  
There was though already a consistent upwards trend in statin usage.   
NICE Guidance – laparoscopic 
surgery for colorectal cancer 
The publication of NICE guidance appears to correspond with a further increase in the rate of 
uptake.  It is too early to confirm a statistical link between guidance publication and change in 
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uptake.  The main limiting factor in uptake is a recognised shortage of surgeons skilled in this 
technique and patient choice. 
NICE Guidance # 40 – Drugs in the 
management of urinary 
incontinence 
This does use interrupted time series analysis.  “This upturn was subjected to time series analysis 
to see if the apparent correspondence between the slight increase in uptake and the guidance 
publication could be confirmed statistically.  The ARIIMA testing technique could not confirm a 
statistical link between guidance publication and change in uptake.  However, this null finding 
may be because, at this stage, there are an insufficient number of monthly data points for 
oxybutynin usage since the guidance was published (sub-section 1.2.6 drug therapies).   
NICE Guidance – Adefair dipivoxil 
to treat Hep B 
Too early to confirm a statistical link between guidance publication and change in uptake.  
Modelled upper and lower trajectories to offer a basic way of understanding the potential uptake 
over time. 
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